EP4308140A1 - Rna-regulated fusion proteins and methods of their use - Google Patents

Abstract

The present disclosure is directed to RNA-regulated fusion proteins comprising a protein of interest and an RNA-regulated destabilization domain. Also disclosed are RNA aptamers that bind specifically to a RNA-regulated destabilization domain. Nucleic acid molecules encoding the RNA-regulated fusion proteins and RNA aptamers and methods of use thereof are also disclosed.

Description

RNA-REGULATED FUSION PROTEINS AND METHODS OF THEIR USE

[0001] This application claims priority benefit of U.S. Provisional Patent

Application No. 62/894,651, filed August 30, 2019, which is hereby incorporated by reference in its entirety.

[0002] This invention was made with government support under Grant Number

MH1 09087 awarded by the National Institutes of Health. The government has certain rights in the invention.

FIELD OF THE DISCLOSURE

[0003] This present disclosure relates to RNA-regulated fusion proteins and methods of their use.

BACKGROUND

[0004] Fluorogenic RNA aptamers are RNA aptamers that bind otherwise nonfluorescent molecules and switch them to a fluorescent form. These fluorogenic dyes can be applied to cells, enabling RNAs tagged with these fluorogenic aptamers to be imaged using fluorescence microscopy (Paige et al., “RNA Mimics of Green Fluorescent Protein,” Science 333:642-646 (2011) and Braselmann et al., “A Multicolor Riboswitch- Based Platform for Imaging of RNA in Live Mammalian Cells,” Nat. Chem. Biol. 14:964-971 (2018)). However, few fluorogenic aptamers have been developed since there are not many fluorogenic dyes that meet the criteria required for use in live cells. For example, most dyes show nonspecific fluorescence activation by cellular lipids or DNA (Lober, G., “The Fluorescence of Dye-Nucleic Acid Complexes,” Journal of Luminescence 22:221-265 (1981) and Fam et al., “Recent Advances in Fluorescent Probes for Lipid Droplets,” Materials (Basel) 11 (2018)). This nonspecific binding leads to background fluorescence that obscures the fluorescence of the RNA-dye complexes. Another problem is that the fluorogenic dyes are not genetically encoded and therefore need to be added exogenously for RNA imaging. A genetically encoded conditionally fluorescent dye would provide a simple alternative to the use of fluorogenic RNA aptamers.

[0005] The present disclosure is directed to overcoming deficiencies in the art. SUMMARY

[0006] A first aspect of the disclosure relates to a nucleic acid molecule encoding an RNA-regulated fusion protein. The nucleic acid molecule includes: a first nucleic acid sequence encoding a protein of interest and a second nucleic acid sequence encoding an RNA-regulated destabilization domain, where the second nucleic acid sequence is operably coupled to the first nucleic acid sequence.

[0007] Another aspect of the disclosure relates to a nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) RNA aptamer sequence.

[0008] A further aspect of the disclosure relates to an RNA-regulated fusion protein comprising a protein of interest and an RNA-regulated destabilization domain. [0009] Yet another aspect of the disclosure relates to a molecular complex comprising: an RNA-regulated fusion protein comprising (i) a protein of interest and (ii) an RNA-regulated destabilization domain; and an RNA aptamer bound specifically to the RNA-regulated destabilization domain.

[0010] Another aspect of the invention relates to a method of imaging RNA in a cell. This method involves providing a first vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or an enzyme fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; transfecting a host cell with the first vector and the second vector; and imaging said transfected cells.

[0011] Yet another aspect of the invention relates to a method of imaging RNA in a cell. This method involves providing a vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or an enzyme fused to an RNA-regulated destabilization domain; transfecting a host cell with the first vector; contacting said transfected cell with an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; and imaging said contacted cells.

[0012] A further aspect of the invention relates to a method of selectively modifying an RNA-binding protein. This method involves providing a first expression vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises an enzyme fused to an RNA-regulated destabilization domain; providing a second expression vector encoding (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; transfecting a host cell with the first and second expression vectors; and allowing the enzyme to be expressed, where the expressed enzyme selectively modifies a protein that binds to the RNA sequence of interest.

[0013] Another aspect of the invention relates to a method of regulating expression of an RNA-stabilized protein of interest. This method involves providing a first vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; providing a host cell comprising a functional ubiquitination system; transfecting the host cell with the first and second expression vectors; and expressing the first and second expression vectors within the host cell, where said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; and where, in the absence of any expressed RNA aptamer sequence in the host cell, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the ubiquitination system; and where the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence.

[0014] Another aspect of the invention relates to a method of regulating expression of an RNA-stabilized protein of interest. This method involves providing a first vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; providing a mammalian cell lysate or solution comprising (i) a ubiquitin ligase, (ii) proteosomal degradation machinery, (iii) transcriptional machinery, and (iv) translational machinery; contacting the mammalian cell lysate or solution with the first and second expression vectors; and expressing the first and second expression vectors , where said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; and where, in the absence of any expressed RNA aptamer sequence in the cell lysate or solution, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the proteosomal degradation system; and where the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence. [0015] Another aspect of the present application relates to a treatment method.

This method involves contacting a cell with an RNA aptamer, where upon said contacting, the aptamer interacts with an RNA-regulated destabilization domain fused to a protein of interest in the cell to stabilize the protein of interest in the cell.

[0016] Another aspect of the present invention relates to a treatment method. This method involves contacting a cell with a vector according to the present application under conditions effective to express an RNA molecule as described herein to treat the cell.

[0017] The examples described herein below demonstrate the use of RNA- regulated fluorescent fusion proteins whose fluorescence is stabilized by RNA aptamers.

In some embodiments, the RNA-regulated fluorescent fusion proteins are highly unstable until they bind RNA aptamers inserted in mRNAs, resulting in fluorescent RNA-protein complexes that enable live imaging of mRNA in living cells. In some embodiments, the technology described herein is an imaging system that bypasseses the limitations of using fluorogenic RNA aptamers and conditionally fluorescent small molecule dyes for imaging. In some embodiments, this is achieved by engineering a peptide degron sequence whose activity can be regulated by an RNA aptamer. When fused to a fluorescent protein, this peptide degron sequence can send the fluorescent protein to degradation. However, this degradation function of the peptide degron is impeded when bound to a specific RNA aptamer sequence. In some embodiments, a peptide degron sequence causes rapid degradation of the unbound fluorescent proteins when expressed in mammalian cells. This is different from previous methods. In some embodiments, methods described herein utilize an RNA aptamer sequence that can effectively abrogate the degradation function of the peptide degron once they are bound. This is also different from previous methods. Methods described herein enable fluorescent proteins and other proteins to carry out their native function only when they are bound to a specific RNA sequence. In the case of enhanced yellow fluorescent protein (EYFP), a 38 fold fluorescent enhancement was observed when bound to the engineered RNA aptamer described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] FIGS. 1 A-1C show the design and optimization of an RNA-regulated protein destabilization domain. FIG. 1 A is a schematic drawing of a Pepper RNA- regulated protein destabilization domain, tDeg. tDeg is a bifunctional peptide that includes the Tat peptide, which is capable of binding to the Pepper RNA aptamer, and the previously described C-terminal Arg-Arg-Arg-Gly degron (Bonger et al., “Small- Molecule Displacement of a Cryptic Degron Causes Conditional Protein Degradation,” Nat. Chem. Biol. 7:531-7 (2011), which is hereby incorporated by reference in its entirety). When fused to a protein of interest, tDeg causes protein degradation. However, the protein destabilization function of tDeg is impeded when it binds to the Pepper RNA aptamer. Amino acids Arg-Gly, highlighted in a black box, are appended to the C- terminus of Tat to make the full Arg-Arg-Arg-Gly degron. FIG. IB demonstrates that Pepper RNA stabilizes EYFP fused to tDeg in cells. To test whether tDeg functions as an RNA-regulated destabilization domain, EYFP-tDeg was coexpressed with different circular RNAs, and the yellow fluorescence in HEK293T cells was imaged. Without circular wild-type TAR RNA or its variants, cells coexpressing EYFP-tDeg and the circular control RNA only showed minimal fluorescence above background fluorescence. Cells exhibit yellow fluorescence only when circular wild-type TAR RNA, TAR Variant- 1, or TAR Vairnat-2 (named Pepper) was coexpressed. Notably, higher yellow fluorescence signals were observed in the cytosol compared to the nucleus when EYFP- tDeg was coexpressed with the circular wild-type TAR RNA or its variants. This is consistent with the cytosolic expression of small circular RNAs using the Tornado expression system (Litke & Jaffrey, “Highly Efficient Expression of Circular RNA Aptamers in Cells Using Autocatalytic Transcripts,” Nat. Biotechnol. 37:667-675 (2019), which is hereby incorporated by reference in its entirety). All cells were stained with Hoechst dye. Scale bar, 40 pm. FIG. 1C shows the summary data of normalized fluorescence of untransfected HEK293T cells, or HEK293T cells expressing EYFP or EYFP-tDeg with different RNAs as in (FIG. IB). Total cellular yellow fluorescence of individual cells is plotted (n = 4 independent cell cultures). Values are means ± s.d.

**** ⁵circularwild-type TAR = 7.9 x 10¹¹³; * * * *p circular TAR Variant- 1 ⁼ 2.1 X 10¹¹⁷; * * * *p circular TAR vanant-2 = 1.7 x lO ¹¹⁵ by one-way ANOVA.

[0019] FIGS. 2A-2B are schematic illustrations showing the design of tDeg, an

RNA-regulated destabilization domain. Shown is a structural representation of how TAR binds to the tDeg, and may therefore obstruct recognition of the Arg-Arg-Arg-Gly degradation-inducing signal. RNA is depicted in grey, and peptide sequence is shown letters of the polypeptide chain. A schematic representation of RNA binding to the tDeg sequence is shown in FIG. 2A. Here, a bifunctional peptide sequence, called tDeg, that functions both as a destabilization domain and as a binding site for the bovine immunodeficiency virus TAR RNA (in grey) was designed. Knowing that the TAR RNA binds to specific amino acids in the Tat peptide including the two C-terminal arginines, an Arg-Gly (highlighted in a black box) was added to the C-terminus of the Tat peptide to make the full Arg-Arg-Arg-Gly degron. When the TAR RNA binds to this bifunctional domain, it impedes the function of the destabilization domain by sterically blocking recognition of the Arg-Arg-Arg-Gly degron by proteasomal machinery. The structure model (FIG. 2B) of the Tat-TAR complex shows that the first two arginines of the Arg- Arg-Arg-Gly degron would be inaccessible to any Arg-Arg-Arg-Gly-binding protein that mediates its degradation. The additional Arg-Gly residues are modeled into the C- terminus of Tat in a black box in FIG. 2B. The structure representation in FIG. 2B is based on the NMR structure of the bovine immunodeficiency virus Tat-TAR complex (PDB entry: 1BIV) (Puglisi et ak, “Solution Structure of a Bovine Immunodeficiency Virus Tat-TAR Peptide-RNA Complex,” Science 270:1200-3 (1995), which is hereby incorporated by reference in its entirety).

[0020] FIGS. 3A-3B demonstrate that tDeg confers protein instability to EYFP by proteasomal degradation. In FIG. IB, it was shown that tDeg confers protein instability to EYFP. However, the lack of yellow fluorescence of EYFP -tDeg in FIG. IB could be due to protein misfolding or aggregation. In FIG. 3 A, whether the lack of yellow fluorescence of EYFP -tDeg is due to proteasomal degradation was examined. In these experiments, HEK293T cells were transiently transfected with a plasmid expressing EYFP -tDeg.

These cells were then treated with vehicle (DMSO) or a proteasome inhibitor (10 mM MG132) for 7 hours, respectively. When treated with vehicle (DMSO), minimal yellow fluorescence was detected. This result is consistent with the result from FIG. IB. However, when proteasome activity was inhibited by treatment of 10 pM MG132 for 7 hours, the yellow fluorescence of EYFP -tDeg was restored. Thus, this confirmed that the tDeg tag markedly reduces the stability of EYFP by inducing its proteasomal degradation. All cells were stained with Hoechst dye. Scale bar, 40 pm. In FIG. 3B, normalized total cellular yellow fluorescence of individual cells is plotted (n = 3 independent cell cultures). Values are means ± s.d. ****P = 5.6 x 10³⁶ by unpaired two-tailed Student’s /-test. [0021] FIGS. 4A-4B demonstrate that engineered TAR variants’ higher efficiency in stabilizing EYFP-tDeg proteins is not due to expression differences in EYFP-tDeg mRNA or the circular TAR RNAs. In FIGS. IB and 1C, it was shown that circular wild- type TAR, Variant-1, and Variant-2 showed 24-fold, 36-fold, and 38-fold fluorescence increases, respectively. However, the improved efficiency in stabilizing EYFP-tDeg protein could be due to uneven expression levels of the EYFP-tDeg mRNA, or the uneven expression levels of the circular TAR RNA variants. Here, the relative expression of EYFP-tDeg mRNA (FIG. 4A) and the relative expression of circular TAR RNA variants (FIG. 4B) was compared. In these experiments, HEK293T cells were transiently transfected with a plasmid expressing EYFP-tDeg and the corresponding circular TAR RNA variant as shown in FIGS. IB and 1C. Total RNA was extracted by TRIzol^® extraction. EYFP-tDeg mRNA expression level was quantified using RT-qPCR. Each circular TAR RNA variant’s expression level was quantified by running the extracted total RNA on a TBE-Urea gel followed by SYBR™ Gold nucleic acid gel staining. These results show that there is no significant expression difference in the EYFP-tDeg mRNA or the circular TAR RNA variants. Thus, this confirms that the engineered circular TAR RNA variants indeed show higher efficiency in stabilizing tDeg-tagged EYFP. Data were collected from two independent cell cultures. Values are means ± s.d.

[0022] FIGS. 5A-5G demonstrate that tDeg can be regulated by the Pepper RNA aptamer in diverse mammalian cell types. In FIGS. 1 A- 1C, it was shown that EYFP-tDeg can be regulated by the Pepper RNA aptamer in HEK293T cells. Here, whether tDeg can be regulated by the Pepper RNA aptamer in various mammalian cell types was examined (FIG. 5 A). In these experiments, U20S cells (FIG. 5B, FIG. 5E), COS-7 cells (FIG. 5C, FIG. 5F), or HeLa cells (FIG. 5D, FIG. 5G) were transiently expressed EYFP-tDeg with and without the circular Pepper RNA aptamer, respectively. In each case, cells showed low or undetectable levels of yellow fluorescence without the circular Pepper RNA aptamer. The yellow fluorescence of EYFP-tDeg was only restored when the circular Pepper RNA aptamer was coexpressed. Thus, tDeg can be regulated by the Pepper RNA aptamer in diverse mammalian cell types. All cells were stained with Hoechst dye. Scale bar, 20 pm. Normalized total cellular fluorescence (FIGS. 5E, 5F, and 5G) of individual cells is plotted (n = 3 independent cell cultures). Values are means ± s.d. **** ^> _U20S = 5.7 x 10⁵⁹; * * * *p cos ⁼ 1.6 x 10⁴⁶; ****p_HeLa = 2.0 x 10 ¹³⁹ by unpaired two-tailed Student’s

/-test. [0023] FIGS. 6A-6G demonstrate that tDeg confers Pepper RNA-dependent regulation to diverse proteins. To test whether Pepper RNA stabilizes different proteins fused to tDeg, HEK293T cells expressing mNeonGreen (FIG. 6B, FIG. 6E), mCherry (FIG. 6C, FIG. 6F), and the luciferase NanoLuc (FIG. 6D, FIG. 6G) fused to a C-terminal tDeg tag with and without circular Pepper RNA (FIG. 6A) were imaged, respectively. In each case, there was a considerable increase of fluorescence (FIG. 6E, FIG. 6F) or bioluminescence (FIG. 6G) of the tDeg-tagged protein only when circular Pepper RNA was coexpressed in cells. For detecting bioluminescence, cells were incubated in media with furimazine (from Promega Nano-Glo® Luciferase Assay System, diluted lOOx) and imaged using a 460 ± 25 nm emission filter cube. All cells were stained with Hoechst dye. Scale bar, 40 pm. Normalized total cellular fluorescence (FIG. 6E and FIG. 6F) or bioluminescence (FIG. 6G) of individual cells is plotted (n = 3 independent cell cultures). Values are means ± s.d. ****P_mNeonGreen-tDeg = Fi x 10 ¹²³; ****P_mcheny-tDeg ⁼

3.0 x 10 ¹³¹; * * * *p _NanoLuc -tDeg ⁼ 1.7 x 10 ' ²⁰ by unpaired two-tailed Student’s /-test.

[0024] FIGS. 7A-7G demonstrate that tDeg confers Pepper RNA-dependent regulation to diverse proteins. In FIGS. 6A-6G, it was shown that tDeg confers Pepper RNA-dependent regulation of different fluorescent proteins and the luciferase, NanoLuc (Hall et al., “Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate,” ACS Chem. Biol. 7:1848-57 (2012), which is hereby incorporated in its entirety). Whether tDeg confers Pepper-dependent regulation to proteins with different functions and localizations in cells was tested here (FIG. 7A). In these experiments, HEK293T cells transiently expressed EGFP-TetR-tDeg (FIG. 7B, FIG. 7E), EGFP-EZH2-tDeg (FIG. 7C, FIG. 7F), or mCherry-NF-KB-tDeg (FIG. 7D, FIG. 7G), with and without the circular Pepper RNA aptamer, respectively. In each case, proteins were nearly undetectable unless coexpressed with the circular Pepper RNA. Furthermore, protein localization of these proteins without tDeg and the circular Pepper RNA was compared to their stabilized counterparts by tDeg and circular Pepper RNA. It was observed that EGFP-TetR-tDeg with circular Pepper RNA showed more green fluorescent signals in the cytosol compared to EGFP-TetR. Significant change of protein localization in the case of EGFP-EZH2-tDeg or mCherry-NF-KB-tDeg with the circular Pepper RNA was not observed. It was concluded that tDeg is a versatile tag for RNA-dependent protein stabilization. All cells were stained with Hoechst dye. Scale bar, 40 pm. Normalized total cellular fluorescence (FIGS. 7E, 7F, and 7G) of individual cells is plotted (n = 3 independent cell cultures). Values are means ± s.d. * * * *p _{EGFP-TetR-tDeg} ⁼ 2.9 1.1 x 10 ¹²°; * * * *p _{mCherry-NF-KB-tDeg} ⁼ 3.5 x 10 ¹¹⁹ by unpaired two-tailed Student’s /-test.

[0025] FIGS. 8A-8B demonstrate the optimization of a concatenated Pepper tag to image mRNAs in live cells. Pepper RNA-regulated fluorescent proteins were used to fluorescently tag mRNAs in live cells. As a first step, the best way to incorporate the Pepper aptamers in the 3’UTR of a transcript of interest was determined. In these experiments, a fluorescent protein (mNeonGreen)₂-tDeg and an mCherry mRNA reporter (FIG. 8 A) containing 3'UTR tags comprising 10 or 20 concatenated Pepper aptamers with and without a folding scaffold, F30, were expressed respectively. In the case of the (Pepper)₂o and (F30-2xPepper)i₀ tags, mobile green fluorescent puncta in the cytosol were observed (FIG. 8B). A signal to noise ratio was evident when the (F30-2xPepper)i₀ tag (signal to noise ratio = 1.8) was used, compared to the (Pepper)₂₀ tag (signal to noise ratio = 1.5). However, puncta were not readily detectable with either the (Pepper)io tag or the (F30-lxPepper)io tag. Therefore, the (F30-2xPepper)i₀ tag was used to image mRNAs in the subsequent experiments. Scale bar, 20 pm. This experiment was performed three times with similar results.

[0026] FIGS. 9A-9D show the design of Pepper tags for imaging mRNA. Design and sequences of four Pepper tags used in FIG. 8B: (Pepper)i₀ (FIG. 9A; SEQ ID NO: 119), (F30-lxPepper)io (FIG. 9B; SEQ ID NO: 120), (Pepper)₂₀ (FIG. 9C; SEQ ID NO: 121), and (F30-lxPepper)i₀ (FIG. 9D; SEQ ID NO: 122).

[0027] FIGS. 10A-10C demonstrate the optimization of the number of fluorescent mNeonGreen monomers in the fluorescent protein for imaging mRNA in live cells. In FIG. 8B, it was observed that (F30-2xPepper)i₀ is the optimal tag for imaging mRNAs in live cells. To further optimize the system of using Pepper RNA-regulated fluorogenic protein to image mRNAs, it was determined whether increasing the number of fluorescent mNeonGreen could increase the fluorescence signal to background noise ratio of the mobile green fluorescent puncta. In these experiments, an mCherry mRNA reporter tagged with (F30-2xPepper)i₀ and tandem fluorescent mNeonGreen with 2, 3, or 4 copies were transiently expressed, respectively, in cells. Here, an increase of fluorescence intensity of the green fluorescent puncta as the number of tandem mNeonGreen increased from 2, 3, to 4 copies, respectively (FIG. 10B) and (FIG. IOC) was observed. mRNAs tagged with (F30-lxPepper)i₀ using the (mNeonGreen)₄-tDeg fluorescent fusion protein were also re-tested. It was shown that puncta were detectable, but not as pronounced as when the (F30-2xPepper)i₀ tag was used. Thus, it was concluded that (mNeonGreen)₄- tDeg provides a high signal to noise ratio for imaging mRNAs. Scale bar, 20 pm. FIG. IOC is a graph showing the fluorescence intensity of green fluorescent puncta of individual cells is plotted (n = 3 independent cell cultures). Values are means ± s.d.

= 2.0 X 10⁹; * * * *p ₍F3o-2xPepper)io:(F30-i xPepper)i o = 5.6 x 10¹⁷ by one-way ANOVA.

[0028] FIGS. 11 A-l 1C demonstrate that Pepper tag enables visualization of both nuclear and cytosolic mRNAs. FIG. 11 A is a schematic representation of the DNA plasmid constructs used for imaging mRNAs in the nucleus and cytosol. To image nascent transcription of mRNA, cells coexpressing an mCherry mRNA reporter containing a 3’UTR green Pepper mRNA tag, (F30-2xPepper)i₀, and a green fluorescent fusion protein, (mNeonGreen) -tDeg were imaged (FIG. 1 IB). Cytosolic green fluorescent puncta reflecting mCherry mRNA transcripts and nuclear green fluorescent puncta, potentially reflecting mCherry mRNA transcripts were observed. Less green fluorescent puncta in the nucleus were observed as compared to the cytosol. This potentially reflects that most of the nuclear mCherry mRNA transcripts were exported out of the nucleus. Scale bar, 20 pm. FIG. 11C is a graph providing summary data of cytosolic and nuclear mRNA fluorescence intensity in FIG. 1 IB (n = 201 fluorescent puncta). Values are means ± s.d. This experiment was performed three times with similar results.

[0029] FIGS. 12A-12D demonstrate that Pepper tag and fluorescent fusion protein enable visualization of individual mRNAs. To examine whether the puncta observed when imaging Pepper-tagged mRNAs might be stable degradation intermediates, northern blot was performed on total RNA extracted from cells expressing (F30-2xPepper)i₀-tagged mCherry RNA transcripts with and without coexpressing the fluorescent fusion protein, (mNeonGreen)₄-tDeg. In these experiments, only full-length mRNA transcript was detected (FIG. 12A). Therefore, it was concluded that the fluorescent puncta in cells largely reflects the full-length transcript, and that degraded or liberated Pepper aptamers do not accumulate in cells. To assess whether the mobile green fluorescent puncta seen in cells expressing Pepper-tagged mRNA represent single mRNAs, a previously described mRNA imaging method in which the resulting puncta were validated to represent single mRNA was used (Yan et al., “Dynamics of Translation of Single mRNA Molecules In Vivo,” Cell 165:976-89 (2016), which is hereby incorporated by reference in its entirety). This system uses 24 PP7 RNA hairpins in the 3 'UTR of a reporter mRNA, and a 3xmCherry-C AAX protein fused to PCP (PP7 coat protein), the PP7-binding protein. The PCP-3xmCherry-CAAX fusion protein is anchored to the membrane via the CAAX sequence, which reduces puncta motility and facilitates quantitative fluorescence measurements. A PP7-containing reporter mRNA was imaged with and without the (F30-2xPepper)i₀ tag (FIG. 12B). The (mNeonGreen) - tDeg fluorescent fusion protein was used to image the Pepper-tagged mRNAs. If the Pepper tag or the green fluorescent fusion protein caused mRNA to aggregate, the Pepper-tagged reporter mRNA puncta would have been expected to have higher red fluorescence (from PCP-3xmCherry-CAAX) compared to the reporter mRNA puncta without the Pepper tag. The results of these experiments showed that the red fluorescence intensity distribution of the reporter mRNA is not significantly different with and without the Pepper tag (FIG. 12C) (Black bars, 19 cells, 485 mRNAs; Shaded bars, 13 cells, 384 mRNAs). This suggests that the Pepper tag and the green fluorescent fusion protein do not cause mRNA aggregation. Furthermore, colocalization between the green and magenta fluorescent puncta was observed only when the reporter mRNA contained the Pepper tag (FIG. 12D). These results suggest that the green fluorescent puncta observed using the Pepper tag and green fluorescent fusion protein are indeed individual mRNAs. Scale bar, 5 pm (left panel in FIG. 12D), 1 pm (right panel in FIG. 12D). In FIG. 12D, the experiment of reporter mRNA with Pepper was performed three times with similar results, the experiment of reporter mRNA without Pepper was performed twice with similar results.

[0030] FIGS. 13A-13E demonstrate that Pepper tag and fluorescent fusion protein do not have observable effects on mRNA turnover kinetics, mRNA translation efficiency, or proteasome activity in cells. To test whether adding the Pepper tag to an mRNA transcript affects its stability, reporter plasmids expressing mCherry transcripts with and without the (F30-2xPepper)i₀ tag were constructed. HEK293T cells were transfected with these two reporter plasmids, respectively. In each case, the same cells were cotransfected with the (mNeonGreen)₄-tDeg fluorescent fusion protein. The cells were treated with 5 pg/mL actinomycin D to inhibit new transcription. The amount of reporter mRNA transcripts remaining at each time point was quantified by RT-qPCR at t = 0, 1, 2, 4, and 6 hours of actinomycin D treatment. The results showed that fusing the Pepper tag to the reporter mRNA (half-life = 5.9 hours) does not significantly affect its turnover rate compared to its untagged counterpart (half-life = 6.0 hours) (FIG. 13 A). Thus, these data suggest that Pepper-tagged mRNA transcripts have similar turnover kinetics as mRNAs without the Pepper tag. Data were collected from 2 independent cell cultures. Values are means ± s.d. To test whether adding the Pepper tag to an mRNA transcript affects its protein translation efficiency, the protein translation efficiency of an mCherry mRNA was compared with and without the (F30-2xPepper)i₀ Pepper tag. HEK293T cells expressing mCherry mRNA or m( 7?cv7y-(F30-2x Pepper) i o mRNA were harvested. The amount of mCherry protein and mCherry mRNA was quantified by western blotting and RT-qPCR, respectively. A slight decrease of mRNA levels in the Pepper-tagged mCherry mRNA was observed compared to its untagged counterpart (FIG. 13C). The same phenomenon was also observed in the mCherry mRNA tagged with the 24xMS2 hairpins (Wu et al., “Synonymous Modification results in High-Fidelity Gene Expression of Repetitive Protein and Nucleotide Sequences,” Genes Dev. 29:876-86 (2015), which is hereby incorporated by reference in its entirety). This may due to the longer transcript length associate with 3’UTR-tagged mRNAs. Protein translation efficiency was calculated by normalizing the amount of mCherry protein to the amount of mCherry mRNA (FIGS. 13B-13D). No significant difference in protein translation efficiency was found between the untagged mCherry mRNA transcript and the Pepper- tagged mCherry mRNA transcript (FIG. 13D). These results suggest that Pepper tag does not significantly affect protein translation of these mRNA reporter transcripts. Data were collected from 2 independent cell cultures. Values are means ± s.d. Since the degradation mechanism of the fluorescent RNA-regulated fusion proteins described herein relies on ubiquitination and subsequent proteasomal degradation, expression of fluorescent RNA- regulated fusion proteins could lead to the overload of proteasome activity in cells. To test whether the expression of fluorescent RNA-regulated fusion proteins overloads proteasome activity, a RNA-regulated fluorescent fusion protein, (mNeonGreen) -tDeg was expressed in HEK293T cells. If the expression of (mNeonGreen)₄-tDeg overloads the activity of the proteasome, an accumulation of the ubiquitinated protein in cells would be expected. FIG. 13E shows western blotting results using an anti-ubiquitin antibody of untransfected cells and cells expressing (mNeonGreen) -tDeg. Significant difference in the ubiquitinated proteins were not observed. As a control, untransfected cells treated with a proteasome inhibitor (10 mM MG132) for 5 hours showed a significant increase of the ubiquitinated proteins (FIG. 13E). Thus, these results suggest that expression of fluorescent RNA-regulated fusion proteins does not overload proteasome activity in cells. Data shown here is a representative image from 2 independent cell cultures. [0031] FIGS. 14A-14D demonstrate that Pepper tag does not disrupt the localization of mRNAs. To determine whether the Pepper tag disrupts an mRNA’s proper cellular localization, an ER-targeting reporter mRNA was chosen, and its localization in cells was imaged using the (F30-2xPepper)i₀ Pepper tag and the (mNeonGreen)₄-tDeg fluorescent fusion protein (FIG. 14A). This ER-targeting reporter mRNA encodes the first 29 amino acids of cytochrome p450, CytERM, and the encoding sequence of mCherry followed by (F30-2xPepper)i₀ in the 3’UTR (FIG. 14A). During protein translation, the CytERM peptide will direct this reporter mRNA to the outer ER membrane, and confine the mRNA’s mobility. Indeed, green fluorescent puncta with low mobility were observed (FIGS. 14B, 14D), suggesting that the reporter mRNA is localized to the outer ER membrane. To further validate the localization of the ER- targeting reporter mRNA, the cells were treated with a translation inhibitor (100 pg/mL, puromycin) to liberate the reporter mRNA from the ER into the cytosol. A significant mobility increase of the green fluorescent puncta was observed (FIG. 14C, FIG. 14D), reflecting the dissociation of the reporter mRNA from the ER. Together, these results confirmed that the Pepper tag does not disrupt the localization of mRNAs. Scale bar in (FIG. 14B, FIG. 14C), 10 pm. Relative diffusion coefficient of mRNA puncta is plotted (n = 2 independent cell cultures). Values are means ± s.d. ****p = 2.7 x 10⁶ by unpaired two-tailed Student’s /-test.

[0032] FIGS. 15A-15C demonstrate the imaging of green Pepper-tagged b-actin mRNA in live cells. FIG. 15A shows DNA plasmid constructs used for imaging b-actin mRNA in live cells. To image b-actin mRNA localization in response to arsenite stress, a b-actin mRNA reporter containing a 3’UTR green Pepper mRNA tag, (F30-2xPepper)i₀ was constructed (FIG. 15B). Cells coexpressing this b-actin mRNA reporter and a green fluorescent RNA-regulated fusion protein, (mNeonGreen)₄-tDeg were imaged before and 45 minutes after arsenite (500 pM) treatment to induce stress granules. Individual mRNA transcripts were observed to rapidly accumulated to form stress granules as evidenced by coexpression of tetramethylrhodamine-labeled HaloTag-G3BPl to label stress granules. Scale bar, 20 pm. FIG. 15C shows the fluorescence ratio of foci/cytosol in untreated cells vs. arsenite treated cells is plotted (n = 3 independent cell cultures). Values are means ± s.d. ****p= 2.5 x 10³¹ by unpaired two-tailed Student’s /-test.

[0033] FIGS. 16A-16B demonstrate that (mNeonGreen)₄-tDeg without the

Pepper-tagged b-actin mRNA does not accumulate in stress granules upon arsenite treatment. In FIGS. 15A-15C, cytosolic green fluorescent puncta were shown to accumulate in stress granules to form foci upon application of 500 mM arsenite. However, the formation of green fluorescent foci in stress granules could be due to aggregation of the fluorescent RNA-regulated fusion protein, (mNeonGreen)₄-tDeg, regardless of the present of the b-actin mRNA. To test whether this is the case, (mNeonGreen)₄-tDeg was coexpressed with circular Pepper RNA in U20S cells (FIG. 16 A). Before arsenite treatment, cytosolic green fluorescent was observed without any puncta, which is consistent with the results in FIGS. 5A-5G. Upon application of 500 mIUΊ arsenite, green fluorescent foci formation was not observed (FIG. 15B). These results confirmed that the formation of green fluorescent foci in FIGS. 15A-15C were indeed due to the b-actin mRNA. This experiment was performed twice with similar results. Scale bar, 20 pm. [0034] FIGS. 17A-17B demonstrate imaging of mRNAs using Pepper RNA- regulated fluorescent fusion proteins with different hues. So far, mRNA imaging using the green Pepper RNA tag, comprising the Pepper aptamer and a Pepper-regulated fluorescent mNeonGreen fusion protein has been described herein. To further expand the color palette for mRNA imaging, (mVenus)₂-tDeg and (mCherry)₂-tDeg were expressed to generate yellow Pepper and red Pepper complexes on mRNA. In these experiments, (mVenus)₂-tDeg was used to image an mCherry mRNA reporter tagged with (F30-2xPepper)io (FIG. 17A), and (mCherry)₂-tDeg was used to image a b-actin mRNA reporter tagged with (F30-2xPepper)i₀ (FIG. 17B), respectively. In both cases, mobile fluorescent puncta were observed in cells. This experiment was performed twice with similar results. Scale bar, 20 pm.

[0035] FIGS. 18A-18D demonstrate the use of the tDeg-Pepper system to selectively biotinylate RNA-binding protein. tDeg was first shown to confer Pepper RNA-dependent regulation of a biotin ligase, TurboID, and a peroxidase, APEX2. HEK293T cells transiently expressed EGFP-TurboID-tDeg (FIG. 18A), and EGFP- APEX2-tDeg (FIG. 18B), with and without the Pepper RNA aptamer, respectively. In each case, proteins were nearly undetectable unless coexpressed with the Pepper RNA. FIG. 18C is a schematic showing that a selectively activated biotin ligase (TurboID-tDeg) specifically biotinylates an RNA-binding protein (CELF1) that bind to the RNA sequence of interest (EDEN15). FIG. 18 D shows that TurboID-tDeg enables selective biotinylation of CELF1, while minimizing nonspecific biotinylation of proteins that do not bind to the RNA of interest (EDEN 15).

[0036] FIG. 19 demonstrates that Tat-GG confers Pepper RNA-dependent

Regulation. In these experiments, U20S cells transiently expressed mNeonGreen-Tat-GG fusion protein with and without the circular Pepper RNA aptamer, respectively. mNeonGreen was nearly undetectable (left panels) unless coexpressed with circular Pepper RNA (right panels). All cells were stained with Hoechst dye. Scale bar, 20 pm. [0037] FIG. 20 demonstrate that HIV Tat-RRRG (SEQ ID NO: 127) confers HIV

TAR RNA-dependent regulation. In these experiments, cells transiently expressed YFP- HIV Tat-RRRG fusion protein with and without the circular HIV TAR RNA aptamer, respectively. YFP was nearly undedetable (top left panel) unless coexpressed with circular HIV TAR RNA aptamer (right panel). Bottom panels show brightfield microscopy of cells transfected with EYFP-HIV Tat-RRRG in the absence (left panel) or presence (right panel) of circular HIV TAR RNA (SEQ ID NO: 128).

DETAILED DESCRIPTION

[0038] A first aspect of the disclosure relates to a nucleic acid molecule encoding an RNA-regulated fusion protein. The nucleic acid molecule includes: a first nucleic acid sequence encoding a protein of interest and a second nucleic acid sequence encoding an RNA-regulated destabilization domain, where the second nucleic acid sequence is operably coupled to the first nucleic acid sequence.

[0039] The terms protein and polypeptide are generally used interchangeably and refer to a single polypeptide chain. It will be appreciated that such polypeptide chains may bind to other polypeptides or proteins, or other molecules such as cofactors. The terms protein and polypeptide also refer to variants, mutants, biologically active fragments, modifications, analogs and/or derivatives of the polypeptides described herein. The term fusion protein refers to a protein that is comprised of two or more amino acid sequences, from two or more proteins or polypeptide sequences that are not found linked in nature and that are physically linked by a peptide bond.

[0040] A protein of interest refers to a protein/ polypeptide that is desired and/or being assessed. In other words, a protein of interest may be any protein. In some embodiments, the protein of interest is a protein that is the subject of research. In some embodiments, the protein of interest is known to be involved in a disease state, and is specifically targeted in treatment of the disease state.

[0041] In some embodiments, the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcriptional regulator. [0042] In some embodiments, the protein of interest is a florescent protein. As used herein, the term “fluorescent protein” refers to a protein or polypeptide which fluoresces, or emits light, when excited with appropriate electromagnetic radiation.

[0043] Suitable fluorescent proteins include, without limitation, Green Fluorescent

Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato. Suitable fluorescent protein amino acid sequences are shown in Table 1 below.

Table 1. Exemplary Fluorescent Protein Amino Acid Sequences

[0044] In other embodiments, the protein of interest is a bioluminescent protein.

As used herein, the term “bioluminescent protein” refers to any protein capable of acting on a suitable substrate and producing luminescence. As used herein, the term “substrate” refers to any molecule capable of producing or absorbing luminescence with a bioluminescent protein. Suitable bioluminescent proteins include, without limitation, luciferase, b-galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b- glucuronidase, and b-glucosidase. Exemplary bioluminescent amino acid sequences are shown in Table 2 below. Table 2. Exemplary Bioluminescent Protein Amino Acid Sequences

[0045] The protein of interest may be an enzyme. In some embodiments, the enzyme is selected from the group consisting of a ligase and a methyltransferase.

[0046] As described herein, the term “ligase” refers to an enzyme that catalyzes the joining of two large molecules by forming a new chemical bond, usually with accompanying hydrolysis of a small pendant chemical group on one of the larger molecules or the enzyme catalyzing the linking together of two compounds. Suitable ligases include, without limitation, DNA ligases, RNA ligases, amino acid-tRNA ligases ( e.g ., tyrosine-tRNA ligase, tryptophan-tRNA ligase, threonine-tRNA ligase, leucine- tRNA ligase, isoleucine-tRNA ligase, lysine-tRNA ligase, alanine-tRNA ligase, valine- tRNA ligase, methionine-tRNA ligase, serine-tRNA ligase, aspartate-tRNA ligase, D- alanine-tRNA ligase, glycine-tRNA ligase, proline-tRNA ligase, cysteine-tRNA ligase, glutamate-tRNA ligase, glutamine-tRNA ligase, arginine-tRNA ligase, phenylalanine- tRNA ligase, histidine-tRNA ligase, asparagine-tRNA ligase, aspartate-tRNA ligase, glutamate-tRNA ligase), acetate-CoA ligase, succinate-CoA ligase, biotin-CoA ligase ( i.e ., biotin ligase), carboxylic acid-CoA ligase, acetate-CoA ligase, and aspartate- ammonia ligase (see, e.g., McDonald, Andrew, “The Enzyme List Class 6 - Ligases,” ExplorEnz Database (2019), which is hereby incorporated by reference in its entirety). [0047] In some embodiments, the ligase is a biotin ligase. As described herein, biotin ligases catalyze the formation of biotin-5 '-AMP anhydride, which diffuses out of the active site to biotinylate proximal endogenous proteins on nucleophilic residues such as lysine. In some embodiments, the biotin ligase is selected from TurboID, miniTurbo, and E. coli BirA (see, e.g., Branon et al., “Efficient Proximity Labeling in Living Cells and Organisms with TurboID,” Nat. Biotechnol. 36(9):880-887 (2018), which is hereby incorporated by reference in its entirety).

[0048] The methyltransferase may be a histone methyltransferase, an N-terminal methyltransferase, a DNA/RNA methyltransferase, a natural product methyltransferase, a non-SAM dependent methyltransferase, or a radical SAM methyltransferase. As described herein, histone methyl transferases catalyze the transfer of one, two, or three methyl groups to lysine and arginine residues of histone proteins. In some embodiments, the histone methyltransferase is a histone-lysine N-methyltransferase selected from the group consisting of enhancer of zeste homolog 1 (EZH1), enhancer of zeste homolog 2 (EZH2), disruptor of telomeric silencing 1-like (DOTl-like), ASH1L, euchromatic histone-lysine N-methyltransferase 1 (EHMT1), euchromatic histone-lysine N- methyltransferase 2 (EHMT2), histone-lysine N-methyltransferase 2A, histone-lysine N- methyltransferase 2D (KMT2D), lysine N-methyltransferase 2C (KMT2C), myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4), lysine methyltransferase 2E, and nuclear receptor binding SET domain protein 1 (NSD1). In other embodiments, the histone methyltransferase is a histone-arginine N-methyltransferases selected from the group consisting of protein arginine N-methyltransferase 1, protein arginine N- methyltransferase 3, protein arginine N-methyltransferase 4, protein arginine N- methyltransferase 5, and protein arginine N-methyltransferase 7.

[0049] Non-limiting examples of suitable enzymes are identified in Table 3 below. Table 3. Exemplary Enzyme Amino Acid Sequences

[0050] Additional suitable proteins of interest include, but are not limited to, a G- protein coupled receptor (GPCR), a nuclear receptor, a voltage gated ion channel, a ligand gated channel, a receptor tyrosine kinase, a growth factor, a phosphatase, a protein kinase, a viral regulator, a bacterial cell division protein, a scaffold protein, a DNA repair protein, a cytoskeletal protein, a ribosome, a histone deacetylase, an apoptosis regulator, a chaperone protein, a kinase, a phosphorylase, a phosphatase, deacetylase, a cytoskeletal protein (e.g., myosin, actin, dynein, kinesin, and tubulin).

[0051] As described herein, a G-protein coupled receptor (GPCR) refers to a membrane protein which binds to a signaling molecule. Upon binding, a conformational change occurs, which allows binding of the GPCR to, and activation of, a G-protein. The activated G-protein then interacts with an effector molecule, which is typically involved in a second messenger pathway. Suitable G-protein coupled receptors may be selected from the group consisting of a luteinizing hormone receptor, a follicle stimulating hormone receptor, a thyroid stimulating hormone receptor, a calcitonin receptor, a glucagon receptor, a glucagon-like peptide 1 receptor (GLP-1), a metabotropic glutamate receptor, a parathyroid hormone receptor, a vasoactive intestinal peptide receptor, a secretin receptor, a growth hormone releasing factor (GRF) receptor, protease-activated receptors (PARs), cholecystokinin receptors, somatostatin receptors, melanocortin receptors, nucleotide receptors ( e.g ., ADP receptors), adenosine receptors, thromboxane receptors, platelet activating factor receptor, adrenergic receptors, 5-hydroxytryptamine (5-HT) receptors, a chemokine receptor (e.g., CXCR4, CCR5), chemokine receptors, neuropeptide receptors, opioid receptors, erythropoietin receptor, von Willebrand receptor, parathyroid hormone (PTH) receptor, vasoactive intestinal peptide (VIP) receptor, and collagen receptors. Exemplary protease-activated receptors include, without limtiation, PARI, PAR2, PAR3, or PAR4 receptors.

[0052] In some embodiments, the protein of interest is a transcription factor.

Transcription factors include proteins that are involved in gene regulation in prokaryotic and/or eukaryotic organisms. In one embodiment, transcription factors have a positive effect on gene expression and, thus, may be referred to as an activator or a transcriptional activation factor. In another embodiment, a transcription factor negatively regulates gene expression and, thus, may be referred to as a repressor or a transcription repression factor. Suitable transcription factors include, without limitation, c-Myc, c-Fos, c-Jun, CREB, GATA-2, GAL4, GAL4Npl6, c-Myb, MyoD, and NFKB, and tetR. Exemplary transcription factors are identified in Table 4 below.

Table 4. Exemplary Transcription Factor Amino Acid Sequences

[0053] Additional exemplary transcription factors are identified in Table 5 below.

Table 5. Additional Exemplary Transcription Factors

[0054] RNA-regulated destabilization domains are amino acid sequences that, when functionally coupled to a protein of interest, modulate the stability of the protein of interest in a RNA-dependent manner. In some embodiments, when the RNA-regulated destabilization domain is fused to a protein of interest, the RNA-regulated destabilization domain mediates protein degradation. In accordance with such embodiments, the protein destabilization function of the RNA-regulated destabilization domain is impeded when it binds to a specific RNA molecule ( e.g ., an aptamer).

[0055] In some embodiments, the RNA-regulated destabilization domain comprises a bifunctional peptide comprising an RNA-binding domain and a degron peptide. The RNA-binding domain may be any peptide to which an RNA molecule can bind, where such binding sterically inhibits the interaction of the degron peptide with a proteosomal pathway component ( e.g ., an E3 ubiquitin ligase). Thus, in some embodiments, the RNA-binding domain is MDARTRRRERRAEKQAQWKAAN (lambdaN; SEQ ID NO: 123), which is derived from the lambda bacteriophage antiterminator protein N. In accordance with such embodiments, the RNA-binding domain is specific for BoxB (SEQ ID NO: 124): GGGCCCUGAAGAAGGGCCC (see, e.g., “NMR Structure of the Bacteriophage Lambda N Peptide/boxB RNA Complex: Recognition of a GNRA Fold by an Arginine-Rich Motif,” Cell 93(2):289-299 (1998), which is hereby incorporated by reference in its entirety).

[0056] In other embodiments, the RNA-binding domain is

DTRQARRNRRRRWRERQRAAAAR (HIV-1 Rev; SEQ ID NO: 125), which is derived from HIV-1 Rev peptide. In accordance with such embodiments, the RNA-binding domain is specific for RRE RNA (SEQ ID NO: 126):

GGUCUGGGCGCAGCGCAAGCUGCGGACAGGCC (see, e.g. , Battiste et al., “Alpha Helix-RNA Major Groove Recognition in an HIV-1 Rev Peptide-RRE RNA Complex,” Science 273:1547-1551 (1996), which is hereby incorporated by reference in its entirety). [0057] The RNA-regulated destabilization domain may comprise a bifunctional peptide comprising a lentiviral transactivator of transcription (Tat) peptide and a degron peptide.

[0058] In some embodiments, the lentiviral Tat peptide is a bovine immunodeficiency virus Tat peptide. In other embodiments, the lentiviral Tat peptide is a human immunodeficiency virus Tat peptide.

[0059] According to some embodiments, the Tat peptide has the sequence of

RKKRRQRRR (SEQ ID NO: 129). See, e.g, Yamamoto et al., “A Novel RNA Motif that Binds Efficiently and Specifically to the Ttat Protein of HIV and Inhibits the Trans- Activation by Tat of Transcription In Vitro and In Vivo,” Genes Cells 5:371-388 (2000), which is hereby incorporated by reference in its entirety.

[0060] According to some embodiments, the Tat peptide has the consensus sequence of SEQ ID NO: 54 as follows: XXXXXXXXXXXXXXXX, where X at position 1 can be S or A; X at position 2 can be G or A; X at position 3 can be P or A; X at position 4 can be R or K; X at position 5 can be P, A, I, Y, K, or R; X at position 6 can be R, K, V, or Y; X at position 7 can be G, A, or R; X at position 8 can be T or A; X at position 9 can be R or K; X at position 10 can be G or A; X at position 11 can be K or A; X at position 12 can be G or A; X at position 13 can be R or K; X at position 14 can be I or A; X at position 15 can be R, K, Y, or G; and X at position 16 can be R, K, V, T, or Y. See, e.g., Athanassiou et al., “Structural Mimicry of Retroviral Tat Proteins by Constrained b-Hairpin Peptidomimetics: Ligands with High Affinity and Selectivity for Viral TAR RNA Regulatory Elements,” J. Am. Chem. Soc. 126:6906-6913 (2004); Chen & Frankel, “A Peptide Interaction in the Major Groove of RNA Resembles Protein Interactions in the Minor Groove of DNA,” Proc. Natl. Acad. Sci. USA 92:5077-5081 (1995); and Koren et al., “The Eukaryotic Proteome is Shaped by E3 Ubiquitin Ligases Targeting C-Terminal Degrons,” Cell 173:1622-1635 (2018), which are hereby incorporated by reference in their entirety). For example, the Tat peptide may have the amino acid sequence of SEQ ID NO: 55 as follows: SGPRPRGTRGKGRIRR.

[0061] In some embodiments, the lentiviral Tat peptide comprises an RNA binding site. The RNA binding site may correspond to amino acid residues 4-17 of SEQ ID NO: 54 or amino acid residues 4-17 of SEQ ID NO: 55.

[0062] In some embodiments, the RNA binding site is specific for an RNA aptamer. An aptamers is a nucleic acid molecule that binds with high affinity and specificity to a target. Nucleic acid aptamers may be single-stranded, partially single- stranded, partially double-stranded, or double-stranded nucleotide sequences. Aptamers include, without limitation, defined sequence segments and sequences comprising nucleotides (e.g, ribonucleotides, nucleotide analogs, modified nucleotides, and nucleotides comprising backbone modifications, branchpoints, and non-nucleotide residues, groups, or bridges). Nucleic acid aptamers include partially and fully single- stranded and double-stranded nucleotide molecules and sequences; synthetic RNA, DNA, and chimeric nucleotides; hybrids; duplexes; heteroduplexes; and any ribonucleotide, deoxyribonucleotide, or chimeric counterpart thereof and/or corresponding complementary sequence, promoter, or primer-annealing sequence needed to amplify, transcribe, or replicate all or part of the aptamer molecule or sequence.

[0063] As described herein, the RNA binding site is specific for an RNA aptamer having the consensus sequence of SEQ ID NO: 56 as follows:

NNNNN SHS YW SBMNNNND SBHB SNNNNN, where N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. Thus, in some embodiments, the RNA aptamer has the sequence of wild-type TAR RNA (SEQ ID NO: 57) as follows: GGCUCGUGUAGCUC AUUAGCUCCGAGCC .

[0064] According to some embodiments, the RNA binding site is specific for an

RNA aptamer having the consensus sequence of SEQ ID NO: 58 as follows: NNNNN SHC Y S W SBMNNNND SBHB SNNNNN, where N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. Thus, in some embodiments, the RNA aptamer has the sequence of TAR Variant-1 (SEQ ID NO: 59) as follows: GGCUCGUCUGAGCUCAUUAGCUCCGAGCC.

[0065] In other embodiments, the RNA binding site is specific for an RNA aptamer having the consensus sequence of SEQ ID NO: 60 as follows:

NNNNN SHY S W SBMNNNND SBHB SNNNNN, where N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. Thus, in some embodiments, the RNA aptamer has the sequence of TAR Variant-2 (Pepper; SEQ ID NO: 61) as follows: GGCUCGUUGAGCUC AUUAGCUCCGAGCC .

[0066] In further embodiments, the RNA binding site is specific for an RNA aptamer having the sequence of HIV TAR (SEQ ID NO: 128) as follows: ACGAAGCUUGAUCCCGUUUGCCGGUCGAUCGCUUCGA.

[0067] As used herein, the term “degron” or “degradation signal” or “degron peptide” refers to an amino acid element within a protein that is sufficient for recognition and degradation by a proteolytic system. In some embodiments, the degron is a ubiquitin- pathway degron. In accordance with such embodiments, the degron comprises a region specific for E3 binding (see, e.g., Ravid & Hochstrasser, “Diversity of Degradation Signals in the Ubiquitin-Proteasome System,” Nat. Rev. Mol. Cell Biol. 9:679-689 (2008), which is hereby incorporated by reference in its entirety).

[0068] The degron peptide may be selected from a monopeptide, a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, or an octapeptide. Exemplary degron peptides are well known in the art and are listed in Table 6 below.

Table 6. Exemplary Degron Peptides [0069] In some embodiments, the degron peptide is SEQ ID NO: 130 as follows:

RRRG. In accordance with such embodiments, the destabilization domain has the sequence of HIV Tat-RRRG (SEQ ID NO: 127) as follows: RKKRRQRRRG.

[0070] In other embodiments, the degron peptide is selected from the group consisting of FKBP12, dihydrofolate reductase, and derivates thereof. See, e.g. , Rakhit et al., “Evaluation of FKBP and DHFR Based Destabilizing Domains in Saccharomyces Cerevisiae,” Bioorg. Med. Chem. Lett. 21:4965-4968 (2011) and Iwamoto et al., “A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System,” Chem. Biol. 17:981-988 (2010), which are hereby incorporated by reference in their entirety). In some embodiments, the FKBP12 is a human FKBP12. In some embodiments, the dihydrofolate reductase is an E. coli dehydrate reductase (ecDHFR). As described herein, aptamers that selectively bind to FKBP 12, DHFR, or derivatives thereof may be used to confer stability to a protein of interest comprising FKBP 12, ecDHFR, or a derivative thereof as a fusion partner.

[0071] In some embodiments, the destabilization domain has the consensus sequence of SEQ ID NO: 62 as follows: XXXXXXXXXXXXXXXXXx, where X at position 1 can be S or A; X at position 2 can be G or A; X at position 3 can be P or A; X at position 4 can be R or K; X at position 5 can be P, A, I, Y, K, or R; X at position 6 can be R, K, V, or Y; X at position 7 can be G, A, or R; X at position 8 can be T or A; X at position 9 can be R or K; X at position 10 can be G or A; X at position 11 can be K or A; X at position 12 can be G or A; X at position 13 can be R or K; X at position 14 can be I or A; X at position 15 can be R, K, Y, or G; X at position 16 can be R, K, V, T, or Y; X at position 17 can be any amino acid but preferably R, G, E, S, or C; and x at position 18 is optional and can be any amino acid, but preferably G, E, O, N, D, or E.

[0072] In some embodiments the destabilization domain has the sequence of tDeg

(SEQ ID NO: 63) as follows: S GPRPRGTRGKGRRIRRRG.

[0073] The nucleic acid molecule described herein may further comprise a third nucleic acid sequence encoding a second protein of interest, wherein the third nucleic acid sequence is located between the first nucleic acid sequence and second nucleic acid sequence. Suitable proteins of interest are described in more detail above and include, without limitation, a fluorescent protein, a bioluminescent protein, an enzyme, or a transcriptional regulator.

[0074] Another aspect of the invention relates to a nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) RNA aptamer sequence. [0075] In some embodiments, the lentiviral transactivator of transcription (Tar)

RNA aptamer sequence is a bovine immunodeficiency virus (BIV) Tar sequence. In other embodiments, the lentiviral transactivator of transcription (Tar) RNA sequence is a human immunodeficiency virus (HIV) Tar sequence.

[0076] According to some embodiments, the nucleic acid molecule encoding the lentiviral Tar RNA sequence is a DNA molecule according to the consensus sequence of SEQ ID NO: 64 as follows: NNNNN SHS YW SBMNNNND SBHB SNNNNN, where N can be A, C, G, or T; S can be C or G; H can be A, C, or T; Y can be C or T; W can be A or T; B can be C, G, or T; M can be A or C; and D can be A, G, or T. For example, the nucleic acid molecule encoding the lentiviral Tar RNA sequence may be a DNA molecule encoding wild-type TAR RNA as follows: GCTCGTGTAGCTCATTAGCTCCGAGCC (SEQ ID NO: 65).

[0077] According to some embodiments, the nucleic acid molecule encoding the lentiviral TAR RNA sequence is a DNA molecule according to the consensus sequence of SEQ ID NO: 66 as follows: NNNNNSHCYSWSBMNNNND SBHB SNNNNN, where N can be A, C, G, or T; S can be C or G; H can be A, C, or T; Y can be C or T; W can be A or T; B can be C, G, or T; M can be A or C; and D can be A, G, or T. For example, the nucleic acid molecule encoding the lentiviral Tar RNA sequence may be a DNA molecule encoding TAR Variant-1 as follows: GGCTCGTCTGAGCTCATTAGCTCCGAGCC (SEQ ID NO: 67).

[0078] According to some embodiments, the nucleic acid molecule encoding the lentiviral TAR RNA sequence is a DNA molecule according to the consensus sequence of SEQ ID NO: 68 as follows: NNNNNSHYSWSBMNNNND SBHB SNNNNN, where N can be A, C, G, or T; S can be C or G; H can be A, C, or T; Y can be C or T; W can be A or T; B can be C, G, or T; M can be A or C; and D can be A, G, or T. For example, the nucleic acid molecule encoding the lentiviral Tar RNA sequence may be a DNA molecule encoding TAR Variant-2 (Pepper) as follows: GGCTCGTTGAGCTCATTAGCTCCGAGCC (SEQ ID NO: 69).

[0079] Suitable additional lentiviral transactivator of transcription (Tar) RNA aptamer sequences of the present application are shown in Table 7 below. Table 7. TAR RNA Sequences

[0080] In some embodiments, the nucleic acid molecule further encodes at least one additional RNA aptamer. Thus, in some embodiments, the nucleic acid molecule may encode a lentiviral transactivator of transcirtion (Tar) RNA aptamer operably coupled to at least one additional RNA aptamer. The at least one additional aptamer may be a S- adenosylmethionine (SAM)-binding aptamer. For example, the nucleic acid moleule may encodesa SAM-binding aptamer operably linked to the lentiviral transactivator of transcription (Tar) RNA aptamer. As described herein, binding of SAM to its aptamer promotes folding of other linked aptamers, such as Pepper. In this way, the expressed RNA is a “sensor” which couples SAM levels to Pepper folding.

[0081] Also contemplated are nucleic acid molecules encoding a protein-binding

RNA sequence. Thus, in some embodiments, the nucleic acid molecule encodes a non- lentiviral transactivator of transcription (Tar) RNA sequence. In accordance with such embodiments, the protein-binding RNA sequence is BoxB or RRE.

[0082] Some embodiments of the present application relate to a vector comprising a nucleic acid molecule described herein (z.e., a nucleic acid molecule encoding an RNA- regulated fusion protein and/or a lentiviral transactivator of transcription (Tar) RNA sequence). As used herein, the term vector means any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc., which is capable of replication when associated with the proper control elements and which is capable of transferring gene sequences between cells. Thus, the term includes cloning and expression vectors, as well as viral vectors. The heterologous nucleic acid molecule is inserted into the expression system or vector in proper sense (5' to 3') orientation and correct reading frame. The vector contains the necessary elements for the transcription and/or translation of the inserted protein and/or RNA coding sequences of the present application.

[0083] In one embodiment, the vector is a plasmid. Numerous vectors suitable for use in the compositions of the present application are known to those of skill in the art, and many are commercially available. The following vectors are provided by way of example; for eukaryotic cells: pcDNA3.1(+), Tornado (Litke & Jaffrey, “Highly Efficient Expression of Circular RNA Aptamers in Cells Using Autocatalytic Transcripts,” Nat. Biotechnol. 37(6):667-675(2019), which is hereby incorporated by reference in its entirety), pXTl, pSG5 (Stratagene), pSVK3, pBPV, pMSG, and pSVLSV40 (Pharmacia). However, any other vector may be used so long as it is compatible with the cell.

[0084] In another embodiment, the vector is a viral vector. Suitable viral expression vectors include, but are not limited to, viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., PCT Patent Application Publication Nos. WO 94/12649 to Gregory et ah, WO 93/03769 to Crystal et ah, WO 93/19191 to Haddada et ah, WO 94/28938 to Wilson et ah, WO 95/11984 to Gregory, and WO 95/00655 to Graham, which are hereby incorporated by reference in their entirety); adeno-associated virus (see, e.g., Flannery et ah, “Efficient Photoreceptor-Targeted Gene Expression In Vivo by Recombinant Adeno- Associated Virus,” PNAS 94:6916-6921 (1997); Bennett et ah, “Real-Time, Noninvasive In Vivo Assessment of Adeno-Associated Virus-Mediated Retinal Transduction,” Invest. Opthalmol. Vis. Sci. 38:2857-2863 (1997); Jomary et ah, “Nonviral Ocular Gene Transfer,” Gene Ther. 4:683-690 (1997); Rolling et ah, “Evaluation of Adeno- Associated Virus-Mediated Gene Transfer into the Rat Retina by Clinical Fluorescence Photography,” Hum. Gene. Ther. 10:641-648 (1999); Ali et ak, “Gene Transfer Into the Mouse Retina Mediated by an Adeno-Associated Viral Vector,” Hum. Mol. Genet. 5:591-594 (1996); Samulski et ak, “Helper-Free Stocks of Recombinant Adeno- Associated Viruses: Normal Integration Does not Require Viral Gene Expression,” J Vir. 63:3822-3828 (1989); Mendelson et ak, “Expression and Rescue of a Nonselected Marker from an Integrated AAV Vector,” Virol. 166: 154-165 (1988); and Flotte et ak, “Stable In Vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator With an Adeno-Associated Virus Vector,” PNAS 90:10613-10617 (1993), which are hereby incorporated by reference in their entirety); SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshi et ak, “Stable and Efficient Gene Transfer into the Retina Using an HIV-Based Lentiviral Vector,” PNAS 94:10319-10323 (1997), which is hereby incorporated by reference in its entirety); a retroviral vector, e.g, Murine Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus and the like. [0085] As described herein supra , the nucleic acid molecules encoding a protein of interest described herein may be inserted into a vector in the sense ( i.e., 5' to 3') direction, such that the nucleic acid sequence encoding an RNA-regulated fusion protein is properly oriented for the expression of the encoded protein under the control of a promoter of choice. In some embodiments, the nucleic acid molecules encoding a RNA aptamer are inserted into the vector in the sense direction, such that the nucleic acid molecule encoding the RNA aptamer is properly oriented for the expression of a desired RNA aptamer. Single or multiple nucleic acid molecules may be ligated into an appropriate vector in this way, under the control of a suitable promoter, to prepare a nucleic acid construct. A promoter is a DNA sequence which contains the binding site for RNA polymerase and initiates transcription of a downstream nucleic acid sequence. In one embodiment, the vector comprises a promoter. Thus, in some embodiments, the vector comprises a nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) aptamer ( e.g ., Pepper) operably coupled to a promoter. In other embodiments, the vector comprises a nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) aptamer (e.g., Pepper) and at least one additional aptamer sequence (e.g, a S-adenosylmethionine (SAM)-binding aptamer) operably coupled to a promoter.

[0086] The promoter may be a constitutively active promoter (i.e., a promoter that is constitutively in an active or “on” state), an inducible promoter (i.e., a promoter whose state, active or inactive state, is controlled by an external stimulus, e.g, the presence of a particular temperature, compound, or protein.), a spatially restricted promoter (i.e., transcriptional control element, enhancer, etc.) (e.g, tissue specific promoter, cell type specific promoter, etc.), or a temporally restricted promoter (i.e., the promoter is in the “on” state or “off’ state during specific stages of a biological process).

[0087] Suitable promoters can be derived from viruses and can therefore be referred to as viral promoters, or they can be derived from any organism, including prokaryotic or eukaryotic organisms. Suitable promoters can be used to drive expression by any RNA polymerase (e.g., RNA Polymerase I, RNA Polymerase II, RNA Polymerase III). The promoter may be a viral promoter. Exemplary promoters include, but are not limited to the SV40 early promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), a rous sarcoma virus (RSV) promoter, a human U6 small nuclear promoter (U6) (Miyagishi et al., “U6 Promoter-Driven siRNAs with Four Uridine 3' Overhangs Efficiently Suppress Targeted Gene Expression in Mammalian Cells,” Nat. Biotechnol. 20:497-500 (2002), which is hereby incorporated by reference in its entirety), an enhanced U6 promoter (e.g, Xia et al., “An Enhanced U6 Promoter for Synthesis of Short Hairpin RNA,” Nucleic Acids Res . 31(17):el00 (2003), which is hereby incorporated by reference in its entirety), a human HI promoter (“HI”), and the like. In some embodiments the promoter is a phage promoter, e.g., a T7 promoter that has been engineered to be expressed in a mammalian cell.

[0088] Examples of inducible promoters include, but are not limited toT7 RNA polymerase promoter, T3 RNA polymerase promoter, isopropyl-beta-D- thiogalactopyranoside (IPTG)-regulated promoter, lactose induced promoter, heat shock promoter, tetracycline-regulated promoter, steroid-regulated promoter, metal-regulated promoter, estrogen receptor-regulated promoter, etc. Inducible promoters can therefore be regulated by molecules including, but not limited to, doxycycline, RNA polymerase, e.g, T7 RNA polymerase, an estrogen receptor, an estrogen receptor fusion, etc.

[0089] In some embodiments, the promoter is a eukaryotic RNA polymerase promoter or a derivative thereof. Exemplary RNA polymerase II promoters include, without limitation, cytomegalovirus (“CMV”), phosphoglycerate kinase- 1 (“PGK-1”), and elongation factor la (“EFla”) promoters. In yet another embodiment, the promoter is a eukaryotic RNA polymerase III promoter selected from the group consisting of U6, HI,

56, 7SK, and derivatives thereof.

[0090] The RNA Polymerase promoter may be mammalian. Suitable mammalian promoters include, without limitation, human, murine, bovine, canine, feline, ovine, porcine, ursine, and simian promoters. In one embodiment, the RNA polymerase promoter sequence is a human promoter.

[0091] According to one embodiment, the vector is a plasmid and has the sequence of pCMV-mCherry-(F30-2xPepper)i₀ (SEQ ID NO: 74; GenBank Accession No. MN052904.1, which is hereby incorporated by reference) as follows:

1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA

301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT

401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT

451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC

501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA

551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA

601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA

651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA

701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA

751 ACAACTCCGC CCCCATTGAC GCAAATGGGC GGTAGGCGTG TACGGTGGGA

801 GGTCTATATA AGCAGAGCTC TCTGGCTAAC T AG AG AAC C C ACTGCTTACT

851 GGCTTATCGA AATTAATACG AC TC AC TATA GGGAGACCCA AGCTGGCTAG

901 CGTTTAAACT TAAGCTTGCC ACCATGGTGA GCAAGGGCGA GGAGGATAAC

951 ATGGCCATCA TCAAGGAGTT CATGCGCTTC AAGGTGCACA TGGAGGGCTC

1001 CGTGAACGGC CACGAGTTCG AGATCGAGGG CGAGGGCGAG GGCCGCCCCT

1051 ACGAGGGCAC CCAGACCGCC AAGCTGAAGG TGACCAAGGG TGGCCCCCTG

1101 CCCTTCGCCT GGGACATCCT GTCCCCTCAG TTCATGTACG GCTCCAAGGC

1151 CTACGTGAAG CACCCCGCCG ACATCCCCGA CTACTTGAAG CTGTCCTTCC

1201 CCGAGGGCTT CAAGTGGGAG CGCGTGATGA ACTTCGAGGA CGGCGGCGTG

1251 GTGACCGTGA CCCAGGACTC CTCCCTGCAG GACGGCGAGT TCATCTACAA

1301 GGTGAAGCTG CGCGGCACCA ACTTCCCCTC CGACGGCCCC GTAATGCAGA

1351 AGAAGACCAT GGGCTGGGAG GCCTCCTCCG AGCGGATGTA CCCCGAGGAC

1401 GGCGCCCTGA AGGGCGAGAT CAAGCAGAGG CTGAAGCTGA AGGACGGCGG

1451 CCACTACGAC GCTGAGGTCA AGACCACCTA CAAGGCCAAG AAGCCCGTGC

1501 AGCTGCCCGG CGCCTACAAC GT C AAC AT C A AGTTGGACAT CACCTCCCAC

1551 AAC GAG G AC T ACACCATCGT GGAACAGTAC GAACGCGCCG AGGGCCGCCA

1601 CTCCACCGGC GGCATGGACG AGCTGTACAA GTAACTCGAG ATCCGTTACG

1651 GCCGGAATCA ATCGCTAATC ACTCAACTTG CCATGTGTAT GTGGGAAGCG

1701 TAGAAAGGCT CGTTGAGCTC ATTAGCTCCG AGCCCGACTA CGTTTCCCAC

1751 ATACTCTGAT GATCCGCTAG CAAAGGCTCG TCTGAGCTCA TTAGCTCCGA

1801 GCCCGAGGTA CCGGATCATT CATGGCAAGT CCAGCGCAAT CTATTACGAA

1851 AATCATCCGA CGTCGCGATG TCTATGCGGG AAGCGTAGAA AGGCTCGTCT

1901 GAGCTCATTA GCTCCGAGCC CGACTACGTT TCCCGCATAG TCTGATCATC

1951 CGCTAGCAAA GGCTCGTTGA GCTCATTAGC TCCGAGCCCG AGGTACCGGA

2001 TGATTCATCG CGACGCTGCG GAAAATCTCA CAAAATCACG TCAAACGTCG

2051 CCGTGTGTGT GTAGGAAGCG TAGAAAGGCT CGTCTGAGCT CATTAGCTCC

2101 GAGCCCGACT ACGTTTCCTA CACACTCTGA CGATCCGCTA GCAAAGGCTC

2151 GTTGAGCTCA TTAGCTCCGA GCCCGAGGTA CCGGATCGTT CACGGCGACG

2201 CCGATAATCC ACAT ACT T AC AATCAGGCAA TCTTGCCATG TGTATGTGGG 2251 AAGCGTAGAA AGGCTCGTTG AGCTCATTAG CTCCGAGCCC GACTACGTTT

2301 CCCACATACT CTGATGATCC GCTAGCAAAG GCTCGTTGAG CTCATTAGCT

2351 CCGAGCCCGA GGTACCGGAT CATTCATGGC AAGTATCAAG ATCGAACGGC

2401 GCAAGATATT GTCACGTCGC GATGTCTATG CGGGAAGCGT AGAAAGGCTC

2451 GTTGAGCTCA TTAGCTCCGA GCCCGACTAC GTTTCCCGCA TAGTCTGATC

2501 ATCCGCTAGC AAAGGCTCGT CTGAGCTCAT TAGCTCCGAG CCCGAGGTAC

2551 CGGATGATTC ATCGCGACGT CCTCGCTAGA TATGTTAGGT TCTTAGGCAT

2601 TTCGCCGTGT GTGTGTAGGA AGCGTAGAAA GGCTCGTTGA GCTCATTAGC

2651 TCCGAGCCCG ACTACGTTTC CTACACACTC TGACGATCCG CTAGCAAAGG

2701 CTCGTCTGAG CTCATTAGCT CCGAGCCCGA GGTACCGGAT CGTTCACGGC

2751 GAAAAGATCG TCTGCAATTC CGATTAGACG TACACTTGCC ATGTGTATGT

2801 GGGAAGCGTA GAAAGGCTCG TCTGAGCTCA TTAGCTCCGA GCCCGACTAC

2851 GTTTCCCACA TACTCTGATG ATCCGCTAGC AAAGGCTCGT TGAGCTCATT

2901 AGCTCCGAGC CCGAGGTACC GGATCATTCA TGGCAAGATC CAAGCTACTT

2951 CCTCCATACC TATCCTCCTC GCGATGTCTA TGCGGGAAGC GTAGAAAGGC

3001 TCGTCTGAGC TCATTAGCTC CGAGCCCGAC TACGTTTCCC GCATAGTCTG

3051 ATCATCCGCT AGCAAAGGCT CGTTGAGCTC ATTAGCTCCG AGCCCGAGGT

3101 ACCGGATGAT TCATCGCGAG ATCATAACGC AATACCGTAC ACTGTCCAAT

3151 CCTCGCCGTG TGTGTGTAGG AAGCGTAGAA AGGCTCGTCT GAGCTCATTA

3201 GCTCCGAGCC CGACTACGTT TCCTACACAC TCTGACGATC CGCTAGCAAA

3251 GGCTCGTTGA GCTCATTAGC TCCGAGCCCG AGGTACCGGA TCGTTCACGG

3301 CGAGGATAAT CAATCCACAT AC AT CACACC ACAATTCTTG CCATGTGTAT

3351 GTGGGAAGCG TAGAAAGGCT CGTCTGAGCT CATTAGCTCC GAGCCCGACT

3401 ACGTTTCCCA CATACTCTGA TGATCCGCTA GCAAAGGCTC GTCTGAGCTC

3451 ATTAGCTCCG AGCCCGAGGT ACCGGATCAT TCATGGCAAG AATTGGTCGT

3501 TCTTCTTGGC GGCCGCTCGA CTAAATCACC GGTAATCTTC TTGTCCATCT

3551 AGACCTTATA AAGATCTTTG TACAAGGGCC CGTTTAAACC CGCTGATCAG

3601 CCTCGACTGT GCCTTCTAGT TGCCAGCCAT CTGTTGTTTG CCCCTCCCCC

3651 GTGCCTTCCT TGACCCTGGA AAGGTGCCAC TCCCACTGTC CTTTCCTAAT

3701 AAAAT GAG G A AATTGCATCG CATTGTCTGA GTAGGTGTCA TTCTATTCTG

3751 GGGGGTGGGG GTGGGGGCAG GACAGCAAGG GGGAGGATTG GGAAGACAAT

3801 AGCAGGCATG CTGGGGATGC GGTGGGCTCT ATGGCTTCTG AGGCGGAAAG

3851 AACCAGCTGG GGCTCTAGGG GGTATCCCCA CGCGCCCTGT AGCGGCGCAT

3901 TAAGCGCGGC GGGTGTGGTG GTTACGCGCA GCGTGACCGC TACACTTGCC

3951 AGCGCCCTAG CGCCCGCTCC TTTCGCTTTC TTCCCTTCCT TTCTCGCCAC

4001 GTTCGCCGGC TTTCCCCGTC AAGCTCTAAA TCGGGGGCTC CCTTTAGGGT

4051 TCCGATTTAG TGCTTTACGG CACCTCGACC CCAAAAAACT TGATTAGGGT

4101 GATGGTTCAC GTAGTGGGCC ATCGCCCTGA TAGACGGTTT TTCGCCCTTT 4151 GACGTTGGAG TCCACGTTCT TTAATAGTGG ACTCTTGTTC CAAACTGGAA

4201 CAACACTCAA CCCTATCTCG GTCTATTCTT TTGATTTATA AGGGATTTTG

4251 CCGATTTCGG CCTATTGGTT AAAAAATGAG CTGATTTAAC AAAAATTTAA

4301 CGCGAATTAA TTCTGTGGAA TGTGTGTCAG TTAGGGTGTG GAAAGTCCCC

4351 AGGCTCCCCA GCAGGCAGAA GTATGCAAAG CATGCATCTC AATTAGTCAG

4401 CAACCAGGTG TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA

4451 AG CAT G CATC TCAATTAGTC AGCAACCATA GTCCCGCCCC TAACTCCGCC

4501 CATCCCGCCC CTAACTCCGC CCAGTTCCGC CCATTCTCCG CCCCATGGCT

4551 GACTAATTTT TTTTATTTAT GCAGAGGCCG AGGCCGCCTC TGCCTCTGAG

4601 CTATTCCAGA AGTAGTGAGG AGGCTTTTTT GGAGGCCTAG GCTTTTGCAA

4651 AAAGCTCCCG GGAGCTTGTA TATCCATTTT CGGATCTGAT CAAGAGACAG

4701 GAT GAG GAT C GTTTCGCATG ATTGAACAAG ATGGATTGCA CGCAGGTTCT

4751 CCGGCCGCTT GGGTGGAGAG GCTATTCGGC TATGACTGGG CACAACAGAC

4801 AATCGGCTGC TCTGATGCCG CCGTGTTCCG GCTGTCAGCG CAGGGGCGCC

4851 CGGTTCTTTT TGTCAAGACC GACCTGTCCG GTGCCCTGAA TGAACTGCAG

4901 GACGAGGCAG CGCGGCTATC GTGGCTGGCC ACGACGGGCG TTCCTTGCGC

4951 AGCTGTGCTC GACGTTGTCA CTGAAGCGGG AAGGGACTGG CTGCTATTGG

5001 GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT CTCACCTTGC TCCTGCCGAG

5051 AAAGTATCCA TCATGGCTGA TGCAATGCGG CGGCTGCATA CGCTTGATCC

5101 GGCTACCTGC CCATTCGACC ACCAAGCGAA ACATCGCATC GAGCGAGCAC

5151 GTACTCGGAT GGAAGCCGGT CTTGTCGATC AGGATGATCT GGACGAAGAG

5201 CATCAGGGGC TCGCGCCAGC CGAACTGTTC GCCAGGCTCA AGGCGCGCAT

5251 GCCCGACGGC GAGGATCTCG TCGTGACCCA TGGCGATGCC TGCTTGCCGA

5301 ATATCATGGT GGAAAATGGC CGCTTTTCTG GATTCATCGA CTGTGGCCGG

5351 CTGGGTGTGG CGGACCGCTA TCAGGACATA GCGTTGGCTA CCCGTGATAT

5401 TGCTGAAGAG CTTGGCGGCG AATGGGCTGA CCGCTTCCTC GTGCTTTACG

5451 GTATCGCCGC TCCCGATTCG CAGCGCATCG CCTTCTATCG CCTTCTTGAC

5501 GAGTTCTTCT GAGCGGGACT CTGGGGTTCG AAATGACCGA CCAAGCGACG

5551 CCCAACCTGC CAT CACGAGA TTTCGATTCC ACCGCCGCCT TCTATGAAAG

5601 GTTGGGCTTC GGAATCGTTT TCCGGGACGC CGGCTGGATG ATCCTCCAGC

5651 GCGGGGATCT CATGCTGGAG TTCTTCGCCC ACCCCAACTT GTTTATTGCA

5701 GCTTATAATG GTTACAAATA AAGCAATAGC ATCACAAATT TCACAAATAA

5751 AGCATTTTTT TCACTGCATT CTAGTTGTGG TTTGTCCAAA CTCATCAATG

5801 TATCTTATCA TGTCTGTATA CCGTCGACCT CTAGCTAGAG CTTGGCGTAA

5851 TCATGGTCAT AGCTGTTTCC TGTGTGAAAT TGTTATCCGC TCACAATTCC

5901 ACACAACATA CGAGCCGGAA GCATAAAGTG TAAAGCCTGG GGTGCCTAAT

5951 GAGTGAGCTA ACTCACATTA ATTGCGTTGC GCTCACTGCC CGCTTTCCAG

6001 TCGGGAAACC TGTCGTGCCA GCTGCATTAA TGAATCGGCC AACGCGCGGG 6051 GAGAGGCGGT TTGCGTATTG GGCGCTCTTC CGCTTCCTCG CTCACTGACT

6101 CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG CGGTATCAGC TCACTCAAAG

6151 GCGGTAATAC GGTTATCCAC AGAATCAGGG GAT AAC G C AG GAAAGAACAT

6201 GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA CCGTAAAAAG GCCGCGTTGC

6251 TGGCGTTTTT CCATAGGCTC CGCCCCCCTG ACGAGCATCA CAAAAATCGA

6301 CGCTCAAGTC AGAGGTGGCG AAACCCGACA GGACTATAAA GATACCAGGC

6351 GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC TCCTGTTCCG ACCCTGCCGC

6401 TTACCGGATA CCTGTCCGCC TTTCTCCCTT CGGGAAGCGT GGCGCTTTCT

6451 CATAGCTCAC GCTGTAGGTA TCTCAGTTCG GTGTAGGTCG TTCGCTCCAA

6501 GCTGGGCTGT GTGCACGAAC CCCCCGTTCA GCCCGACCGC TGCGCCTTAT

6551 CCGGTAACTA TCGTCTTGAG TCCAACCCGG TAAGACACGA CTTATCGCCA

6601 CTGGCAGCAG CCACTGGTAA CAGGATTAGC AGAGCGAGGT ATGTAGGCGG

6651 TGCTACAGAG TTCTTGAAGT GGTGGCCTAA CTACGGCTAC ACTAGAAGAA

6701 CAGTATTTGG TATCTGCGCT CTGCTGAAGC CAGTTACCTT CGGAAAAAGA

6751 GTTGGTAGCT CTTGATCCGG CAAACAAACC ACCGCTGGTA GCGGTTTTTT

6801 TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC

6851 CTTTGATCTT TTCTACGGGG TCTGACGCTC AGT GGAACGA AAACTCACGT

6901 TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT

6951 TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA

7001 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG

7051 ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT

7101 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC

7151 CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA

7201 GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT

7251 CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA

7301 ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACGC

7351 TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG

7401 AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC

7451 CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT

7501 AT GGCAGC AC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT

7551 TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC

7601 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGCGCCA

7651 CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG

7701 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA

7751 CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT

7801 GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC

7851 G AC AC G G AAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA

7901 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT 7951 TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC

8001 ACCTGACGTC

[0092] According to one embodiment, the vector is a plasmid and has the sequence of pminiCMV-(mNeonGreen)₄-tDeg (SEQ ID NO: 75; GenBank Accession No. MN052905.1, which is hereby incorporated by reference) as follows:

1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGGTAGG CGTGTACGGT 251 GGGAGGCCTA TATAAGCAGA GCTAAGCTTG CCACCATGGT GAGCAAGGGC 301 GAGGAGGATA ACATGGCCTC TCTCCCAGCG ACACATGAGT TACACATCTT 351 TGGCTCCATC AACGGTGTGG ACTTTGACAT GGTGGGTCAG GGCACCGGCA 401 ATCCAAATGA TGGTTATGAG GAGTTAAACC TGAAGTCCAC CAAGGGTGAC 451 CTCCAGTTCT CCCCCTGGAT TCTGGTCCCT CATATCGGGT ATGGCTTCCA 501 TCAGTACCTG CCCTACCCTG ACGGGATGTC GCCTTTCCAG GCCGCCATGG 551 TAGATGGCTC CGGATACCAA GTCCATCGCA CAATGCAGTT TGAAGATGGT 601 GCCTCCCTTA CTGTTAACTA CCGCTACACC TACGAGGGAA GCCACATCAA 651 AGGAGAGGCC CAGGTGAAGG GGACTGGTTT CCCTGCTGAC GGTCCTGTGA 701 TGACCAACTC GCTGACCGCT GCGGACTGGT GCAGGTCGAA GAAGACTTAC 751 CCCAACGACA AAACCATCAT CAGTACCTTT AAGTGGAGTT ACACCACTGG 801 AAATGGCAAG CGCTACCGGA GCACTGCGCG GACCACCTAC ACCTTTGCCA 851 AGCCAATGGC GGCTAACTAT CTGAAGAACC AGCCGATGTA CGTGTTCCGT 901 AAGACGGAGC TCAAGCACTC CAAGACCGAG CTCAACTTCA AGGAGTGGCA 951 AAAGGCCTTT ACCGATGTGA TGGGCATGGA CGAGCTGTAC AAGGGTGGAC 1001 ATATGGGCAC AGGGTCCACA GGCGGTACCG GCGGAGTTTC CAAAGGAGAA 1051 GAAGACAATA TGGCATCACT CCCCGCAACC CACGAGTTGC ATATTTTCGG 1101 TTCAATTAAT GGAGTAGATT TCGATATGGT TGGCCAGGGA ACAGGAAACC 1151 CAAACGACGG ATATGAAGAG CTTAATCTCA AAAGTACCAA AGGCGATCTG 1201 CAATTTTCTC CGTGGATACT CGTGCCACAC ATTGGATACG GATTTCACCA 1251 ATATCTCCCG TATCCGGATG GAATGTCCCC CTTTCAAGCA GCAATGGTGG 1301 ACGGGAGTGG TTATCAGGTA CACAGAACCA TGCAGTTCGA GGACGGGGCT 1351 TCTCTGACCG TAAATTATAG GTATACTTAT GAAGGCTCAC ATATTAAGGG 1401 CGAAGCACAG GTTAAAGGAA CCGGGTTTCC TGCGGATGGC CCCGTCATGA 1451 CTAATTCTCT GACAGCCGCA GATTGGTGTC GCTCCAAAAA GACATACCCG 1501 AATGATAAGA CTATAATCTC AACATTCAAA TGGTCCTATA CGACAGGCAA 1551 CGGGAAACGA TATAGATCCA CGGCTCGAAC AACTTACACA TTCGCTAAAC 1601 CTATGGCCGC CAATTACCTC AAAAATCAGC CCATGTATGT GTTTAGGAAA

1651 ACCGAATTGA AGCATTCTAA AACGGAACTT AATTTTAAGG AATGGCAGAA

1701 GGCTTTCACA GACGTAATGG GG AT GG AT GA ACTCTATAAA TCAGGTCTCG

1751 AGTCCTCAGG GGGAACGGGT GGGTCCGGAG GAGTTAGTAA AGGT GAAGAG

1801 GACAAT AT GG CAAGTTTGCC TGCGACTCAC GAGCTTCATA TCTTTGGGTC

1851 TATAAATGGC GTTGACTTCG ATATGGTTGG CCAAGGTACT GGCAACCCCA

1901 ATGACGGTTA CGAGGAGTTG AATCTCAAGT CCACAAAAGG TGATCTTCAG

1951 TTCAGCCCTT GGATTCTCGT ACCTCATATT GGATATGGCT TTCACCAGTA

2001 CCTTCCATAC CCAGACGGTA TGTCACCCTT TCAAGCTGCG ATGGTGGATG

2051 GTTCCGGCTA TCAGGTCCAC CGAACGATGC AATTCGAGGA CGGGGCCAGC

2101 CTCACCGTTA ATTATAGGTA CACCTATGAG GGAAGTCACA TAAAGGGAGA

2151 AGCCCAAGTG AAAGGAACAG GATTCCCAGC TGATGGTCCA GTAATGACGA

2201 ACTCCTTGAC AGCGGCTGAC TGGTGTAGAA GCAAAAAGAC GTATCCTAAT

2251 GACAAGACCA TCATTAGCAC TTTCAAATGG AGT TAT ACC A CAGGAAACGG

2301 CAAACGGTAC AGAAGCACTG CTAGAACTAC CTACACTTTC GCAAAGCCGA

2351 TGGCTGCAAA CTATTTGAAG AATCAGCCCA TGTACGTGTT TCGAAAAACG

2401 GAACTTAAGC ACAGTAAGAC TGAACTTAAT TTCAAGGAGT GGCAGAAGGC

2451 GTTCACGGAT GTCATGGGTA TGGATGAACT GTATAAGGGA GGGTCTGGCA

2501 CTGGGGGCAC TGCCAGCAGC GGATCCGGTG GCGGTGTGAG CAAGGGCGAG

2551 GAGGATAACA TGGCCTCTCT CCCAGCGACA CATGAGTTAC ACATCTTTGG

2601 CTCCATCAAC GGTGTGGACT TTGACATGGT GGGTCAGGGC ACCGGCAATC

2651 CAAATGATGG TTATGAGGAG TTAAACCTGA AGTCCACCAA GGGTGACCTC

2701 CAGTTCTCCC CCTGGATTCT GGTCCCTCAT ATCGGGTATG GCTTCCATCA

2751 GTACCTGCCC TACCCTGACG GGATGTCGCC TTTCCAGGCC GCCATGGTAG

2801 ATGGCTCCGG ATACCAAGTC CATCGCACAA TGCAGTTTGA AGATGGTGCC

2851 TCCCTTACTG TTAACTACCG CTACACCTAC GAGGGAAGCC AC AT C AAAGG

2901 AGAGGCCCAG GTGAAGGGGA CTGGTTTCCC TGCTGACGGT CCTGTGATGA

2951 CCAACTCGCT GACCGCTGCG GACTGGTGCA GGTCGAAGAA GACTTACCCC

3001 AACGACAAAA C CAT CATC AG TACCTTTAAG TGGAGTTACA CCACTGGAAA

3051 TGGCAAGCGC TACCGGAGCA CTGCGCGGAC CACCTACACC TTTGCCAAGC

3101 CAATGGCGGC TAACTATCTG AAGAACCAGC CGATGTACGT GTTCCGTAAG

3151 ACGGAGCTCA AGCACTCCAA GACCGAGCTC AACTTCAAGG AGTGGCAAAA

3201 GGCCTTTACC GATGTGATGG GC AT GG AC GA GCTGTACAAG GGCGGAAGAT

3251 CCGGTGGTGG TTCTGGTCCT CGTCCCCGTG GTACTCGTGG TAAAGGTCGC

3301 CGTATTCGTC GCCGCGGTTA ATCTAGAGGG CCCGTTTAAA CCCGCTGATC

3351 AGCCTCGACT GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT TGCCCCTCCC

3401 CCGTGCCTTC CTTGACCCTG GAAAGGTGCC ACTCCCACTG TCCTTTCCTA

3451 AT AAAAT GAG GAAATTGCAT CGCATTGTCT GAGTAGGTGT CATTCTATTC 3501 TGGGGGGTGG GGGTGGGGGC AGGACAGCAA GGGGGAGGAT TGGGAAGACA

3551 ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT CTATGGCTTC TGAGGCGGAA

3601 AGAACCAGCT GGGGCTCTAG GGGGTATCCC CACGCGCCCT GTAGCGGCGC

3651 ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACC GCTACACTTG

3701 CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC CTTTCTCGCC

3751 ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC TCCCTTTAGG

3801 GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA CTTGATTAGG

3851 GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT

3901 TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT TCCAAACTGG

3951 AACAACACTC AACCCTATCT CGGTCTATTC TTTTGATTTA TAAGGGATTT

4001 TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA ACAAAAATTT

4051 AACGCGAATT AATTCTGTGG AATGTGTGTC AGTTAGGGTG TGGAAAGTCC

4101 CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AGCATGCATC TCAATTAGTC

4151 AGCAACCAGG TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC AGAAGTATGC

4201 AAAGCATGCA TCTCAATTAG TCAGCAACCA TAGTCCCGCC CCTAACTCCG

4251 CCCATCCCGC CCCTAACTCC GCCCAGTTCC GCCCATTCTC CGCCCCATGG

4301 CTGACTAATT TTTTTTATTT ATGCAGAGGC CGAGGCCGCC TCTGCCTCTG

4351 AGCTATTCCA GAAGTAGTGA GGAGGCTTTT TTGGAGGCCT AGGCTTTTGC

4401 AAAAAGCTCC CGGGAGCTTG TATATCCATT TTCGGATCTG ATCAAGAGAC

4451 AG GAT GAG G A TCGTTTCGCA TGATTGAACA AGATGGATTG CACGCAGGTT

4501 CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG GGCACAACAG

4551 ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG CGCAGGGGCG

4601 CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG AATGAACTGC

4651 AGGACGAGGC AGCGCGGCTA TCGTGGCTGG CCACGACGGG CGTTCCTTGC

4701 GCAGCTGTGC TCGACGTTGT CACTGAAGCG GGAAGGGACT GGCTGCTATT

4751 GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT GCTCCTGCCG

4801 AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA TACGCTTGAT

4851 CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA TCGAGCGAGC

4901 ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT CTGGACGAAG

4951 AGCATCAGGG GCTCGCGCCA GCCGAACTGT TCGCCAGGCT CAAGGCGCGC

5001 ATGCCCGACG GCGAGGATCT CGTCGTGACC CATGGCGATG CCTGCTTGCC

5051 GAATATCATG GTGGAAAATG GCCGCTTTTC TGGATTCATC GACTGTGGCC

5101 GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC TACCCGTGAT

5151 ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC TCGTGCTTTA

5201 CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT CGCCTTCTTG

5251 ACGAGTTCTT CTGAGCGGGA CTCTGGGGTT CGAAATGACC GACCAAGCGA

5301 CGCCCAACCT GCCATCACGA GATTTCGATT CCACCGCCGC CTTCTATGAA

5351 AGGTTGGGCT TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA 5401 GCGCGGGGAT CTCATGCTGG AGTTCTTCGC CCACCCCAAC TTGTTTATTG

5451 CAGCTTATAA TGGTTACAAA TAAAGCAATA GCATCACAAA TTTCACAAAT

5501 AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA AACTCATCAA

5551 TGTATCTTAT CATGTCTGTA TACCGTCGAC CTCTAGCTAG AGCTTGGCGT

5601 AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC GCTCACAATT

5651 CCACACAACA TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA

5701 ATGAGTGAGC TAACTCACAT TAATTGCGTT GCGCTCACTG CCCGCTTTCC

5751 AGTCGGGAAA CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG

5801 GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT CGCTCACTGA

5851 CTCGCTGCGC TCGGTCGTTC GGCTGCGGCG AGCGGTATCA GCTCACTCAA

5901 AGGCGGTAAT ACGGTTATCC ACAGAATCAG GGGATAACGC AGGAAAGAAC

5951 ATGTGAGCAA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA AGGCCGCGTT

6001 GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT CACAAAAATC

6051 GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA AAGATACCAG

6101 GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC CGACCCTGCC

6151 GCTTACCGGA TACCTGTCCG CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT

6201 CTCATAGCTC ACGCTGTAGG TATCTCAGTT CGGTGTAGGT CGTTCGCTCC

6251 AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC GCTGCGCCTT

6301 ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC GACTTATCGC

6351 CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG GTATGTAGGC

6401 GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG

6451 AACAGTATTT GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA

6501 GAGTTGGTAG CTCTTGATCC GGCAAACAAA CCACCGCTGG TAGCGGTTTT

6551 TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA

6601 TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC

6651 GTTAAGGGAT TTTGGTCATG AG AT TAT C AA AAAGGATCTT CACCTAGATC

6701 CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA

6751 AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG

6801 CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG

6851 ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT

6901 AC C G C GAG AC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC

6951 CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC

7001 ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT

7051 TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC

7101 GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG

7151 CGAGTTACAT GATCCCCCAT GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG

7201 TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA TCACTCATGG

7251 TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC 7301 TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT

7351 GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC

7401 CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG

7451 CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC

7501 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT

7551 CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG

7601 GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG

7651 AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA

7701 TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG

7751 CCACCTGACG TC

[0093] According to one embodiment, the vector is a plasmid and has the sequence of pCM V-CytERM-mCherry-(F30-2x Pepper) _|0 (SEQ ID NO: 76; GenBank Accession No. MN052906.1, which is hereby incorporated by reference) as follows:

1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT GATTATTGAC 251 TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG 351 CCCAACGACC CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT 401 AACGCCAATA GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT 451 AAACTGCCCA CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC 501 CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA 551 CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA 651 TAGCGGTTTG ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA 701 TGGGAGTTTG TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA 751 ACAACTCCGC CCCCATTGAC GCAAATGGGC GGTAGGCGTG TACGGTGGGA 801 GGTCTATATA AGCAGAGCTC TCTGGCTAAC TAGAGAACCC ACTGCTTACT 851 GGCTTATCGA AATTAATACG ACTCACTATA GGGAGACCCA AGCTGGCTAG 901 CGTTTAAACT TGCCACCATG GACCCTGTGG TGGTGCTGGG GCTCTGTCTC 951 TCCTGTTTGC TTCTCCTTTC ACTCTGGAAA CAGAGCTATG GGGGAGGGAA 1001 ACTGGGCGGA AGCGGAGGGA CGGGGGGTTC AGGAACTTCA GGGGGTGTGA 1051 GCAAGGGCGA GGAGGATAAC ATGGCCATCA TCAAGGAGTT CATGCGCTTC 1101 AAGGTGCACA TGGAGGGCTC CGTGAACGGC CACGAGTTCG AGATCGAGGG 1151 CGAGGGCGAG GGCCGCCCCT ACGAGGGCAC CCAGACCGCC AAGCTGAAGG 1201 TGACCAAGGG TGGCCCCCTG CCCTTCGCCT GGGACATCCT GTCCCCTCAG

1251 TTCATGTACG GCTCCAAGGC CTACGTGAAG CACCCCGCCG ACATCCCCGA

1301 CTACTTGAAG CTGTCCTTCC CCGAGGGCTT CAAGTGGGAG CGCGTGATGA

1351 ACTTCGAGGA CGGCGGCGTG GTGACCGTGA CCCAGGACTC CTCCCTGCAG

1401 GACGGCGAGT TCATCTACAA GGTGAAGCTG CGCGGCACCA ACTTCCCCTC

1451 CGACGGCCCC GTAATGCAGA AGAAGACCAT GGGCTGGGAG GCCTCCTCCG

1501 AGCGGATGTA CCCCGAGGAC GGCGCCCTGA AGGGCGAGAT CAAGCAGAGG

1551 CTGAAGCTGA AGGACGGCGG CCACTACGAC GCTGAGGTCA AGACCACCTA

1601 CAAGGCCAAG AAGCCCGTGC AGCTGCCCGG CGCCTACAAC GT C AAC AT C A

1651 AGTTGGACAT CACCTCCCAC AAC GAG G AC T ACACCATCGT GGAACAGTAC

1701 GAACGCGCCG AGGGCCGCCA CTCCACCGGC GGCATGGACG AGCTGTACAA

1751 GTAACTCGAG ATCCGTTACG GCCGGAATCA ATCGCTAATC ACTCAACTTG

1801 CCATGTGTAT GTGGGAAGCG TAGAAAGGCT CGTTGAGCTC ATTAGCTCCG

1851 AGCCCGACTA CGTTTCCCAC ATACTCTGAT GATCCGCTAG CAAAGGCTCG

1901 TCTGAGCTCA TTAGCTCCGA GCCCGAGGTA CCGGATCATT CATGGCAAGT

1951 CCAGCGCAAT CTATTACGAA AATCATCCGA CGTCGCGATG TCTATGCGGG

2001 AAGCGTAGAA AGGCTCGTCT GAGCTCATTA GCTCCGAGCC CGACTACGTT

2051 TCCCGCATAG TCTGATCATC CGCTAGCAAA GGCTCGTTGA GCTCATTAGC

2101 TCCGAGCCCG AGGTACCGGA TGATTCATCG CGACGCTGCG GAAAATCTCA

2151 CAAAATCACG TCAAACGTCG CCGTGTGTGT GTAGGAAGCG TAGAAAGGCT

2201 CGTCTGAGCT CATTAGCTCC GAGCCCGACT ACGTTTCCTA CACACTCTGA

2251 CGATCCGCTA GCAAAGGCTC GTTGAGCTCA TTAGCTCCGA GCCCGAGGTA

2301 CCGGATCGTT CACGGCGACG CCGATAATCC ACAT ACT T AC AATCAGGCAA

2351 TCTTGCCATG TGTATGTGGG AAGCGTAGAA AGGCTCGTTG AGCTCATTAG

2401 CTCCGAGCCC GACTACGTTT CCCACATACT CTGATGATCC GCTAGCAAAG

2451 GCTCGTTGAG CTCATTAGCT CCGAGCCCGA GGTACCGGAT CATTCATGGC

2501 AAGTATCAAG ATCGAACGGC GCAAGATATT GTCACGTCGC GATGTCTATG

2551 CGGGAAGCGT AGAAAGGCTC GTTGAGCTCA TTAGCTCCGA GCCCGACTAC

2601 GTTTCCCGCA TAGTCTGATC ATCCGCTAGC AAAGGCTCGT CTGAGCTCAT

2651 TAGCTCCGAG CCCGAGGTAC CGGATGATTC ATCGCGACGT CCTCGCTAGA

2701 TATGTTAGGT TCTTAGGCAT TTCGCCGTGT GTGTGTAGGA AGCGTAGAAA

2751 GGCTCGTTGA GCTCATTAGC TCCGAGCCCG ACTACGTTTC CTACACACTC

2801 TGACGATCCG CTAGCAAAGG CTCGTCTGAG CTCATTAGCT CCGAGCCCGA

2851 GGTACCGGAT CGTTCACGGC GAAAAGATCG TCTGCAATTC CGATTAGACG

2901 TACACTTGCC ATGTGTATGT GGGAAGCGTA GAAAGGCTCG TCTGAGCTCA

2951 TTAGCTCCGA GCCCGACTAC GTTTCCCACA TACTCTGATG ATCCGCTAGC

3001 AAAGGCTCGT TGAGCTCATT AGCTCCGAGC CCGAGGTACC GGATCATTCA

3051 TGGCAAGATC CAAGCTACTT CCTCCATACC TATCCTCCTC GCGATGTCTA 3101 TGCGGGAAGC GTAGAAAGGC TCGTCTGAGC TCATTAGCTC CGAGCCCGAC

3151 TACGTTTCCC GCATAGTCTG ATCATCCGCT AGCAAAGGCT CGTTGAGCTC

3201 ATTAGCTCCG AGCCCGAGGT ACCGGATGAT TCATCGCGAG ATCATAACGC

3251 AATACCGTAC ACTGTCCAAT CCTCGCCGTG TGTGTGTAGG AAGCGTAGAA

3301 AGGCTCGTCT GAGCTCATTA GCTCCGAGCC CGACTACGTT TCCTACACAC

3351 TCTGACGATC CGCTAGCAAA GGCTCGTTGA GCTCATTAGC TCCGAGCCCG

3401 AGGTACCGGA TCGTTCACGG CGAGGATAAT CAATCCACAT AC AT CACACC

3451 ACAATTCTTG CCATGTGTAT GTGGGAAGCG TAGAAAGGCT CGTCTGAGCT

3501 CATTAGCTCC GAGCCCGACT ACGTTTCCCA CATACTCTGA TGATCCGCTA

3551 GCAAAGGCTC GTCTGAGCTC ATTAGCTCCG AGCCCGAGGT ACCGGATCAT

3601 TCATGGCAAG AATTGGTCGT TCTTCTTGGC GGCCGCTCGA CTAAATCACC

3651 GGTAATCTTC TTGTCCATCT AGACCTTATA AAGATCTTTG TACAAGGGCC

3701 CGTTTAAACC CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT

3751 CTGTTGTTTG CCCCTCCCCC GTGCCTTCCT TGACCCTGGA AAGGTGCCAC

3801 TCCCACTGTC CTTTCCTAAT AAAAT GAG G A AATTGCATCG CATTGTCTGA

3851 GTAGGTGTCA TTCTATTCTG GGGGGTGGGG GTGGGGGCAG GACAGCAAGG

3901 GGGAGGATTG GGAAGACAAT AGCAGGCATG CTGGGGATGC GGTGGGCTCT

3951 ATGGCTTCTG AGGCGGAAAG AACCAGCTGG GGCTCTAGGG GGTATCCCCA

4001 CGCGCCCTGT AGCGGCGCAT TAAGCGCGGC GGGTGTGGTG GTTACGCGCA

4051 GCGTGACCGC TACACTTGCC AGCGCCCTAG CGCCCGCTCC TTTCGCTTTC

4101 TTCCCTTCCT TTCTCGCCAC GTTCGCCGGC TTTCCCCGTC AAGCTCTAAA

4151 TCGGGGGCTC CCTTTAGGGT TCCGATTTAG TGCTTTACGG CACCTCGACC

4201 CCAAAAAACT TGATTAGGGT GATGGTTCAC GTAGTGGGCC ATCGCCCTGA

4251 TAGACGGTTT TTCGCCCTTT GACGTTGGAG TCCACGTTCT TTAATAGTGG

4301 ACTCTTGTTC CAAACTGGAA CAACACTCAA CCCTATCTCG GTCTATTCTT

4351 TT GATT TATA AGGGATTTTG CCGATTTCGG CCTATTGGTT AAAAAATGAG

4401 CTGATTTAAC AAAAATTTAA CGCGAATTAA TTCTGTGGAA TGTGTGTCAG

4451 TTAGGGTGTG GAAAGTCCCC AGGCTCCCCA GCAGGCAGAA GTATGCAAAG

4501 CATGCATCTC AATTAGTCAG CAACCAGGTG TGGAAAGTCC CCAGGCTCCC

4551 CAGCAGGCAG AAGTATGCAA AG CAT G CATC TCAATTAGTC AGCAACCATA

4601 GTCCCGCCCC TAACTCCGCC CATCCCGCCC CTAACTCCGC CCAGTTCCGC

4651 CCATTCTCCG CCCCATGGCT GACTAATTTT TTTTATTTAT GCAGAGGCCG

4701 AGGCCGCCTC TGCCTCTGAG CTATTCCAGA AGTAGTGAGG AGGCTTTTTT

4751 GGAGGCCTAG GCTTTTGCAA AAAGCTCCCG GGAGCTTGTA TATCCATTTT

4801 CGGATCTGAT CAAGAGACAG GAT GAG GAT C GTTTCGCATG ATTGAACAAG

4851 ATGGATTGCA CGCAGGTTCT CCGGCCGCTT GGGTGGAGAG GCTATTCGGC

4901 TATGACTGGG CACAACAGAC AATCGGCTGC TCTGATGCCG CCGTGTTCCG

4951 GCTGTCAGCG CAGGGGCGCC CGGTTCTTTT TGTCAAGACC GACCTGTCCG 5001 GTGCCCTGAA TGAACTGCAG GACGAGGCAG CGCGGCTATC GTGGCTGGCC

5051 ACGACGGGCG TTCCTTGCGC AGCTGTGCTC GACGTTGTCA CTGAAGCGGG

5101 AAGGGACTGG CTGCTATTGG GCGAAGTGCC GGGGCAGGAT CTCCTGTCAT

5151 CTCACCTTGC TCCTGCCGAG AAAGTATCCA TCATGGCTGA TGCAATGCGG

5201 CGGCTGCATA CGCTTGATCC GGCTACCTGC CCATTCGACC ACCAAGCGAA

5251 ACATCGCATC GAG C GAG C AC GTACTCGGAT GGAAGCCGGT CTTGTCGATC

5301 AG GAT GAT CT GGACGAAGAG CATCAGGGGC TCGCGCCAGC CGAACTGTTC

5351 GCCAGGCTCA AGGCGCGCAT GCCCGACGGC GAGGATCTCG TCGTGACCCA

5401 TGGCGATGCC TGCTTGCCGA ATATCATGGT GGAAAATGGC CGCTTTTCTG

5451 GATT CAT CGA CTGTGGCCGG CTGGGTGTGG CGGACCGCTA TCAGGACATA

5501 GCGTTGGCTA CCCGTGATAT T G C T G AAG AG CTTGGCGGCG AATGGGCTGA

5551 CCGCTTCCTC GTGCTTTACG GTATCGCCGC TCCCGATTCG CAGCGCATCG

5601 CCTTCTATCG CCTTCTTGAC GAGTTCTTCT GAGCGGGACT CTGGGGTTCG

5651 AAATGACCGA CCAAGCGACG CCCAACCTGC CAT CACGAGA TTTCGATTCC

5701 ACCGCCGCCT TCTATGAAAG GTTGGGCTTC GGAATCGTTT TCCGGGACGC

5751 CGGCTGGATG ATCCTCCAGC GCGGGGATCT CATGCTGGAG TTCTTCGCCC

5801 ACCCCAACTT GTTTATTGCA GCTTATAATG GTTACAAATA AAGCAATAGC

5851 ATCACAAATT TCACAAATAA AGCATTTTTT TCACTGCATT CTAGTTGTGG

5901 TTTGTCCAAA CTCATCAATG TATCTTATCA TGTCTGTATA CCGTCGACCT

5951 CTAGCTAGAG CTTGGCGTAA TCATGGTCAT AGCTGTTTCC TGTGTGAAAT

6001 TGTTATCCGC TCACAATTCC ACACAACATA CGAGCCGGAA GCATAAAGTG

6051 TAAAGCCTGG GGTGCCTAAT GAGTGAGCTA ACTCACATTA ATTGCGTTGC

6101 GCTCACTGCC CGCTTTCCAG TCGGGAAACC TGTCGTGCCA GCTGCATTAA

6151 TGAATCGGCC AACGCGCGGG GAGAGGCGGT TTGCGTATTG GGCGCTCTTC

6201 CGCTTCCTCG CTCACTGACT CGCTGCGCTC GGTCGTTCGG CTGCGGCGAG

6251 CGGTATCAGC TCACTCAAAG GCGGTAATAC GGTTATCCAC AGAATCAGGG

6301 GAT AAC GC AG GAAAGAACAT GTGAGCAAAA GGCCAGCAAA AGGCCAGGAA

6351 CCGTAAAAAG GCCGCGTTGC TGGCGTTTTT CCATAGGCTC CGCCCCCCTG

6401 AC GAGC AT C A CAAAAATCGA CGCTCAAGTC AGAGGTGGCG AAACCCGACA

6451 GG AC TAT AAA GATACCAGGC GTTTCCCCCT GGAAGCTCCC TCGTGCGCTC

6501 TCCTGTTCCG ACCCTGCCGC TTACCGGATA CCTGTCCGCC TTTCTCCCTT

6551 CGGGAAGCGT GGCGCTTTCT CATAGCTCAC GCTGTAGGTA TCTCAGTTCG

6601 GTGTAGGTCG TTCGCTCCAA GCTGGGCTGT GTGCACGAAC CCCCCGTTCA

6651 GCCCGACCGC TGCGCCTTAT CCGGTAACTA TCGTCTTGAG TCCAACCCGG

6701 TAAGACACGA CTTATCGCCA CTGGCAGCAG CCACTGGTAA CAGGATTAGC

6751 AGAGCGAGGT ATGTAGGCGG TGCTACAGAG TTCTTGAAGT GGTGGCCTAA

6801 CTACGGCTAC ACT AG AAG AA CAGTATTTGG TATCTGCGCT CTGCTGAAGC

6851 CAGTTACCTT C GG AAAAAG A GTTGGTAGCT CTTGATCCGG CAAACAAACC 6901 ACCGCTGGTA GCGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA

6951 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC

7001 AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA

7051 AGGATCTTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT

7101 CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA

7151 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC

7201 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG

7251 CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT

7301 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT

7351 GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG

7401 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA

7451 CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC

7501 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA

7551 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG

7601 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC

7651 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC

7701 ATTCTGAGAA TAGTGTATGC GGCGACCGAG TTGCTCTTGC CCGGCGTCAA

7751 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT

7801 GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG

7851 ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT

7901 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC

7951 GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT

8001 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG

8051 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC

8101 ACATTTCCCC GAAAAGTGCC ACCTGACGTC

[0094] According to one embodiment, the vector is a plasmid and has the sequence of pUbC-(mNeonGreen)₄-tDeg (SEQ ID NO: 77; GenBank Accession No. MN052907.1, which is hereby incorporated by reference) as follows:

1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC 51 TGCTCTGATG CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT 101 GGAGGTCGCT GAGTAGTGCG CGAGCAAAAT TTAAGCTACA ACAAGGCAAG 151 GCTTGACCGA CAATTGCATG AAGAATCTGC TTAGGGTTAG GCGTTTTGCG 201 CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGGCCTC CGCGCCGGGT 251 TTTGGCGCCT CCCGCGGGCG CCCCCCTCCT CACGGCGAGC GCTGCCACGT 301 CAGACGAAGG GCGCAGCGAG CGTCCTGATC CTTCCGCCCG GACGCTCAGG 351 ACAGCGGCCC GCTGCTCATA AGACTCGGCC TTAGAACCCC AGTATCAGCA 401 GAAGGACATT TTAGGACGGG ACTTGGGTGA CTCTAGGGCA CTGGTTTTCT 451 TTCCAGAGAG CGGAACAGGC GAGGAAAAGT AGTCCCTTCT CGGCGATTCT

501 GCGGAGGGAT CTCCGTGGGG CGGTGAACGC C GAT GAT TAT ATAAGGACGC

551 GCCGGGTGTG GCACAGCTAG TTCCGTCGCA GCCGGGATTT GGGTCGCGGT

601 TCTTGTTTGT GGATCGCTGT GATCGTCACT TGGAAGCTTG CCACCATGGT

651 GAGCAAGGGC GAGGAGGATA ACATGGCCTC TCTCCCAGCG ACACATGAGT

701 TACACATCTT TGGCTCCATC AACGGTGTGG ACTTTGACAT GGTGGGTCAG

751 GGCACCGGCA ATCCAAATGA TGGTTATGAG GAGTTAAACC TGAAGTCCAC

801 CAAGGGTGAC CTCCAGTTCT CCCCCTGGAT TCTGGTCCCT CATATCGGGT

851 ATGGCTTCCA TCAGTACCTG CCCTACCCTG ACGGGATGTC GCCTTTCCAG

901 GCCGCCATGG TAGATGGCTC CGGATACCAA GTCCATCGCA CAATGCAGTT

951 TGAAGATGGT GCCTCCCTTA CTGTTAACTA CCGCTACACC TACGAGGGAA

1001 GC C AC AT C AA AGGAGAGGCC CAGGTGAAGG GGACTGGTTT CCCTGCTGAC

1051 GGTCCTGTGA TGACCAACTC GCTGACCGCT GCGGACTGGT GCAGGTCGAA

1101 GAAGACTTAC CCCAACGACA AAAC CAT CAT CAGTACCTTT AAGTGGAGTT

1151 ACACCACTGG AAATGGCAAG CGCTACCGGA GCACTGCGCG GACCACCTAC

1201 ACCTTTGCCA AGCCAATGGC GGCTAACTAT CTGAAGAACC AGCCGATGTA

1251 CGTGTTCCGT AAGACGGAGC TCAAGCACTC CAAGACCGAG CTCAACTTCA

1301 AGGAGTGGCA AAAGGCCTTT ACCGATGTGA TGGGCATGGA CGAGCTGTAC

1351 AAGGGT GGAC ATATGGGCAC AGGGTCCACA GGCGGTACCG GCGGAGTTTC

1401 CAAAGGAGAA GAAGACAATA TGGCATCACT CCCCGCAACC CACGAGTTGC

1451 ATATTTTCGG TTCAATTAAT GGAGTAGATT TCGATATGGT TGGCCAGGGA

1501 ACAGGAAACC CAAACGACGG AT AT GAAGAG CTTAATCTCA AAAGTACCAA

1551 AGGCGATCTG CAATTTTCTC CGTGGATACT C GT GC C AC AC ATTGGATACG

1601 GATTTCACCA ATATCTCCCG TATCCGGATG GAATGTCCCC CTTTCAAGCA

1651 GCAATGGTGG ACGGGAGTGG TTATCAGGTA CACAGAACCA TGCAGTTCGA

1701 GGACGGGGCT TCTCTGACCG TAAATTATAG GT AT ACT TAT GAAGGCTCAC

1751 ATATTAAGGG CGAAGCACAG GTTAAAGGAA CCGGGTTTCC TGCGGATGGC

1801 CCCGTCATGA CTAATTCTCT GACAGCCGCA GATTGGTGTC GCTCCAAAAA

1851 GACATACCCG AATGATAAGA CTATAATCTC AACATTCAAA TGGTCCTATA

1901 CGACAGGCAA CGGGAAACGA TATAGATCCA CGGCTCGAAC AACTTACACA

1951 TTCGCTAAAC CTATGGCCGC CAATTACCTC AAAAATCAGC CCATGTATGT

2001 GTTTAGGAAA ACCGAATTGA AGCATTCTAA AACGGAACTT AATTTTAAGG

2051 AATGGCAGAA GGCTTTCACA GACGTAATGG G GAT G GAT G A AC T C TAT AAA

2101 TCAGGTCTCG AGTCCTCAGG GGGAACGGGT GGGTCCGGAG GAGTTAGTAA

2151 AGGT GAAGAG GACAATATGG CAAGTTTGCC TGCGACTCAC GAGCTTCATA

2201 TCTTTGGGTC TATAAATGGC GTTGACTTCG ATATGGTTGG CCAAGGTACT

2251 GGCAACCCCA ATGACGGTTA CGAGGAGTTG AATCTCAAGT CCACAAAAGG

2301 TGATCTTCAG TTCAGCCCTT GGATTCTCGT ACCTCATATT GGATATGGCT 2351 TTCACCAGTA CCTTCCATAC CCAGACGGTA TGTCACCCTT TCAAGCTGCG

2401 ATGGTGGATG GTTCCGGCTA TCAGGTCCAC CGAACGATGC AATTCGAGGA

2451 CGGGGCCAGC CTCACCGTTA AT T AT AGGT A CACCTATGAG GGAAGTCACA

2501 TAAAGGGAGA AGCCCAAGTG AAAGGAACAG GATTCCCAGC TGATGGTCCA

2551 GTAATGACGA ACTCCTTGAC AGCGGCTGAC TGGTGTAGAA GCAAAAAGAC

2601 GTATCCTAAT GACAAGACCA TCATTAGCAC TTTCAAATGG AGTTATACCA

2651 CAGGAAACGG CAAACGGTAC AGAAGCACTG CTAGAACTAC CTACACTTTC

2701 GCAAAGCCGA TGGCTGCAAA CTATTTGAAG AATCAGCCCA TGTACGTGTT

2751 TCGAAAAACG GAACTTAAGC ACAGTAAGAC TGAACTTAAT TTCAAGGAGT

2801 GGCAGAAGGC GTTCACGGAT GTCATGGGTA TGGATGAACT GTATAAGGGA

2851 GGGTCTGGCA CTGGGGGCAC TGCCAGCAGC GGATCCGGTG GCGGTGTGAG

2901 CAAGGGCGAG GAGGATAACA TGGCCTCTCT CCCAGCGACA CAT GAG TT AC

2951 ACATCTTTGG CTCCATCAAC GGTGTGGACT TTGACATGGT GGGTCAGGGC

3001 ACCGGCAATC CAAATGATGG TTATGAGGAG TTAAACCTGA AGTCCACCAA

3051 GGGTGACCTC CAGTTCTCCC CCTGGATTCT GGTCCCTCAT ATCGGGTATG

3101 GCTTCCATCA GTACCTGCCC TACCCTGACG GGATGTCGCC TTTCCAGGCC

3151 GCCATGGTAG ATGGCTCCGG ATACCAAGTC CATCGCACAA TGCAGTTTGA

3201 AGATGGTGCC TCCCTTACTG TTAACTACCG CTACACCTAC GAGGGAAGCC

3251 AC AT C AAAGG AGAGGCCCAG GTGAAGGGGA CTGGTTTCCC TGCTGACGGT

3301 CCTGTGATGA CCAACTCGCT GACCGCTGCG GACTGGTGCA GGTCGAAGAA

3351 GACTTACCCC AACGACAAAA CCATCATCAG TACCTTTAAG TGGAGTTACA

3401 CCACTGGAAA TGGCAAGCGC TACCGGAGCA CTGCGCGGAC CACCTACACC

3451 TTTGCCAAGC CAATGGCGGC TAACTATCTG AAGAACCAGC CGATGTACGT

3501 GTTCCGTAAG ACGGAGCTCA AGCACTCCAA GACCGAGCTC AACTTCAAGG

3551 AGTGGCAAAA GGCCTTTACC GATGTGATGG GCATGGACGA GCTGTACAAG

3601 GGCGGAAGAT CCGGTGGTGG TTCTGGTCCT CGTCCCCGTG GTACTCGTGG

3651 TAAAGGTCGC CGTATTCGTC GCCGCGGTTA ATCTAGAGGG CCCGTTTAAA

3701 CCCGCTGATC AGCCTCGACT GTGCCTTCTA GTTGCCAGCC ATCTGTTGTT

3751 TGCCCCTCCC CCGTGCCTTC CTTGACCCTG GAAAGGTGCC ACTCCCACTG

3801 TCCTTTCCTA AT AAAAT GAG GAAATTGCAT CGCATTGTCT GAGTAGGTGT

3851 CATTCTATTC TGGGGGGTGG GGGTGGGGGC AGGACAGCAA GGGGGAGGAT

3901 TGGGAAGACA ATAGCAGGCA TGCTGGGGAT GCGGTGGGCT CTATGGCTTC

3951 TGAGGCGGAA AGAACCAGCT GGGGCTCTAG GGGGTATCCC CACGCGCCCT

4001 GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG CAGCGTGACC

4051 GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC

4101 CTTTCTCGCC ACGTTCGCCG GCTTTCCCCG TCAAGCTCTA AATCGGGGGC

4151 TCCCTTTAGG GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAAAAAA

4201 CTTGATTAGG GTGATGGTTC ACGTAGTGGG CCATCGCCCT GATAGACGGT 4251 TTTTCGCCCT TTGACGTTGG AGTCCACGTT CTTTAATAGT GGACTCTTGT

4301 TCCAAACTGG AACAACACTC AACCCTATCT CGGTCTATTC TTTTGATTTA

4351 TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA

4401 ACAAAAATTT AACGCGAATT AATTCTGTGG AATGTGTGTC AGTTAGGGTG

4451 TGGAAAGTCC CCAGGCTCCC CAGCAGGCAG AAGTATGCAA AG CAT G CATC

4501 TCAATTAGTC AGCAACCAGG TGTGGAAAGT CCCCAGGCTC CCCAGCAGGC

4551 AGAAGTATGC AAAGC AT GCA TCTCAATTAG TCAGCAACCA TAGTCCCGCC

4601 CCTAACTCCG CCCATCCCGC CCCTAACTCC GCCCAGTTCC GCCCATTCTC

4651 CGCCCCATGG CTGACTAATT TTTTT ATTT ATGCAGAGGC CGAGGCCGCC

4701 TCTGCCTCTG AGCTATTCCA GAAGTAGTGA GGAGGCTTTT TTGGAGGCCT

4751 AGGCTTTTGC AAAAAGCTCC CGGGAGCTTG TATATCCATT TTCGGATCTG

4801 ATCAAGAGAC AGGATGAGGA TCGTTTCGCA TGATTGAACA AGATGGATTG

4851 CACGCAGGTT CTCCGGCCGC TTGGGTGGAG AGGCTATTCG GCTATGACTG

4901 GGCACAACAG ACAATCGGCT GCTCTGATGC CGCCGTGTTC CGGCTGTCAG

4951 CGCAGGGGCG CCCGGTTCTT TTTGTCAAGA CCGACCTGTC CGGTGCCCTG

5001 AATGAACTGC AGGACGAGGC AGCGCGGCTA TCGTGGCTGG CCACGACGGG

5051 CGTTCCTTGC GCAGCTGTGC TCGACGTTGT CACTGAAGCG GGAAGGGACT

5101 GGCTGCTATT GGGCGAAGTG CCGGGGCAGG ATCTCCTGTC ATCTCACCTT

5151 GCTCCTGCCG AGAAAGTATC CATCATGGCT GATGCAATGC GGCGGCTGCA

5201 TACGCTTGAT CCGGCTACCT GCCCATTCGA CCACCAAGCG AAACATCGCA

5251 TCGAGCGAGC ACGTACTCGG ATGGAAGCCG GTCTTGTCGA TCAGGATGAT

5301 CTGGACGAAG AGC AT CAGGG GCTCGCGCCA GCCGAACTGT TCGCCAGGCT

5351 CAAGGCGCGC ATGCCCGACG GCGAGGATCT CGTCGTGACC CATGGCGATG

5401 CCTGCTTGCC G AAT AT CAT G GTGGAAAATG GCCGCTTTTC TGGATTCATC

5451 GACTGTGGCC GGCTGGGTGT GGCGGACCGC TATCAGGACA TAGCGTTGGC

5501 TACCCGTGAT ATTGCTGAAG AGCTTGGCGG CGAATGGGCT GACCGCTTCC

5551 TCGTGCTTTA CGGTATCGCC GCTCCCGATT CGCAGCGCAT CGCCTTCTAT

5601 CGCCTTCTTG ACGAGTTCTT CTGAGCGGGA CTCTGGGGTT CGAAATGACC

5651 GACCAAGCGA CGCCCAACCT GCCATCACGA GATTTCGATT CCACCGCCGC

5701 CTTCTATGAA AGGTTGGGCT TCGGAATCGT TTTCCGGGAC GCCGGCTGGA

5751 TGATCCTCCA GCGCGGGGAT CTCATGCTGG AGTTCTTCGC CCACCCCAAC

5801 TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA GC AT C AC AAA

5851 TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA

5901 AACTCATCAA TGTATCTTAT CATGTCTGTA TACCGTCGAC CTCTAGCTAG

5951 AGCTTGGCGT AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC

6001 GCTCACAATT CCACACAACA TACGAGCCGG AAGCATAAAG TGTAAAGCCT

6051 GGGGTGCCTA AT GAG T GAG C TAACTCACAT TAATTGCGTT GCGCTCACTG

6101 CCCGCTTTCC AGT CGGGAAA CCTGTCGTGC CAGCTGCATT AATGAATCGG 6151 CCAACGCGCG GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT

6201 CGCTCACTGA CTCGCTGCGC TCGGTCGTTC GGCTGCGGCG AGCGGTATCA

6251 GCTCACTCAA AGGCGGTAAT ACGGTTATCC ACAGAATCAG GGGATAACGC

6301 AGGAAAGAAC AT G T GAG C AA AAGGCCAGCA AAAGGCCAGG AACCGTAAAA

6351 AGGCCGCGTT GCTGGCGTTT TTCCATAGGC TCCGCCCCCC TGACGAGCAT

6401 CACAAAAATC GACGCTCAAG TCAGAGGTGG CGAAACCCGA CAGGACTATA

6451 AAGATACCAG GCGTTTCCCC CTGGAAGCTC CCTCGTGCGC TCTCCTGTTC

6501 CGACCCTGCC GCTTACCGGA TACCTGTCCG CCTTTCTCCC TTCGGGAAGC

6551 GTGGCGCTTT CTCATAGCTC ACGCTGTAGG TAT CT CAGT T CGGTGTAGGT

6601 CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTT CAGCCCGACC

6651 GCTGCGCCTT ATCCGGTAAC TATCGTCTTG AGTCCAACCC GGTAAGACAC

6701 GACTTATCGC CACTGGCAGC AGCCACTGGT AACAGGATTA GCAGAGCGAG

6751 GTATGTAGGC GGTGCTACAG AGTTCTTGAA GTGGTGGCCT AACTACGGCT

6801 ACACTAGAAG AACAGTATTT GGTATCTGCG CTCTGCTGAA GCCAGTTACC

6851 TTCGGAAAAA GAGTTGGTAG CTCTTGATCC GGCAAACAAA CCACCGCTGG

6901 TAGCGGTTTT TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT

6951 CTCAAGAAGA TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC

7001 GAAAAC T C AC GTTAAGGGAT TTTGGTCATG AG AT T AT C AA AAAGGATCTT

7051 CACCTAGATC CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA

7101 TATATGAGTA AACTTGGTCT GACAGTTACC AATGCTTAAT CAGT GAGGCA

7151 CCTATCTCAG CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC

7201 CGTCGTGTAG ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG

7251 CTGCAATGAT ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA

7301 ATAAACCAGC CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT

7351 ATCCGCCTCC ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA

7401 GTTCGCCAGT TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC

7451 GTGGTGTCAC GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA

7501 ACGATCAAGG CGAGTTACAT GATCCCCCAT GTTGTGCAAA AAAGCGGTTA

7551 GCTCCTTCGG TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA

7601 TCACTCATGG TTATGGCAGC ACTGCATAAT TCTCTTACTG T CAT GC CATC

7651 CGTAAGATGC TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG

7701 AATAGTGTAT GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT

7751 AATACCGCGC CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG

7801 TTCTTCGGGG CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT

7851 CGATGTAACC CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC

7901 ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA

7951 GGGAATAAGG GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC

8001 AATATTATTG AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA 8051 TTTGAATGTA TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC

8101 CCGAAAAGTG CCACCTGACG TC

[0095] According to one embodiment, the vector is a plasmid and has the sequence of pAV-U6+27-Tomado-F30-Pepper(TAR Variant-2) (SEQ ID NO: 78; GenBank Accession No. MN052908.1, which is hereby incorporated by reference in its entirety) as follows:

1 GCCGGATCCA AGGTCGGGCA GGAAGAGGGC CTATTTCCCA TGATTCCTTC 51 ATATTTGCAT ATACGATACA AGGCTGTTAG AGAGATAATT AGAATTAATT 101 TGACTGTAAA CACAAAGATA TTAGTACAAA ATACGTGACG TAGAAAGTAA 151 TAATTTCTTG GGTAGTTTGC AGTTTTAAAA TTATGTTTTA AAATGGACTA 201 TCATATGCTT ACCGTAACTT GAAAGTATTT CGATTTCTTG GCTTTATATA 251 TCTTGTGGAA AGGACGAAAC ACCGTGCTCG CTTCGGCAGC ACATATACTA 301 GTCGACGGGC CGCACTCGCC GGTCCCAAGC CCGGATAAAA TGGGAGGGGG 351 CGGGAAACCG CCTAACCATG CCGAGTGCGG CCGCTTGCCA TGTGTATGTG 401 GGACGCGTTG CCACGTTTCC CACATACTCT GATGATCCGC TAGCAAAGGC 451 TCGTTGAGCT CATTAGCTCC GAGCCCGAGG TACCGGATCA TTCATGGCAA 501 GCGGCCGCGG TCGGCGTGGA CTGTAGAACA CTGCCAATGC CGGTCCCAAG 551 CCCGGATAAA AGTGGAGGGT ACAGTCCACG CTCTAGAGCG GACTTCGGTC 601 CGCTTTTTAC TAGGACCTGC AGGCATGCAA GCTTGACGTC GGTTACCGAT 651 ATCCATATGG CGACCGCATC GATCTCGAGC CGAGGACTAG TAACTTGTTT 701 ATTGCAGCTT ATAATGGTTA CAAATAAAGC AATAGCATCA CAAATTTCAC 751 AAATAAAGCA TTTT T CAC TGCATTCTAG TTGTGGTTTG TCCAAACTCA 801 TCAATGTATC TTATCATGTC TTACGTAGAT AAGTAGCATG GCGGGTTAAT 851 CATTAACTAC AAGGAACCCC TAGTGATGGA GTTGGCCACT CCCTCTCTGC 901 GCGCTCGCTC GCTCACTGAG GCCGGGCGAC CAAAGGTCGC CCGACGCCCG 951 GGCTTTGCCC GGGCGGCCTC AGTGAGCGAG CGAGCGCGCA GAGAGGGAGT 1001 GGCCAAAGAT CTCTGGCGTA ATAGCGAAGA GGCCCGCACC GATCGCCCTT 1051 CCCAACAGTT GCGCAGCCTG AATGGCTAAT GGGAAATTGT AAACGTTAAT 1101 ATTTTGTTAA TATTTTGTTA AAATTCGCGT TAAATTTTTG TTAAATCAGC 1151 TCATTTTTTA ACCAATAGGC CGAAATCGGC AAAATCCCTT ATAAATCAAA 1201 AGAATAGACC GAGATAGGGT TGAGTGTTGT TCCAGTTTGG AACAAGAGTC 1251 CACTATTAAA GAACGTGGAC TCCAACGTCA AAGGGCGAAA AACCGTCTAT 1301 CAGGGCGATG GCCCACTACG TGAACCATCA CCCTAATCAA GTTTTTTGGG 1351 GTCGAGGTGC CGTAAAGCAC TAAATCGGAA CCCTAAAGGG ATGCCCCGAT 1401 TTAGAGCTTG ACGGGGAAAG CCGGCGAACG TGGCGAGAAA GGAAGGGAAG 1451 AAAGCGAAAG GAGCGGGCGC TAGGGCGCTG GCAAGTGTAG CGGTCACGCT 1501 GCGCGTAACC ACCACACCCG CCGCGCTTAA TGCGCCGCTA CAGGGCGCGT 1551 CAGGTGGCAC TTTTCGGGGA AATGTGCGCG GAACCCCTAT TTGTTTATTT

1601 TTCTAAATAC ATTCAAATAT GTATCCGCTC ATGAGACAAT AACCCTGATA

1651 AATGCTTCAA TAATATTGAA AAAGGAAGAG TATGAGTATT CAACATTTCC

1701 GTGTCGCCCT TATTCCCTTT TTTGCGGCAT TTTGCCTTCC TGTTTTTGCT

1751 C AC C C AG AAA CGCTGGTGAA AGTAAAAGAT GCTGAAGATC AGTTGGGTGC

1801 ACGAGTGGGT TACATCGAAC TGGATCTCAA CAGCGGTAAG ATCCTTGAGA

1851 GTTTTCGCCC CGAAGAACGT TTTCCAATGA TGAGCACTTT TAAAGTTCTG

1901 CTATGTGGCG CGGTATTATC CCGTATTGAC GCCGGGCAAG AGCAACTCGG

1951 TCGCCGCATA CACTATTCTC AGAATGACTT GGTTGAGTAC TCACCAGTCA

2001 CAGAAAAGCA TCTTACGGAT GGCATGACAG TAAGAGAATT ATGCAGTGCT

2051 GCCATAACCA TGAGTGATAA CACTGCGGCC AACTTACTTC TGACAACGAT

2101 CGGAGGACCG AAGGAGCTAA CCGCTTTTTT GCACAAC AT G GGGGATCATG

2151 TAACTCGCCT TGATCGTTGG GAACCGGAGC TGAATGAAGC CATACCAAAC

2201 GACGAGCGTG ACACCACGAT GCCTGTAGCA ATGGCAACAA CGTTGCGCAA

2251 ACTATTAACT GGCGAACTAC TTACTCTAGC TTCCCGGCAA CAATTAATAG

2301 ACTGGATGGA GGCGGATAAA GTTGCAGGAC CACTTCTGCG CTCGGCCCTT

2351 CCGGCTGGCT GGTTTATTGC TGATAAATCT GGAGCCGGTG AGCGTGGGTC

2401 TCGCGGTATC ATTGCAGCAC TGGGGCCAGA TGGTAAGCCC TCCCGTATCG

2451 TAGTTATCTA CACGACGGGG AGTCAGGCAA CTATGGATGA ACGAAATAGA

2501 CAGATCGCTG AGATAGGTGC CTCACTGATT AAGCATTGGT AACTGTCAGA

2551 CCAAGTTTAC T CAT AT AT AC TTTAGATTGA TTTAAAACTT CATTTTTAAT

2601 TTAAAAGGAT CTAGGTGAAG ATCCTTTTTG ATAATCTCAT GACCAAAATC

2651 CCTTAACGTG AGTTTTCGTT CCACTGAGCG TCAGACCCCG TAGAAAAGAT

2701 CAAAGGAT CT TCTTGAGATC CTTTTTTTCT GCGCGTAATC TGCTGCTTGC

2751 AAACAAAAAA ACCACCGCTA CCAGCGGTGG TTTGTTTGCC GGATCAAGAG

2801 CTACCAACTC TTTTTCCGAA GGTAACTGGC TTCAGCAGAG CGCAGATACC

2851 AAATACTGTC CTTCTAGTGT AGCCGTAGTT AGGCCACCAC TTCAAGAACT

2901 CTGTAGCACC GCCTACATAC CTCGCTCTGC TAATCCTGTT ACCAGTGGCT

2951 GCTGCCAGTG GCGATAAGTC GTGTCTTACC GGGTTGGACT CAAGACGATA

3001 GTTACCGGAT AAGGCGCAGC GGTCGGGCTG AACGGGGGGT TCGTGCAACA

3051 CAGCCAGCTT GGAGCGAACG ACCTACACCG AAC T GAG AT A CCTACAGCGT

3101 GAGC AT T GAG AAAGCGCCAC GCTTCCCGAA GGGAGAAAGG CGGACAGGTA

3151 TCCGGTAAGC GGCAGGGTCG GAACAGGAGA GCGCACGAGG GAGCTTCCAG

3201 GGGGAAACGC CTGGTATCTT TATAGTCCTG TCGGGTTTCG CCACCTCTGA

3251 CTTGAGCGTC GATTTTTGTG ATGCTCGTCA GGGGGGCGGA GCCTATGGAA

3301 AAACGCCAGC AACGCGGCCT TTTTACGGTT CCTGGCCTTT TGCTGGCCTT

3351 TTGCTCACAT GTTCTTTCCT GCGTTATCCC CTGATTCTGT GGATAACCGT

3401 ATTACCGCCT TTGAGTGAGC TGATACCGCT CGCCGCAGCC GAACGACCGA 3451 GCGCAGCGAG TCAGTGAGCG AGGAAGCGGA AGAGCGCCCA ATACGCAAAC

3501 CGCCTCTCCC CGCGCGTTGG CCGATTCATT AATGCAGAGA TCTTTGGCCA

3551 CTCCCTCTCT GCGCGCTCGC TCGCTCACTG AGGCCGGGCG ACCAAAGGTC

3601 GCCCGACGCC CGGGCTTTGC CCGGGCGGCC TCAGTGAGCG AGCGAGCGCG

3651 CAGAGAGGGA GTGGCCAACT CCATCACTAG GGGTTCCTGG AGGGGTGGAG

3701 TCGTGACGTG AATTACGTCA TAGGGTTAGG GAGGTCCTGG ATCGATCCAG

3751 ACATGATAAG ATACATTGAT GAGTTTGGAC AAACCACAAC TAGAATGCAG

3801 TGAAAAAAAT GCTTTATTTG TGAAATTTGT GATGCTATTG CTTTATTTGT

3851 AACCATTATA AGCTGCAATA AACAAGTTAA CAACAACAAT TGCATTCATT

3901 TTATGTTTCA GGTTCAGGGG GAGGTGTGGG AGGTTTTTTA AAGCAAGTAA

3951 AACCTCTACA AATGTGGTAT GGCTGATTAT GATCTCTAGT CAAGGCACTA

4001 TACATCAAAT ATTCCTTATT AACCCCTTTA CAAATTAAAA AGCTAAAGGT

4051 ACACAATTTT TGAGCATAGT TATTAATAGC AG AC AC T C T A TGCCTGTGTG

4101 GAGTAAGAAA AAACAGT AT G TTATGATTAT AACTGTTATG CCTACTTATA

4151 AAGGTTACAG AATATTTTTC CATAATTTTC TTGTATAGCA GTGCAGCTTT

4201 TTCCTTTGTG GTGTAAATAG CAAAGCAAGC AAGAGTTCTA TTACTAAACA

4251 CAGCATGACT CAAAAAACTT AGCAATTCTG AAGGAAAGTC CTTGGGGTCT

4301 TCTACCTTTC TCTTCTTTTT TGGAGGAGTA GAATGTTGAG AGTCAGCAGT

4351 AGCCTCATCA TCACTAGATG GCATTTCTTC TGAGCAAAAC AGGTTTTCCT

4401 CATTAAAGGC ATTCCACCAC TGCTCCCATT CATCAGTTCC ATAGGTTGGA

4451 ATCTAAAATA CACAAACAAT TAGAATCAGT AGTTTAACAC ATTATACACT

4501 TAAAAATTTT ATATTTACCT TAGAGCTTTA AATCTCTGTA GGTAGTTTGT

4551 CCAATTATGT C AC ACC AC AG AAGTAAGGTT CCTTCACAAA GATCCGGGAC

4601 CAAAGCGGCC ATCGTGCCTC CCCACTCCTG CAGTTCGGGG GCATGGATGC

4651 GCGGATAGCC GCTGCTGGTT TCCTGGATGC CGACGGATTT GCACTGCCGG

4701 TAGAACTCCG CGAGGTCGTC CAGCCTCAGG CAGCAGCTGA ACCAACTCGC

4751 GAGGGGATCG AGCCCGGGGT GGGCGAAGAA CTCCAGCATG AGATCCCCGC

4801 GCTGGAGGAT CATCCAGCCG GCGTCCCGGA AAACGATTCC GAAGCCCAAC

4851 CTTTCATAGA AGGCGGCGGT GGAATCGAAA TCTCGTGATG GCAGGTTGGG

4901 CGTCGCTTGG TCGGTCATTT CGAACCCCAG AGTCCCGCTC AGAAGAACTC

4951 GTCAAGAAGG CGATAGAAGG CGATGCGCTG CGAATCGGGA GCGGCGATAC

5001 CGTAAAGCAC GAGGAAGCGG TCAGCCCATT CGCCGCCAAG CTCTTCAGCA

5051 ATATCACGGG TAGCCAACGC TATGTCCTGA TAGCGGTCCG CCACACCCAG

5101 CCGGCCACAG TCGATGAATC CAGAAAAGCG GCCATTTTCC ACCATGATAT

5151 TCGGCAAGCA GGCATCGCCA TGGGTCACGA CGAGATCCTC GCCGTCGGGC

5201 ATGCGCGCCT TGAGCCTGGC GAACAGTTCG GCTGGCGCGA GCCCCTGATG

5251 CTCTTGTCCA GATCATCCTG ATCGACAAGA CCGGCTTCCA TCCGAGTACG

5301 TGCTCGCTCG ATGCGATGTT CGCTTGGTGG TCGAATGGGC AGGTAGCCGG 5351 ATCAAGCGTA TGCAGCCGCC GCATTGCATC AGCCATGATG GATACTTTCT 5401 CGGCAGGAGC AAGGTGAGAT GACAGGAGAT CCTGCCCCGG CACTTCGCCC 5451 AATAGCAGCC AGTCCCTTCC CGCTTCAGTG ACAACGTCGA GCACAGCTGC 5501 GCAAGGAACG CCCGTCGTGG CCAGCCACGA TAGCCGCGCT GCCTCGTCCT 5551 GCAGTTCATT CAGGGCACCG GACAGGTCGG TCTTGACAAA AAGAACCGGG 5601 CGCCCCTGCG CTGACAGCCG GAACACGGCG GCATCAGAGC AGCCGATTGT 5651 CTGTTGTGCC CAGTCATAGC CGAATAGCCT CTCCACCCAA GCGGCCGGAG 5701 AACCTGCGTG CAATCCATCT TGTTCAATCA TGCGAAACGA TCCTCATCCT 5751 GTCTCTTGAT CAGATCTTGA TCCCCTGCGC CATCAGATCC TTGGCGGCAA 5801 GAAAGCCATC CAGTTTACTT TGCAGGGCTT CCCAACCTTA CCAGAGGGCG 5851 CCCCAGCTGG CAATTCCGGT TCGCTTGCTG TCCATAAAAC CGCCCAGTCT 5901 AGCTATCGGC ATGTAAGCCC ACTGCAAGCT ACCTGCTTTC TCTTTGCGCT 5951 TGCGTTTTCC CTTGTCCAGA TAGCCCAGTA GCTGACATTC ATCCGGGGTC 6001 AGCACCGTTT CTGCGGACTG GCTTTCTACG TGTTCCGCTT CCTTTAGCAG 6051 CCCTTGCGCC CTGAGTGCTT GCGGCAGCGT GAAGCTTTTT GCAAAAGCCT 6101 AGGCCTCCAA AAAAGCCTCC TCACTACTTC TGGAATAGCT CAGAGGCCGA 6151 GGCGGCCTCG GCCTCTGCAT AAATAAAAAA AATTAGTCAG CCATGGGGCG 6201 GAGAATGGGC GGAACTGGGC GGAGTTAGGG GCGGGATGGG CGGAGTTAGG 6251 GGCGGGACTA TGGTTGCTGA CTAATTGAGA TGCATGCTTT GCATACTTCT 6301 GCCTGCTGGG GAGCCTGGGG ACTTTCCACA CCTGGTTGCT GACTAATTGA 6351 GATGCATGCT TTGCATACTT CTGCCTGCTG GGGAGCCTGG GGACTTTCCA 6401 CACCCTAACT GACACACATT CCACA

[0096] According to one embodiment, the vector is a plasmid and has the sequence of pAV-U6+27-Tomado-F30-TAR Variant-1 (SEQ ID NO: 79; GenBank

Accession No. MN052909.1, which is hereby incorporated by reference in its entirety) as follows:

1 GCCGGATCCA AGGTCGGGCA GGAAGAGGGC CTATTTCCCA TGATTCCTTC 51 ATATTTGCAT ATACGATACA AGGCTGTTAG AGAGATAATT AGAATTAATT 101 TGACTGTAAA CACAAAGATA TTAGTACAAA ATACGTGACG TAGAAAGTAA 151 TAATTTCTTG GGTAGTTTGC AGTTTTAAAA TTATGTTTTA AAATGGACTA 201 TCATATGCTT ACCGTAACTT GAAAGTATTT CGATTTCTTG GCTTTATATA 251 TCTTGTGGAA AGGACGAAAC ACCGTGCTCG CTTCGGCAGC ACATATACTA 301 GTCGACGGGC CGCACTCGCC GGTCCCAAGC CCGGATAAAA TGGGAGGGGG 351 CGGGAAACCG CCTAACCATG CCGAGTGCGG CCGCTTGCCA TGTGTATGTG 401 GGACGCGTTG CCACGTTTCC CACATACTCT GATGATCCGC TAGCAAAGGC 451 TCGTCTGAGC TCATTAGCTC CGAGCCCGAG GTACCGGATC ATTCATGGCA 501 AGCGGCCGCG GTCGGCGTGG ACTGTAGAAC ACTGCCAATG CCGGTCCCAA 551 GCCCGGATAA AAGTGGAGGG TACAGTCCAC GCTCTAGAGC GGACTTCGGT

601 CCGCTTTTTA CTAGGACCTG CAGGCATGCA AGCTTGACGT CGGTTACCGA

651 TATCCATATG GCGACCGCAT CGATCTCGAG CCGAGGACTA GTAACTTGTT

701 TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA

751 CAAATAAAGC _ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC

801 ATCAATGTAT CTTATCATGT CTTACGTAGA TAAGTAGCAT GGCGGGTTAA

851 TCATTAACTA CAAGGAACCC CTAGTGATGG AGTTGGCCAC TCCCTCTCTG

901 CGCGCTCGCT CGCTCACTGA GGCCGGGCGA CCAAAGGTCG CCCGACGCCC

951 GGGCTTTGCC CGGGCGGCCT CAGTGAGCGA GCGAGCGCGC AGAGAGGGAG

1001 TGGCCAAAGA TCTCTGGCGT AATAGCGAAG AGGCCCGCAC CGATCGCCCT

1051 TCCCAACAGT TGCGCAGCCT GAATGGCTAA TGGGAAATTG TAAACGTTAA

1101 TATTTTGTTA ATATTTTGTT AAAATTCGCG TTAAATTTTT GTTAAATCAG

1151 CTCATTTTTT AACCAATAGG CCGAAATCGG CAAAATCCCT TATAAATCAA

1201 AAGAATAGAC CGAGATAGGG TTGAGTGTTG TTCCAGTTTG GAACAAGAGT

1251 CCACTATTAA AGAACGTGGA CTCCAACGTC AAAGGGCGAA AAACCGTCTA

1301 TCAGGGCGAT GGCCCACTAC GTGAACCATC ACCCTAATCA AGTTTTTTGG

1351 GGTCGAGGTG CCGTAAAGCA CTAAATCGGA ACCCTAAAGG GATGCCCCGA

1401 TTTAGAGCTT GACGGGGAAA GCCGGCGAAC GTGGCGAGAA AGGAAGGGAA

1451 GAAAGC GAAA GGAGCGGGCG CTAGGGCGCT GGCAAGTGTA GCGGTCACGC

1501 TGCGCGTAAC CACCACACCC GCCGCGCTTA ATGCGCCGCT ACAGGGCGCG

1551 TCAGGTGGCA CTTTTCGGGG AAATGTGCGC GGAACCCCTA TTTGTTTATT

1601 TTTCTAAATA CATTCAAATA TGTATCCGCT CAT GAGAC AA TAACCCTGAT

1651 AAATGCTTCA ATAATATTGA AAAAGGAAGA GTATGAGTAT TCAACATTTC

1701 CGTGTCGCCC TTATTCCCTT TTTTGCGGCA TTTTGCCTTC CTGTTTTTGC

1751 TCACCCAGAA ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG

1801 CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA GATCCTTGAG

1851 AGTTTTCGCC CCGAAGAACG TTTTCCAATG ATGAGCACTT TTAAAGTTCT

1901 GCTATGTGGC GCGGTATTAT CCCGTATTGA CGCCGGGCAA GAGCAACTCG

1951 GTCGCCGCAT ACACTATTCT CAGAATGACT TGGTTGAGTA CTCACCAGTC

2001 ACAGAAAAGC ATCTTACGGA TGGCATGACA GTAAGAGAAT TATGCAGTGC

2051 TGCCATAACC AT GAG T GAT A ACACTGCGGC CAACTTACTT CTGACAACGA

2101 TCGGAGGACC GAAGGAGCTA ACCGCTTTTT TGCACAACAT GGGGGATCAT

2151 GTAACTCGCC TTGATCGTTG GGAACCGGAG CTGAATGAAG CCATACCAAA

2201 CGACGAGCGT GACACCACGA TGCCTGTAGC AATGGCAACA ACGTTGCGCA

2251 AACTATTAAC TGGCGAACTA CTTACTCTAG CTTCCCGGCA ACAATTAATA

2301 GACTGGATGG AGGCGGATAA AGTTGCAGGA CCACTTCTGC GCTCGGCCCT

2351 TCCGGCTGGC TGGTTTATTG CTGATAAATC TGGAGCCGGT GAGCGTGGGT

2401 CTCGCGGTAT CATTGCAGCA CTGGGGCCAG ATGGTAAGCC CTCCCGTATC 2451 GTAGTTATCT ACACGACGGG GAGT CAGGCA ACTATGGATG AACGAAATAG

2501 ACAGATCGCT GAGATAGGTG CCTCACTGAT TAAGCATTGG TAACTGTCAG

2551 ACCAAGTTTA CTCATATATA CTTTAGATTG ATTTAAAACT TCATTTTTAA

2601 TTTAAAAGGA TCTAGGTGAA GATCCTTTTT GATAATCTCA TGACCAAAAT

2651 CCCTTAACGT GAGTTTTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA

2701 TCAAAGGATC TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG

2751 CAAACAAAAA AACCACCGCT ACCAGCGGTG GTTTGTTTGC CGGATCAAGA

2801 GCTACCAACT CTTTTTCCGA AGGTAACTGG CTTCAGCAGA GCGCAGATAC

2851 CAAAT ACT GT CCTTCTAGTG TAGCCGTAGT TAGGCCACCA CTTCAAGAAC

2901 TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT TACCAGTGGC

2951 TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT

3001 AGTTACCGGA TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCAAC

3051 ACAGCCAGCT TGGAGCGAAC GACCTACACC G AAC T GAG AT ACCTACAGCG

3101 TGAGCATTGA GAAAGCGCCA CGCTTCCCGA AGGGAGAAAG GCGGACAGGT

3151 ATCCGGTAAG CGGCAGGGTC GGAACAGGAG AGCGCACGAG GGAGCTTCCA

3201 GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC GCCACCTCTG

3251 ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA

3301 AAAACGCCAG CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT

3351 TTTGCTCACA TGTTCTTTCC TGCGTTATCC CCTGATTCTG TGGATAACCG

3401 TATTACCGCC TTTGAGTGAG CTGATACCGC TCGCCGCAGC CGAACGACCG

3451 AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG AAGAGCGCCC AATACGCAAA

3501 CCGCCTCTCC CCGCGCGTTG GCCGATTCAT TAATGCAGAG ATCTTTGGCC

3551 ACTCCCTCTC TGCGCGCTCG CTCGCTCACT GAGGCCGGGC GACCAAAGGT

3601 CGCCCGACGC CCGGGCTTTG CCCGGGCGGC CTCAGTGAGC GAGCGAGCGC

3651 GCAGAGAGGG AGTGGCCAAC TCCATCACTA GGGGTTCCTG GAGGGGTGGA

3701 GTCGTGACGT GAATTACGTC ATAGGGTTAG GGAGGTCCTG GATCGATCCA

3751 G AC AT GAT AA GATACATTGA TGAGTTTGGA CAAACCACAA CTAGAATGCA

3801 GTGAAAAAAA TGCTTTATTT GTGAAATTTG TGATGCTATT GCTTTATTTG

3851 TAACCATTAT AAGCTGCAAT AAACAAGTTA ACAACAACAA TTGCATTCAT

3901 TTTATGTTTC AGGTTCAGGG GGAGGTGTGG GAGGTTTTTT AAAGCAAGTA

3951 AAACCTCTAC AAATGTGGTA TGGCTGATTA TGATCTCTAG TCAAGGCACT

4001 AT AC AT CAAA TATTCCTTAT TAACCCCTTT ACAAATTAAA AAGCTAAAGG

4051 TACACAATTT TTGAGCATAG TTATTAATAG CAGACACTCT ATGCCTGTGT

4101 GGAGTAAGAA AAAACAGTAT GT TAT GATT A TAACTGTTAT GCCTACTTAT

4151 AAAGGTTACA GAATATTTTT CCATAATTTT CTTGTATAGC AGTGCAGCTT

4201 TTTCCTTTGT GGTGTAAATA GCAAAGCAAG CAAGAGTTCT ATTACTAAAC

4251 ACAGCATGAC TCAAAAAACT TAGCAATTCT GAAGGAAAGT CCTTGGGGTC

4301 TTCTACCTTT CTCTTCTTTT TTGGAGGAGT AGAATGTTGA GAGTCAGCAG 4351 TAGCCTCATC ATCACTAGAT GGCATTTCTT CTGAGCAAAA CAGGTTTTCC

4401 T CAT T AAAGG CATTCCACCA CTGCTCCCAT TCATCAGTTC CATAGGTTGG

4451 AATCTAAAAT ACACAAACAA TTAGAATCAG TAGTTTAACA CATTATACAC

4501 TTAAAAATTT TATATTTACC TTAGAGCTTT AAATCTCTGT AGGTAGTTTG

4551 TCCAATTATG T CACACC AC A GAAGTAAGGT TCCTTCACAA AGATCCGGGA

4601 CCAAAGCGGC CATCGTGCCT CCCCACTCCT GCAGTTCGGG GGCATGGATG

4651 CGCGGATAGC CGCTGCTGGT TTCCTGGATG CCGACGGATT TGCACTGCCG

4701 GTAGAACTCC GCGAGGTCGT CCAGCCTCAG GCAGCAGCTG AACCAACTCG

4751 CGAGGGGATC GAGCCCGGGG TGGGCGAAGA ACTCCAGCAT GAGATCCCCG

4801 CGCTGGAGGA TCATCCAGCC GGCGTCCCGG AAAACGATTC CGAAGCCCAA

4851 CCTTTCATAG AAGGCGGCGG TGGAATCGAA ATCTCGTGAT GGCAGGTTGG

4901 GCGTCGCTTG GTCGGTCATT TCGAACCCCA GAGTCCCGCT CAGAAGAACT

4951 CGTCAAGAAG GCGATAGAAG GCGATGCGCT GCGAATCGGG AGCGGCGATA

5001 CCGTAAAGCA CGAGGAAGCG GTCAGCCCAT TCGCCGCCAA GCTCTTCAGC

5051 AATATCACGG GTAGCCAACG CTATGTCCTG ATAGCGGTCC GCCACACCCA

5101 GCCGGCCACA GTCGATGAAT CCAGAAAAGC GGCCATTTTC CACCATGATA

5151 TTCGGCAAGC AGGCATCGCC ATGGGTCACG ACGAGATCCT CGCCGTCGGG

5201 CATGCGCGCC TTGAGCCTGG CGAACAGTTC GGCTGGCGCG AGCCCCTGAT

5251 GCTCTTGTCC AGATCATCCT GATCGACAAG ACCGGCTTCC ATCCGAGTAC

5301 GTGCTCGCTC GATGCGATGT TCGCTTGGTG GTCGAATGGG CAGGTAGCCG

5351 GATCAAGCGT ATGCAGCCGC CGCATTGCAT CAGCCATGAT GGATACTTTC

5401 TCGGCAGGAG CAAGGTGAGA TGACAGGAGA TCCTGCCCCG GCACTTCGCC

5451 CAATAGCAGC CAGTCCCTTC CCGCTTCAGT GACAACGTCG AGCACAGCTG

5501 CGCAAGGAAC GCCCGTCGTG GCCAGCCACG ATAGCCGCGC TGCCTCGTCC

5551 TGCAGTTCAT TCAGGGCACC GGACAGGTCG GTCTTGACAA AAAGAACCGG

5601 GCGCCCCTGC GCTGACAGCC GGAACACGGC GGC AT CAGAG CAGCCGATTG

5651 TCTGTTGTGC CCAGTCATAG CCGAATAGCC TCTCCACCCA AGCGGCCGGA

5701 GAACCTGCGT GCAATCCATC TTGTTCAATC ATGCGAAACG ATCCTCATCC

5751 TGTCTCTTGA TCAGATCTTG ATCCCCTGCG CCATCAGATC CTTGGCGGCA

5801 AGAAAGCCAT CCAGTTTACT TTGCAGGGCT TCCCAACCTT ACCAGAGGGC

5851 GCCCCAGCTG GCAATTCCGG TTCGCTTGCT GTCCATAAAA CCGCCCAGTC

5901 TAGCTATCGG CATGTAAGCC CACTGCAAGC TACCTGCTTT CTCTTTGCGC

5951 TTGCGTTTTC CCTTGTCCAG ATAGCCCAGT AGCTGACATT CATCCGGGGT

6001 CAGCACCGTT TCTGCGGACT GGCTTTCTAC GTGTTCCGCT TCCTTTAGCA

6051 GCCCTTGCGC CCTGAGTGCT TGCGGCAGCG TGAAGCTTTT TGCAAAAGCC

6101 TAGGCCTCCA AAAAAGCCTC CTCACTACTT CTGGAATAGC TCAGAGGCCG

6151 AGGCGGCCTC GGCCTCTGCA TAAATAAAAA AAATTAGTCA GCCATGGGGC

6201 GGAGAATGGG CGGAACTGGG CGGAGTTAGG GGCGGGATGG GCGGAGTTAG 6251 GGGCGGGACT ATGGTTGCTG ACTAATTGAG ATGCATGCTT TGCATACTTC 6301 TGCCTGCTGG GGAGCCTGGG GACTTTCCAC ACCTGGTTGC TGACTAATTG 6351 AGATGCATGC TTTGCATACT TCTGCCTGCT GGGGAGCCTG GGGACTTTCC 6401 ACACCCTAAC TGACACACAT TCCACA

[0097] As described herein, the vector may comprise two, three, four, five, or more nucleic acid sequences according to the present application. In some embodiments, the vector comprises a first nucleic acid sequences encoding a first RNA-regulated fusion protein and a second nucleic acid sequence encoding a second RNA-regulated fusion protein. In other embodiments, the vector may further comprise a third nucleic acid molecule encoding a third RNA-regulated fusion protein, etc. For example, the vector may comprise 3-10 or more nucleic acid molecules, each encoding an independently selected RNA fusion protein according to the present application.

[0098] In some embodiments, where the vector encodes multiple RNA-regulated fusion proteins, each independent fusion protein may comprise a component of a metabolic pathway. In some embodiments, the metabolic pathway is glucose metabolism and the independent fusion proteins comrprise insulin, glucagon, and/or protein kinase C epsilon. In other embodiments, the metabolic pathway is a GPCR signaling pathway and the independent fusion proteins are selected from the group consisting of a, b, and g subunits of G-proteins.

[0099] In other embodiments, where the vector encodes multiple RNA-regulated fusion proteins, each RNA-regulated fusion protein comprises a distinct protein of interest. Suitable proteins of interest are described in detail above. In some embodiments, the proteins of interest comprise fluorescent proteins. In accordance with such embodiments, the fluorescent proteins have fluorescent emission spectra that do not substantially overlap with one another.

[0100] In some embodiments, the present application relates to an expression system comprising an expression vector into which is inserted a nucleic acid molecule described herein. In one embodiment, the expression system comprises a first vector encoding an RNA-regulated fusion protein and a second vector encoding a lentiviral transactivator of transcription (Tar) RNA aptamer.

[0101] Some embodiments of the present application relate to a host cell comprising a nucleic acid molecule (i.e., a nucleic acid molecule encoding an RNA- regulated fusion protein and/or a lentiviral transactivator of transcription (Tar) RNA sequence) or a vector (i.e., a vector comprising a nucleic acid molecule encoding an RNA- regulated fusion protein and/or a lentiviral transactivator of transcription (Tar) RNA sequence) described herein.

[0102] In some embodiments, the host cell is a mammalian cell. Suitable mammalian cells include, without limitation, rodent cells (i.e., mouse or rat cells), rabbit cells, guinea pig cells, feline cells, canine cells, porcine cells, equine cells, bovine cell, ovine cells, monkey cells, non-human primate, or human cells. In some embodiments, the host cell is a human cell. Suitable cells comprising the nucleic acid molecule or vector as described herein include primary or immortalized embryonic cells, fetal cells, or adult cells, at any stage of their lineage, e.g ., totipotent, pluripotent, multipotent, or differentiated cells.

[0103] The nucleic acid molecules and/or vectors described herein may be introduced into cells via transformation, particularly transduction, conjugation, lipofection, protoplast fusion, mobilization, particle bombardment, microinjection, transfection, or electroporation. In some embodiments, the nucleic acid molecules described herein are incorporated into the host cell using standard cloning procedures known in the art, as described by Sambrook et ah, Molecular Cloning: A Laboratory Manual , Second Edition, Cold Springs Laboratory, Cold Springs Harbor, New York (1989), which is hereby incorporated by reference in its entirety.

[0104] In some embodiments, the host cell may comprise an endogenous RNA ligase. As described herein, the endogenous RNA ligase has the ability to catalyze the circularization of a ribonucleic acid molecule having a 5'-OH and a 2'-3'-cyclic phosphate. In accordance with this embodiment, the endogenous RNA ligase is RtcB.

[0105] Another aspect of the present application relates to an RNA-regulated fusion protein comprising a protein of interest and an RNA-regulated destabilization domain. Suitable proteins of interest and RNA-regulated destabilization domains are described in more detail supra.

[0106] In some embodiments, the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor. Suitable fluorescent proteins, bioluminescent proteins, enzymes, or transcription factors are described in more detail supra.

[0107] In some embodiments, the RNA-regulated destabilization domain has the consensus sequence of SEQ ID NO: 62 as follows: XXXXXXXXXXXXXXXXXx, where X at position 1 can be S or A; X at position 2 can be G or A; X at position 3 can be P or A; X at position 4 can be R or K; X at position 5 can be P, A, I, Y, K, or R; X at position 6 can be R, K, V, or Y; X at position 7 can be G, A, or R; X at position 8 can be T or A; X at position 9 can be R or K; X at position 10 can be G or A; X at position 11 can be K or A; X at position 12 can be G or A; X at position 13 can be R or K; X at position 14 can be I or A; X at position 15 can be R, K, Y, or G; X at position 16 can be R, K, V, T, or Y; X at position 17 can be any amino acid but preferably R, G, E, S, or C; and x at position 18 is optional and can be any amino acid, but preferably G, E, O, N, D, or E.

[0108] In some embodiments the RNA-regulated destabilization domain has the sequence of tDeg (SEQ ID NO: 63) as follows: S GPRPRGTRGKGRRIRRRG.

[0109] Exemplary RNA-regulated fusion proteins are identified in Table 8 below.

Table 8. Exemplary RNA-Regulated Fusion Proteins

[0110] Yet another aspect of the disclosure relates to a molecular complex comprising an RNA-regulated fusion protein comprising (i) a protein of interest and (ii) an RNA-regulated destabilization domain and an RNA aptamer bound specifically to the RNA-regulated destabilization domain.

[0111] In some embodiments, the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor. Suitable fluorescent proteins, bioluminescent proteins, enzymes, and transcription factors are described in detail supra.

[0112] In some embodiments, the RNA-regulated destabilization domain has the sequence of SEQ ID NO: 62, where X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R,

K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid. For example, the RNA-regulated destabilization domain may be tDeg (SEQ ID NO: 63).

[0113] Suitable RNA aptamer sequences are described in detail supra. In some embodiments, the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. For example, the RNA aptamer may comprise the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

[0114] Additional exemplary RNA aptamers may be selected from the group consisting of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, and SEQ ID NO: 73. [0115] Some embodiments of the present application relate to a host cell comprising a molecular complex described herein (i.e., a molecular complex comprising an RNA-regulated fusion protein and an RNA aptamer bound specifically to the RNA- regulated destabilization domain). Suitable host cells are described in detail supra.

[0116] In some embodiments, the host cell is a mammalian cell. As described herein above, suitable mammalian cells include, without limitation, rodent cells (i.e., mouse or rat cells), rabbit cells, guinea pig cells, feline cells, canine cells, porcine cells, equine cells, bovine cell, ovine cells, monkey cells, non-human primate, or human cells.

In some embodiments, the host cell is a human cell.

[0117] Another aspect of the invention relates to a method of imaging RNA in a cell. This method involves providing a first vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or an enzyme fused to an RNA-regulated destabilization domain; providing second vector encoding an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; transfecting a host cell with the first vector and the second vector; and imaging said contacted cells.

[0118] Suitable vectors for carrying out the methods of imaging RNA in a cell are described in more detail supra and include, e.g, a plasmid ( e.g. , an expression vector) and a viral vector (e.g, a lentiviral or adenoviral vector).

[0119] Suitable RNA-regulated fusion proteins for carrying out the methods of the present application are described in more detail supra. In some embodiments of the methods described herein, the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

[0120] In other embodiments of the methods described herein, the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, b-galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b -glucuronidase, and b- glucosidase. In some embodiments, the bioluminescent protein is a luciferase selected from the group consisting of Nanoluc luciferase (Nluc), Firefly luciferase, and Renilla luciferase (Rluc).

[0121] In further embodiments of the methods described herein, the RNA- regulated fusion protein is an enzyme, wherein the enzyme is a biotin ligase. Suitable biotin ligases are described in detail supra and include, e.g ., TurboID, miniTurbo, or A. coli BirA.

[0122] As described in more detail supra , the RNA-regulated destabilization domain may comprise a bifunctional peptide having a lentiviral transactivator of transcription (Tat) peptide and a degron peptide. Lentiviral transactivator of transcription (Tat) peptides and a degron peptides are described in more detail supra.

[0123] In some embodiments of the methods described herein, the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, where X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid. Thus, in some embodiments, the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

[0124] As used herein, an RNA of interest is an RNA molecule that is desired and/or is being assessed. The RNA of interest may be a messenger RNA (mRNA) or a noncoding RNA (ncRNA). A messenger RNA or “mRNA” refers to a single-stranded RNA molecule that specifies the amino acid sequence of a protein. The mRNA molecule may comprise a 5' untranslated region (5' UTR), a coding region, and a 3 ' untranslated region (3' UTR). A 5' UTR is an untranslated nucleotide segment in an RNA molecule immediately preceding the AUG start codon. A 3' UTR is an untranslated nucleotide segment in an RNA molecule immediately following the translation termination codon. [0125] In some embodiments, the RNA of interest is an mRNA and the RNA aptamer is located within a coding region of the mRNA. In other embodiment, the RNA of interest is a mRNA and the RNA aptamer is located upstream of the 5' UTR, within the 5 ' UTR, within the 3 ' UTR, or downstream of the 3 ' UTR.

[0126] In other embodiments, the RNA of interest is a noncoding RNA (ncRNA).

As described herein, a noncoding RNA refers to a functional RNA molecule that is not translated into a protein. The RNA of interest may be a noncoding RNA selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA (e.g, siRNA, miRNA, microRNA, etc.).

[0127] In some embodiments, the RNA of interest is an artificial, engineered synthetic RNA.

[0128] Suitable RNA aptamers are described in detail supra. In some embodiments of the methods described herein, the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, where N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. For example, the RNA aptamer may comprise the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61). In some embodiments of the methods described herein, the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

[0129] Methods of transfecting a host cell are well known in the art and described in more detail supra. According to some embodiments of the methods described herein, transfecting the host cell with the first vector and the second vector is carried out simultaneously. In other embodiments, transfecting the host cell with the first vector and the second vector is carried out sequentially.

[0130] Methods of imaging cells are well known in the art. In some embodiments, imaging said transfected cells is carried out by fluorescence microscopy or imaging flow cytometry (see, e.g, Wu et ah, “Live Imaging of mRNA Using RNA- Stabilized Fluorogenic Proteins,” Nature Methods 16:862-565 (2019) and Wu & Jaffrey, Live Imaging of mRNA Using Pepper RNA-Stabilized Fluorgenic Proteins,” Nature Methods, DOI: 10.21203/rs.2.11494/vl (2019), which are hereby incorporated by reference in their entirety).

[0131] Yet another aspect of the invention relates to a method of imaging RNA in a cell. This method involves providing a vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or an enzyme fused to an RNA-regulated destabilization domain; transfecting a host cell with the first vector; contacting said transfected cell with an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; and imaging said contacted cells.

[0132] Suitable vectors for carrying out the methods of imaging RNA in a cell are described in more detail supra and include, e.g ., a plasmid ( e.g. , an expression vector) and a viral vector (e.g, a lentiviral or adenoviral vector).

[0133] Suitable RNA-regulated fusion proteins for carrying out the methods of the present application are described in more detail supra. In some embodiments of the methods described herein, the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

[0134] In other embodiments of the methods described herein, the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, b-galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b -glucuronidase, and b- glucosidase. In some embodiments, the bioluminescent protein is a luciferase selected from the group consisting of Nanoluc luciferase (Nluc), Firefly luciferase, and Renilla luciferase (Rluc).

[0135] In further embodiments of the methods described herein, the RNA- regulated fusion protein is an enzyme, wherein the enzyme is a biotin ligase. Suitable biotin ligases are described in detail supra and include, e.g, TurboID, miniTurbo, or A. coli BirA.

[0136] As described in more detail supra, the RNA-regulated destabilization domain may comprise a bifunctional peptide having a lentiviral transactivator of transcription (Tat) peptide and a degron peptide. Lentiviral transactivator of transcription (Tat) peptides and a degron peptides are described in more detail supra.

[0137] In some embodiments of the methods described herein, the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, where X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid. Thus, in some embodiments, the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

[0138] In some embodiments, the RNA of interest is a mRNA and the RNA aptamer is located within a coding region of the mRNA. In other embodiment, the RNA of interest is a mRNA and the RNA aptamer is located upstream of the 5' UTR, within the 5 ' UTR, within the 3 ' UTR, or downstream of the 3 ' UTR.

[0139] In other embodiments, the RNA of interest is a noncoding RNA (ncRNA).

As described herein, the term “noncoding RNA” refers to a functional RNA molecule that is not translated into a protein. The RNA of interest may be a noncoding RNA selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA (e.g, siRNA, miRNA, microRNA, etc.).

[0140] Suitable RNA aptamers are described in detail supra. In some embodiments of the methods described herein, the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A,

C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. For example, the RNA aptamer may comprise the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61). In some embodiments of the methods described herein, the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

[0141] The RNA molecule comprising the (i) RNA sequence of interest and (ii) the RNA aptamer sequence may be a circular RNA molecule or a linear RNA molecule. [0142] Methods of transfecting a host cell are well known in the art and described in more detail supra.

[0143] Contacting the transfected cell may be carried out by allowing the RNA molecule comprising the (i) RNA sequence of interest and (ii) the RNA aptamer sequence may be a circular RNA molecule or a linear RNA molecule to diffuse into the cell.

[0144] Methods of imaging cells are well known in the art. In some embodiments, imaging said contacted cells is carried out by fluorescence microscopy or imaging flow cytometry.

[0145] A further aspect of the invention relates to a method of selectively modifying an RNA-binding protein. This method involves providing a first expression vector encoding a RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises an enzyme fused to an RNA-regulated destabilization domain; providing a second expression vector encoding (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequences; transfecting a host cell with the first and second expression vectors; and allowing the enzyme to be expressed, wherein the expressed enzyme selectively modifies a protein that binds to the RNA sequence of interest.

[0146] Suitable enzymes are described in more detail supra. In some embodiments, the enzyme is selected from the group consisting of a ligase, a peroxidase, and a methyltransferase.

[0147] In some embodiments of the methods described herein, the enzyme is a biotin ligase selected from the group consisting of TurboID, miniTurbo, and E. coli BirA. [0148] In some embodiments of the methods described herein, the enzyme is a peroxidase selected from the group consisting of an ascorbate peroxidase and a horseradish peroxidase. The ascorbate peroxidase may be APEX2.

[0149] As described in more detail supra , the RNA-regulated destabilization domain may comprise a bifunctional peptide having a lentiviral transactivator of transcription (Tat) peptide and a degron peptide. Lentiviral transactivator of transcription (Tat) peptides and a degron peptides are described in more detail supra.

[0150] In some embodiments of the methods described herein, the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, where X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid. Thus, in some embodiments, the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

[0151] In some embodiments, the RNA of interest is a mRNA and the RNA aptamer is located within a coding region of the mRNA. In other embodiment, the RNA of interest is a mRNA and the RNA aptamer is located upstream of the 5' UTR, within the 5 ' UTR, within the 3 ' UTR, or downstream of the 3 ' UTR.

[0152] In other embodiments, the RNA of interest is a noncoding RNA (ncRNA).

As described herein, the term “noncoding RNA” refers to a functional RNA molecule that is not translated into a protein. The RNA of interest may be a noncoding RNA selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA (e.g, siRNA, miRNA, microRNA, etc.).

[0153] Suitable RNA aptamers are described in detail supra. In some embodiments of the methods described herein, the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A,

C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. For example, the RNA aptamer may comprise the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61). In some embodiments of the methods described herein, the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

[0154] In some embodiments of the methods of selectively modifying an RNA- binding protein described herein, the method further involves identifying a protein that is selectively modified by the enzyme within the transfected cells. See , e.g. , Ramanathan et al., “RNA-Protein Interaction Detection in Living Cells,” Nature Methods 15:207-212 (2018), which is hereby incorporated by reference in its entirety.

[0155] Another aspect relates to a method of regulating expression of an RNA- stabilized protein of interest. This method involves providing a first vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; providing a host cell comprising a functional ubiquitination system; transfecting the host cell with the first and second expression vectors; and expressing the first and second expression vectors within the host cell, where said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; and where, in the absence of any expressed RNA aptamer sequence in the host cell, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the ubiquitination system; and where the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence.

[0156] Another aspect of the invention relates to a method of regulating expression of an RNA-stabilized protein of interest. This method involves providing a first vector encoding an RNA-regulated fusion protein, where the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; providing a mammalian cell lysate or solution comprising (i) a ubiquitin ligase, (ii) proteosomal degradation machinery, (iii) transcriptional machinery, and (iv) translational machinery; contacting the mammalian cell lysate or solution with the first and second expression vectors; and expressing the first and second expression vectors , where said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; and where, in the absence of any expressed RNA aptamer sequence in the cell lysate or solution, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the proteosomal degradation system; and where the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence. [0157] Suitable proteins of interest for use in the methods described herein are described in more detail supra. In some embodiments, the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor. In other embodiments, the protein of interest is selected from the group consisting of a G- protein coupled receptor (GPCR), a nuclear receptor, a voltage gated ion channel, a ligand gated channel, a receptor tyrosine kinase, a growth factor, a phosphatase, a protein kinase, a viral regulator, a bacterial cell division protein, a scaffold protein, a DNA repair protein, a cytoskeletal protein, a ribosome, a histone deacetylase, an apoptosis regulator, a chaperone protein, a kinase, a phosphorylase, a phosphatase, deacetylase, a cytoskeletal protein ( e.g ., myosin, actin, dynein, kinesin, and tubulin).

[0158] Suitable expression vectors encoding RNA-regulated fusion proteins and vectors encoding an RNA aptamer sequence for use in the methods described herein are described in detail supra and include, e.g., a plasmid (e.g, an expression vector) and a viral vector (e.g, a lentiviral or adenoviral vector).

[0159] As described in more detail supra, the RNA-regulated destabilization domain may comprise a bifunctional peptide having a lentiviral transactivator of transcription (Tat) peptide and a degron peptide. Lentiviral transactivator of transcription (Tat) peptides and a degron peptides are described in more detail supra.

[0160] In some embodiments of the methods described herein, the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, where X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid. Thus, in some embodiments, the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

[0161] Suitable RNA aptamer sequences for use in the methods described herein are described in more detail supra. In some embodiments, the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U. For example, the RNA aptamer may comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61). In other embodiments, the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

[0162] Suitable host cells for use in the methods described herein are described in more detail supra. In some embodiments, the host cell is a mammalian cell.

[0163] Suitable mammalian cell lysates include, for example and without limitation, human cell lysates, non-human primate cell lysates, feline cell lysates, canine cell lysates, ovine cell lysates, hircine cell lysates, bovine cell lysates, equine cell lysates, porcine cell lysates, leporine cell lysates, and murine cell lysates.

[0164] Suitable solutions comprising (i) a ubiquitin ligase, (ii) proteosomal degradation machinery, (iii) transcriptional machinery, and (iv) translational machinery are well known in the art.

[0165] Exemplary ubiquitin ligases include, without limitation, ubiquitin E3 ligases (Li et al., “Genome-Wide and Functional Annotation of Human E3 Ubiquitin Ligases Identifies MULAN, A Mitochondrial E3 that Regulates the Organelle's Dynamics and Signaling,” PLoS One 3(l):el487 (2008); Berndsen & Wolberger, “New Insights into Ubiquitin E3 Ligase Mechanism,” Nat. Struct. Mol. Biol. 21(4):301-307 (2014), which are hereby incorporated by reference in their entirety). In some embodiments, the ubiquitin E3 ligase is selected form the group consisting of Really Interesting New Gene/U-box (RING) E3 ligase, Homologous to E6AP C-Terminus (HECT) E3 ligase, and RING between RING (RBR) E3 ligase (see, e.g. , Metzger et al., “RING-Type E3 Ligases: Master Manipulators of E2 Ubiquitin-Conjugating Enzymes and Ubiquitination,”

Biochim. Biophys. Acta. 1843(l):47-60 (2014); Rotin & Kumar, “Physiological Functions of the HECT Family of Ubiquitin Ligases,” Nat. Rev. Mol. Cell. Biol. 10(6): 398-409 (2009); Sluimer & Distel, “Regulating the Human HECT E3 Ligases,” Cell Mol. Life Sci. 75(17):3121-3141 (2018); Reiter & Klevit, “Characterization of RING-Between-RING E3 Ubiquitin Transfer Mechanisms,” Methods. Mol. Biol. 1844:3-17 (2018); and Dove & Klevit, “RING-Between-RING E3 Ligases: Emerging Themes Amid the Variations,” J. Mol. Biol. 429(22):3363-3375 (2017), which are hereby incorporated by reference in their entirety).

[0166] Methods of transfecting cells are well known in the art and described in more detail supra.

[0167] Another aspect of the present application relates to a treatment method.

This method involves contacting a cell with an RNA aptamer, where upon said contacting, the aptamer interacts with an RNA-regulated destabilization domain fused to a protein of interest in the cell to stabilize the protein of interest in the cell.

[0168] According to one embodiment, this and other treatment methods described herein are effective to treat a cell, e.g, a cell under a stress or disease condition. Exemplary cell stress conditions may include, without limitation, exposure to a toxin; exposure to chemotherapeutic agents, irradiation, or environmental genotoxic agents such as polycyclic hydrocarbons or ultraviolet (UV) light; exposure of cells to conditions such as glucose starvation, inhibition of protein glycosylation, disturbance of Ca2+ homeostasis and oxygen; exposure to elevated temperatures, oxidative stress, or heavy metals; and exposures to a pathological disease state (e.g., diabetes, Parkinson's disease, cardiovascular disease (e.g., myocardial infarction, end-stage heart failure, arrhythmogenic right ventricular dysplasia, and Adriamycin-induced cardiomyopathy), and various cancers (Fulda et al., "Cellular Stress Responses: Cell Survival and Cell Death," Int. J Cell Biol. (2010), which is hereby incorporated by reference in its entirety). [0169] In some embodiments, contacting a cell with an RNA molecule (aptamer) of the present application involves introducing an RNA molecule into a cell. Suitable methods of introducing RNA molecules into cells are well known in the art and include, but are not limited to, the use of transfection reagents, electroporation, microinjection, or via viruses.

[0170] The cell may be a eukaryotic cell. Exemplary eukaryotic cells include a yeast cell, an insect cell, a fungal cell, a plant cell, and an animal cell (e.g., a mammalian cell). Suitable mammalian cells include, for example without limitation, human, non-human primate, cat, dog, sheep, goat, cow, horse, pig, rabbit, and rodent cells.

[0171] The RNA molecule of the present invention may be isolated or present in in vitro conditions for extracellular expression and/or processing. According to this embodiment, the RNA molecule is contacted by an RNAligase (e.g., RtcB) in vitro, purified, circularized, and then the circularized RNA molecule is administered to a cell or subject for treatment.

[0172] Treating cells also includes treating the organism in which the cells reside.

Thus, by this and the other treatment methods of the present invention, it is contemplated that treatment of a cell includes treatment of a subject in which the cell resides.

[0173] In some embodiments, the treatment method further comprises introducing the protein of interest into the cell prior to said contacting.

[0174] In some embodiments, the cell is in a patient.

[0175] In some embodiments, introducing is carried out by any one or more of injecting mRNA encoding for the protein of interest into the patient, injecting a plasmid encoding for the protein of interest into the patient, injecting the protein of interest into the patient, or systemically delivering the protein of interest into the patient.

[0176] In some embodients, the patient is a human.

[0177] Another aspect of the present application relates to a treatment method. This method involves contacting a cell with a vector according to the present application under conditions effective to express an RNA molecule as described herein to treat the cell.

[0178] A further aspect of the present application relates to a kit comprising a vector encoding an RNA-regualted destabilization domain and a vector encoding an RNA aptamer that specifically binds to said RNA-regulated destabilization domain. Suitable RNA-regulated destabilization domains and RNA aptamers are described in detail supra. [0179] In some embodiments, the kit comprises a vector encoding tDeg and vector encoding a Pepper aptamer.

EXAMPLES

[0180] The following examples are provided to illustrate embodiments of the present invention but they are by no means intended to limit its scope.

Materials and Methods for Examples 1-5

[0181] General methods and materials. Single stranded synthetic DNA oligonucleotides for PCR were purchased from Integrated DNA Technologies. Phusion^® High-Fidelity DNA Polymerase (NEB M0530) was used for routine PCR amplifications. PCR products were run on 1% TAE agarose gels. PCR products with correct size were then excised and purified with the Qiaquick Gel Extraction kit (Qiagen 28704).

Restriction endonucleases used for restriction digest were purchased from New England Biolabs, and used according to the manufacturer’s recommended protocol. DNA ligation reactions were carried out using the Quick Ligation™ Kit (NEB M2200L). DNA plasmids were propagated using chemically competent E. coli (Agilent 200314). The QIAprep Spin Plasmid Miniprep Kit (Qiagen 27106) was used for DNA plasmid extraction and purification from E. coli. DNA sequencing (GENEWIZ) was used to verify the inserted gene sequences.

[0182] Cell culture and transfection. HEK293T/17 (ATCC CRL-11268), U20S

(ATCC HTB-96), COS-7 (ATCC CRL-1651), and HeLa (ATCC CCL-2) cells were cultured in DMEM (Thermo Fisher Scientific 11995-065) supplemented with 10% fetal bovine serum (Coming 35-010-CV), 100 U ml^-1 penicillin and 100 pgmE¹ of streptomycin (Thermo Fisher Scientific 15140122) under 37°C with 5% CO2. TrypLE Express (Thermo Fisher Scientific 12604013) was used for detaching cells from culture flasks during cell passage. All cell lines used in this study were transfected using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. Prior to live cell imaging, cells were changed to imaging media: phenol red-free DMEM (Thermo Fisher Scientific 31053-028) supplemented with 10% fetal bovine serum (Corning 35- 010-CV), 100 U ml^-1 penicillin and 100 pgml^-1 of streptomycin (Thermo Fisher Scientific 15140122), lx GlutaMAX™(Thermo Fisher Scientific 35050-061), and 1 mM sodium pyruvate (Thermo Fisher Scientific 11360-070). [0183] Fluorescence and bioluminescence imaging of tDeg-tagged proteins. To construct an expression vector for EYFP, EYFP-tDeg, mNeonGreen-tDeg, mCherry-tDeg, NanoLuc-tDeg, EGFP-TetR-tDeg, EGFP-EZH2-tDeg, or mCherry-NF-KB-tDeg, a pcDNA3.1 (+) vector was digested by Mlul and Xbal and ligated to an insert comprising a miniCMV promoter (5 ’ -GGTAGGCGTGTACGGTGGGAGGCCTATATAAGC AG AGCT-3’ (SEQ ID NO: 93), a ///Will restriction site, a Kozak sequence (5’-GCCACC- 3’), and the gene encoding EYFP, EYFP, mNeonGreen, mCherry, NanoLuc, EGFP-TetR, EGFP-EZH2, or mCherry-NF-kB, respectively, fused with tDeg. These expression vectors were called miniCMV-EYFP, miniCMV-EYFP-tDeg, miniCMV-mNeon Green - tDeg, miniCMV-mCherry-tDeg, miniCMV-NanoLuc-tDeg, miniCMV-EGFP-TetR-tDeg, miniCMV-EGFP-EZH2-tDeg, and miniCMV-mCherry-NF-KB-tDeg respectively. For control constructs of miniCMV-EGFP-TetR, miniCMV-EGFP-EZH2, and miniCMV- mCherry-NF-kB, a stop codon was inserted on the immediate upstream of the coding sequence of tDeg using QuikChange Site-Directed Mutagenesis Kits (Agilent).

[0184] To construct an expression vector for different circular RNAs, the Tornado expression plasmid (Litke et ak, Highly Efficient Expression of Circular RNA Aptamers in Cells using Autocatalytic Transcripts,” Nat. Biotechnol. 37:667-675 (2019), which is hereby incorporated by reference in is entirety) containing an F30 scaffold was digested, then ligated to inserts encoding the following sequences, respectively: wild-type TAR RNA (5’-GGCTCGTGTAGCTCATTAGCTCCGAGCC-3’ (SEQ ID NO: 65)), TAR Variant-1 (5’-GGCTCGTCTGAGCTCATTAGCTCCGAGCC-3’(SEQ ID NO: 67)), Pepper (TAR Variant-2) (5 ’ -GGCTCGTTGAGCTC ATTAGCTCCGAGCC-3 ’ (SEQ ID NO: 69), or a control RNA, the MS2 hairpin (5 ’ - AC ATGAGGATC ACCC ATGT -3 ’ (SEQ ID NO: 94)). These vectors were called: U6+27-tnd-wildtype TAR, TAR Variant-1, Pepper (TAR Variant-2), control RNA, respectively.

[0185] For live-cell imagining experiments with HEK293T cells, HEK293T cells were seeded into 12-well flat bottom cell culture plates (Coming™ 3513) with 2 x 10⁵ cells per well, and were cultured overnight. On the next day, cells were transfected using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. Specifically, for imaging experiments in FIGS. 1 A-C, 550 ng of miniCMV-EYFP-tDeg were cotransfected with 550 ng of U6+27-tnd-wildtype TAR, TAR Variant-1, Pepper (TAR Variant-2), or control RNA, respectively. In the case of EYFP, 550 ng of miniCMV- EYFP was transfected with 550 ng of diluent DNA (pUC19 plasmid) to maintain 1.1 pg of total plasmid DNA per well. For imaging experiments in FIGS. 6A-6G and FIGS. 7A- 7G, 550 ng of miniCMV-protein X-tDeg (protein X = mNeonGreen, mCherry, NanoLuc, EGFP-TetR, EGFP-EZH2, or mCherry -NF-kB) was cotransfected with 550 ng of circular Pepper (TAR Variant-2) or with 550 ng of diluent DNA (pUC 19 plasmid). At 24 hours after transfection, cells were subcultured into 35 mm imaging dishes precoated with poly- D-lysine (Mattek Corporation P35GC-1.5-14C) and mouse laminin I (Cultrex® 3401- 010-02) in culture media. Cells were then cultured overnight. Cell culture media was changed imaging media prior to fluorescence or bioluminescence live-cell imaging.

[0186] For live-cell imagining experiments in FIGS. 4A-4B, U20S cells, COS-7 cells, or HeLa cells were seeded into 35 mm imaging dishes precoated with poly-D-lysine (Mattek Corporation P35GC-1.5-14C) with 2 x 10⁵ cells per dish, respectively. On the next day, cells were transfected using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. Specifically, 1.4 pg of miniCMV-EYFP-tDeg was cotransfected with 1.4 pg of circular Pepper (TAR Variant-2) or 1.4 pg of diluent DNA (pUC19 plasmid). At 48 hours after transfection, cell culture media was changed imaging media prior to fluorescence live-cell imaging.

[0187] Prior to live-cell fluorescence or bioluminescence imaging, 1 pL of

Hoechst 33342 (Thermo Fisher Scientific H3570) per 2 ml of imaging media was added to the cells. In the case of proteasome inhibitor treatment, cells were treated with either DMSO or 10 pM (final concentration in the media) MG132 for 7 hours prior to live-cell imaging. In the case of bioluminescence imaging of NanoLuc, 20 pL of furimazine (Promega Nano-Glo^® Luciferase Assay System) per 2 ml of imaging media was added to the cells prior to bioluminescence imaging.

[0188] For live-cell fluorescence or bioluminescence imaging, an epifluorescence inverted microscope (Nikon Eclipse TE2000-E) equipped with a Cool Snap HQ2 CCD camera and a 130-W Nikon mercury lamp was used. The NIS-Elements Advanced Research software (Nikon) was used to control the microscope and camera. Cells were imaged with a 20x/0.75-NA (numerical aperture) or a 40 /0.75-NA air objective (Nikon) at 37°C. A FITC filter cube (with excitation filter 470 ± 20 nm, dichroic mirror 495 nm (long pass), and emission filter 525 ± 25 nm) was used for detecting EGFP-TetR-tDeg or EGFP-EZH2-tDeg with an exposure time of 500 msec. A YFP filter cube (with excitation filter 500±12 nm, dichroic mirror 520 nm (long pass), and emission filter 542±13.5 nm) was used for detecting EYFP, EYFP-tDeg, or mNeonGreen-tDeg with an exposure time of 500 msec. A TRITC filter cube (with excitation filter 560 ± 20 nm, dichroic mirror 585 nm (long pass), and emission filter 630 ± 37.5nm) was used for detecting mCherry-tDeg, or mCherry-NF-KB-tDeg with an exposure time of 500 msec. A filter cube (with emission filter 460 ± 25 nm) was used for detecting the bioluminescence of NanoLuc with an exposure time of 3 minutes. A DAPI filter cube (with 350 ± 25 nm excitation filter, 400 nm (long pass) dichroic mirror, and 460 ± 25 nm emission filter) was used for detecting the Hoechst-stained nuclei in cells with an exposure time of 100-500 msec. All filters used in these filter cubes are purchased from Chroma Technology. Cell fluorescence/bioluminescence was calculated using ImageJ by measuring the mean fluorescence/bioluminescence signal in a cell’s area and subtracting background based on average signal of culture media. Normalized fluorescence/bioluminescence was calculated by dividing the cell fluorescence/bioluminescence intensity of each cell to the averaged cell fluorescence/bioluminescence of the whole cell population.

[0189] RT-qPCR. Total RNA was isolated from cells using Trizol according to the manufacturer’s instruction. To remove residual DNA contaminations, the purified RNA was treated with DNasel (Thermo-Fisher) according to the manufacturer’s instructions. The same amount of DNasel-treated RNA was reverse transcribed to cDNA using Superscript IV First-Strand kit (Invitrogen) with random hexamers according to the manufacturer’s instructions. To measure relative expression levels of the RNAs of interest, qPCR measurements were performed using the iQ SYBR Green Supermix with 0.250 ng of cDNA in the final reaction mix. For the amplification, the following protocol was used: 98°C for 2 minutes, 40 cycles of 95°C for 10 seconds, 60°C for 40 seconds. Primer sets for amplifying the cDNA of EYFP and mCherry are listed in Table 9. Every primer set was tested for its efficiency. To test primer specificity, melting curves were performed at the end of the 40 cycles of amplification. In the case of mCherry quantification, an untrasfected sample was added as additional negative control. Relative measurements (2 ^" -ACq) of mCherry, EYFP were performed using GAPDH and RPS18 as housekeeping genes. Biological replicates were tested.

Table 9. ssDNA oligo probes used in RT-qPCR

[0190] Gel staining. Total RNA was isolated from cells using TRIzol^® according to the manufacturer’s instruction. Then, 2.5 pg of isolated total RNA was separated using a precast 6% TBE-Urea Gel (Life Technologies EC68655). This gel was run at 200 V in TBE buffer until completion, and stained with SYBR Gold (ThermoFisher SI 1494) diluted 1 : 10,000 in TBE buffer for 15 minutes. After SYBR Gold staining, RNA bands were imaged on a ChemiDoc XRS+ system (Bio-Rad).

[0191] mRNA imaging using tDeg and Pepper. To construct an expression vector for RNA-regulated fluorescent fusion proteins used in mRNA imaging, a pcDNA3.1 (+) vector was digested by Mlul and Xbal and ligated to an insert comprising a miniCMV promoter (5 ’ -GGTAGGCGTGTACGGTGGGAGGCCTATATAAGC AGAG CT-3’ (SEQ ID NO: 118)), a Hindlll restriction site, a Kozak sequence (5’-GCCACC-3’), and the gene encoding tandem copies of mNeonGreen, mVenus, or mCherry, respectively. To construct an expression vector for an mCherry mRNA reporter containing different 3’UTR tags comprising 10 or 20 concatenated Pepper aptamers, a pcDNA3.1(+) vector was first digested by Hindlll and Xbal and ligated to an insert encoding the gene of mCherry followed by Xhol after its stop codon. This vector was called CMV-mCherry. CMV-mCherry was then digested Xhol and Xbal, and ligated to different Pepper tags, respectively. All the Pepper tags were synthesized by GenScript.

[0192] U20S cells were seeded into 35 mm imaging dishes precoated with poly-

D-lysine (Mattek Corporation P35GC-1.5-14C) with 2 x 10⁵ cells per dish. On the next day, cells were transfected using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. Specifically, 1.4 pg of RNA-reguated fluorescent fusion protein plasmids were cotransfected with 1.4 pg of mRNA reporter plasmids. At 48 hours after transfection, cell culture media was changed to imaging media prior to imaging experiments.

[0193] For mRNA imaging experiments, an epifluorescence inverted microscope

(Olympus IX-70) equipped with a Evolve® 512 EMCCD OEM camera (Photometries) and an Insight SSI 7 color solid state illumination system (Applied Precision) was used. The Resolve3D softWoRx- Acquire Version: 6.5.2 was used to control the microscope and camera. Cells were imaged with a 100x/1.4-NA oil objective at 37°C, with N = 1.520 immersion oil (Applied Precision). A FITC filter cube (with excitation filter 475 ± 14 nm, dichroic mirror with a reflection band of 481-502 nm, and a transmission band of 506-543 nm), and emission filter 525 ± 25 nm) was used for detecting mNeonGreen with an exposure time of 50 msec. A YFP filter cube (with excitation filter 513 ± 8.5 nm, dichroic mirror with a reflection band of 496-528 nm, and a transmission band of 537-550 nm, and emission filter 559 ± 19 nm) was used for detecting mVenus with an exposure time of 100 msec. A TRITC filter cube (with excitation filter 542 ± 13.5 nm, dichroic mirror with a reflection band of 547-565 nm, and a transmission band of 576-630 nm, and emission filter 594 ± 22.5nm) was used for detecting reporter plasmids encoding mCherry with an exposure time of 10-100 msec. Signal -to-noise ratio of the fluorescent puncta was calculated by the mean fluorescence intensity of each mRNA puncta divided by the mean fluorescence intensity of the adjacent cytosolic background fluorescence.

[0194] Northern blot. HEK293T cells were seeded into 10 cm culture dish with 3 x 10⁶ cells per dish. On the next day, cells were cotransfected with CMV-mCherry-(F30- 2xPepper)io and miniCMV-(mNeonGreen)₄-tDeg or pUC19, respectively. A total amount of 19 pg plasmid DNA was used for each culture dish, and pUC19 vector was used here as a diluent DNA to ensure the same amount of plasmid DNA transfected to the cells. All transfections were performed using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. Cells were harvested after 48 hours of transfection. Total RNA was extracted with TRIzol^® (Thermo Fisher Scientific 15596026) followed by isopropanol precipitation. The purified total RNA was then subjected to RNase-free DNase I (Thermo Fisher Scientific AM2224) digestion at 37°C for 1 hour. After digestion, the RNA was subjected to phenol -chloroform (Thermo Fisher Scientific AM9720) extraction and ethanol purification.

[0195] For gel electrophoresis, a 1.5% agarose/formaldehyde gel (20 mM MOPS,

5 mM sodium acetate, 1 mM EDTA, 1.5% w/v agarose, 2% formaldehyde) was used. 20 pg of total RNA was loaded in each lane. The RNA was resuspended in 20 pL of RNA sample buffer (20 mM MOPS, 5 mM sodium acetate, 1 mM EDTA, 50% v/v formamide, 3.7% formaldehyde). The RNA samples were heated at 70°C for 10 minutes, and then chilled on ice for more than 1 minute. Before loading the RNA samples into the gel, the RNA samples were mixed with 2 pL of loading buffer (50% glycerol, 5 mM EDTA, 0.4% bromophenol blue, 0.4% xylene cyanol). The gel was run at 70 V for 2 hours. After electrophoresis, the gel was stained with lx SYBR™ Gold Nucleic Acid Gel Stain (Thermo Fisher Scientific SI 1494) to assess the quality of the RNA and check for separation. All solutions mentioned above were made in diethylpyrocarbonate (DEPC)- treated water.

[0196] After electrophoresis, the RNA was transferred to Amersham Hybond-N+ nylon membrane (GE Healthcare Life Sciences RPN203B) using the VacuGene XL Vacuum Blotting System (GE Healthcare Life Sciences) according to the manufacturer’s instructions. The RNA was then UV crosslinked to the nylon membrane. The membrane was washed with NorthernMax® Prehybridization/Hybridization Buffer (Thermo Fisher Scientific AM8677) at 42°C for at least 30 minutes. Biotinylated (at 5’) single-stranded DNA probes (Integrated DNA Technologies) as shown in Table 10 were mixed with NorthernMax® Prehybridization/Hybridization Buffer and incubated with the membrane at 42°C overnight. On the following day, the membrane was washed in 50 mL of wash buffer 1 (2xSSC, 0.1% SDS) twice at 42°C for 10 minutes each time, and then washed with wash buffer 2 (O.lxSSC, 0,1% SDS) twice at 42°C for 15 minutes. The membrane was visualized by Chemiluminescent Nucleic Acid Detection Module Kit (Thermo Fisher Scientific 89880).

Table 10. ssDNA oligo probes used in FIG. 12A

[0197] Imaging membrane-tethered mRNA. U20S cells were seeded 72 hours before imaging in 96-well glass bottom dishes (Matriplates, Brooks Life Science Systems) at 40% confluency. Cells were transfected with DNA plasmids that encode miniCMV- (mNeonGreen)₄-tDeg, PCP-3xmCherry-CAAX and the mRNA reporter 48 hours before imaging using 0.5 mΐ FuGENE 6 (Promega) and 200-300 ng DNA per well. The transfection mix was prepared in OptiMEM (Sigma-Aldrich) and added to the cells in a total volume 150-200 pi of medium.

[0198] Twenty-four hours prior to imaging, transcription of the reporters was induced by addition of doxycycline (1 pg/ml) (Sigma-Aldrich). Thirty minutes before imaging, the cell culture medium was replaced with pre-warmed C0₂-independent Leibovitz’s- 15 medium (Gibco) with doxycycline. Images were acquired using a Nikon TI inverted microscope with perfect focus system equipped with a Yokagawa CSU-X1 spinning disc, a lOOx 1.49 NA objective and an iXon Ultra 897 EMCCD camera (Andor) and was controlled by NIS software (Nikon). During the experiment, cells were maintained at a constant temperature of 37°C. Single Z-plane images were acquired, with the bottom plasma membrane of the cell in the focal plane. Camera exposure times of 500 ms were used for both mNeonGreen and mCherry.

[0199] To determine the fluorescence intensity of mRNA foci, mean spot intensities were measured in Image J in a region of interest (ROI) 0.53 x 0.53 pm in size. For each spot, local background fluorescence intensity was measured in a ROI (0.53 x 0.53 pm in size) directly next to the spot of interest, and mean background fluorescence intensities were subtracted from the mean spot intensity. Cells with very high number of mRNAs (more than ~50) were excluded from the analysis.

[0200] Western Blotting. Cells were lysed in whole cell lysis buffer (10 mM Tris-

HC1 pH 7.4, 10 mM EDTA, 50 mM NaCl, 1% Triton X-100, 0.1% SDS) containing IX protease and phosphatase inhibitor (Pierce, 78440). Lysates were cleared by centrifugation (12,000g for 10 minutes). Protein quantification was performed using the Pierce BCA protein assay kit according to the manufacturer’s instruction (Thermo Fisher Scientific, 23227). Equal quantities of proteins were mixed with loading dye, and incubated at 95°C for 5 minutes before they were separated on 4-12% Bis-Tris gels (Invitrogen) and transferred onto a PVDF membrane at constant 350 mA at 4°C for 1 hour. Membranes were blocked by incubation in 5% milk for 1 hour at room temperature under agitation and then incubated with the following primary antibodies: mouse anti- GAPDH (Santa Cruz) with a 1:5000 dilution in l%milk overnight, or rabbit anti -mCherry (Abeam, abl67453) with a 1:1000 dilution in l%milk overnight, or rabbit anti-ubiquitin (Abeam, ab 19247) with a 1 : 1000 dilution in l%milk overnight. After incubation with the appropriate secondary antibodies conjugated to HRP and extensive washing, blots were imaged on a ChemiDoc XRS+ system (Bio-Rad).

[0201] Imaging ER-targeting mRNA. To construct an expression vector for an

ER-targeting mRNA reporter, DNA sequence that encodes the first 29 amino acids of cytochrome p450, CytERM, and a linker sequence

(MDP V V VLGLCL S CLLLL SLWKQ S Y GGGKLGGS GGT GGS GT S GG (SEQ ID NO: 116) was cloned into the upstream of the mCherry sequence of the CMV-mCherry-(F30- 2xPepper)io plasmid to make CMV-CytERM-mCherry-(F30-2xPepper)i_0. To construct the plasmid that encodes the RNA-regulated fluorescent fusion protein used in this experiment, the miniCMV promoter sequence in miniCMV-(mNeonGreen)4-tDeg was replaced with the human ubiquitin C promoter sequence to make UbC-(mNeonGreen) - tDeg.

[0202] U20S cells were seeded into 35 mm imaging dishes precoated with poly-

D-lysine (Mattek Corporation P35GC-1.5-14C) with 2 x 10⁵ cells per dish. On the following day, cells were cotransfected with 1.4 pg of CMV-CytERM-mCherry-(F30- 2xPepper)io, 0.28 pg of UbC-(mNeonGreen)₄-tDeg, and 1.12 pg of pUC19 (as a diluent DNA) using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. At 48 hours after transfection, cell culture media was changed to imaging media prior to imaging experiments. This imaging setup for these experiments are the same as the one used for mRNA imaging using tDeg and Pepper.

[0203] Imaging b-actin mRNA after arsenite stress. To construct an expression vector for a b-actin mRNA reporter containing a (F30-2xPepper)i₀ tag, the full length b- actin gene (from Addgene Plasmid #27123) was amplified by PCR and digested by Xhol and Hindlll , and then ligated to a vector from CMV-mcherry-(F30-2xPepper)io digested by the same restriction endonucleases to cut out the gene encoding mCherry. This expression vector was called CMV-P-actin-(F30-2xPepper)i_0.

[0204] U20S cells stably expresses Halo-G3BPl were seeded into 35 mm imaging dishes precoated with poly-D-lysine (Mattek Corporation P35GC-1.5-14C) with 2 x 10⁵ cells per dish. On the following day, cells were cotransfected with 1.4 pg of miniCMV-(mNeonGreen)₄-tDeg with 1.4 pg of CMV-P-actin-(F30-2xPepper)i₀ using FuGENE HD (Promega 2311) according to the manufacturer’s instructions. For control experiments, 1.4 pg of miniCMV-(mNeonGreen) -tDeg with 1.4 pg of U6+27-tnd-Pepper was used following the same transfection protocol. At ~40 hours after transfection, cell culture media was changed to imaging media with the HaloTag® TMRDirect™ Ligand (Promega G2991) for 5 hours. Cells were then rinsed with lxPBS (Thermo Fisher Scientific 10010049) and incubated in imaging media prior to imaging experiments. The same microscope setup as in the above mRNA imaging experiments was used. To induce stress granule formation, 1 mL of imaging media supplemented with 1000 pM of sodium arsenite was added to the cells cultured in 1 mL of imaging media to reach a final concentration of 500 pM of sodium arsenite.

[0205] Statistical analysis. All data were expressed as means ± s.d. with sample sizes (n) listed for each experiment. Statistical analyses were performed using Excel (Microsoft) and Prism (Graphpad). For different circular TAR variants’ inhibition of tDeg’s destabilizing effect, and optimization of the number of fluorescent mNeonGreen monomers in the RNA-regulated fluorescent fusion protein for imaging mRNA in live cells, one-way ANOVA was used to analyze significant differences between group means. For Pepper RNA-dependent regulation of protein stability, imaging green Pepper-tagged b-actin mRNA, proteasomal inhibition, imaging membrane-tethered mRNA, two tailed Student’s t-tests were used to analyze significant differences between group means. P values were reported for each experiment.

Example 1 - tDeg Reduces Protein Stability by Inducing Proteasomal Degradation

[0206] In order to expand fluorescent aptamer-based imaging, Applicant sought to create a new class of RNA-regulated fluorescent dyes that are genetically encoded. Fluorescent proteins are particularly useful since a diverse array of spectrally distinct proteins have been described (Rodriguez et al., “The Growing and Glowing Toolbox of Fluorescent and Photoactive Proteins,” Trends Biochem. Sci. 42: 111-129 (2017), which is hereby incorporated by reference in its entirety). However, these proteins are constitutively fluorescent. To make them dependent on RNA, Applicant considered making them rapidly degraded in cells except when bound by a specific RNA aptamer. In this way, fluorescence would be selectively associated with RNA-protein complexes, and not with unbound fluorescent protein. This would be functionally equivalent to RNA- induced fluorescence of small molecule dyes.

[0207] First, a “destabilization domain” that can be inhibited by an RNA aptamer was developed. Previously, the Arg-Arg-Arg-Gly (SEQ ID NO: 117) was described as a degron sequence when appended to the C-terminus of proteins (Bonger et al., “Small- Molecule Displacement of a Cryptic Degron Causes Conditional Protein Degradation,” Nat. Chem. Biol. 7:531-537 (2011), which is hereby incorporated by reference in its entirety). This sequence is similar to the arginine-rich RNA-binding domain of the Tat protein, which contains Arg-Arg as its last two amino acids. Therefore, Arg-Gly was appended to extend this Arg-Arg sequence so that the full Arg-Arg-Arg-Gly (SEQ ID NO: 117) degron is at the C-terminus of this peptide (FIGS. 1 A-1B and FIGS. 2A-2B). This 19-amino acid-long bifunctional peptide was termed “tDeg.” Tat binds a 28 nt-long RNA hairpin termed TAR (Ye et al., “Molecular Recognition in the Bovine Immunodeficiency Virus Tat Peptide-TAR RNA Complex,” Chem. Biol. 2:827-40 (1995) and Puglisi et al., “Solution Structure of a Bovine Immunodeficiency Virus Tat-TAR Peptide-RNA Complex,” Science 270: 1200-1203 (1995), which are hereby incorporated by reference in their entirety), which may shield the degron and thus prevent recruitment of the proteasomal machinery needed for proteolysis (FIG. 1 A and FIGS. 2A-2B).

[0208] Whether tDeg confers instability to proteins was first investigated. To do so, tDeg was fused to the C-terminus of enhanced yellow fluorescent protein (EYFP), and the resulting fusion protein (EYFP -tDeg) was expressed in HEK293T cells. While EYFP was readily detectable, EYFP -tDeg was nearly undetectable (FIGS. 1B-1C). EYFP -tDeg was restored by proteasome inhibition (FIGS. 3 A-3B) indicated that tDeg reduces protein stability by inducing proteasomal degradation.

Example 2 - tDeg is Regulated by TAR RNA and TAR RNA Variants

[0209] Whether the tDeg can be regulated by the TAR RNA was next investigated. The TAR RNA was expressed as a circular RNA using the Tornado ribozyme-assisted circularization approach to achieve high expression in mammalian cells (Litke & Jaffrey, “Highly Efficient Expression of Circular RNA Aptamers in Cells Using Autocatalytic Transcripts,” Nat. Biotechnol. 37:667-675 (2019), which is hereby incorporated by reference in its entirety). When TAR was expressed, EYFP-tDeg- expressing cells exhibited a 24-fold increase of fluorescence relative to control RNA (FIGS. 1B-1C). TAR variants that bind Tat with higher affinity, Variant-1 and Variant-2 (Smith et al., “Altering the Context of an RNA Bulge Switches the Binding Specificities of Two Viral Tat Proteins,” Biochemistry 37:10808-10814 (1998), which is hereby incorporated by reference in its entirety), were even more efficient at inducing EYFP- tDeg, with Variant-2 exhibiting a 38-fold increase in cellular fluorescence (FIGS. 1B-1C; FIGS. 4A-4B). Expression of Variant-2 induced EYFP -tDeg cellular fluorescence levels similar to levels in cells expressing EYFP without the tDeg (FIG. 1C). Furthermore, Variant-2 induced EYFP-tDeg fluorescence in diverse cell types (FIGS. 5A-5G). Thus, the EYFP-tDeg is a RNA-regulated fluorescent fusion protein that is regulated by TAR. [0210] Because the TAR Variant-2 aptamer can control the expression of different colored fluorescent proteins, as described infra , this aptamer was named after the multicolored vegetable Pepper, in keeping with the vegetable nomenclature system used previously for fluorogenic RNA aptamers.

Example 3 - tDeg Tag is a Versatile Tag for Pepper-Dependent Protein Stabilization

[0211] Whether the expression level of other proteins could be controlled by the

Pepper RNA was next investigated. Addition of tDeg to the C-terminus of mNeonGreen, mCherry, NanoLuc, tetracycline repressor protein (TetR), EZH2, and NF-KB, resulted in minimal or undetectable protein levels in control cells and clear induction in circular Pepper-expressing cells (FIGS. 6A-6G and FIGS. 7A-7G). Taken together, these data indicate that the tDeg tag is a versatile tag for RNA-dependent protein stabilization.

Example 4 - Intracellular Imaging Using Pepper-Modified mRNA

[0212] mRNAs are commonly imaged using tethered fluorescent proteins. For example, a GFP fusion with MS2 phage coat protein (MCP) can be recruited to mRNAs containing 24-48 consecutive MS2 RNA hairpins in their 3’UTRs (Bertrand et al., “Localization of ASH1 mRNA Particles in Living Yeast,” Mol. Cell 2:437-45 (1998), which is hereby incorporated by reference in its entirety). In this way, many GFPs are recruited to single mRNAs resulting in an aggregate fluorescence that can be detected by fluorescence microscopy. Typically nuclear localization elements are added to the GFP- MCP fusion to remove the unbound fluorescent protein from the cytoplasm into the nucleus (Bertrand et al., “Localization of ASH1 mRNA Particles in Living Yeast,” Mol. Cell 2:437-45 (1998), which is hereby incorporated by reference in its entirety). This can reduce the fluorescence background in the cytosol, facilitating mRNA detection.

However, this may introduce a potential artifact since the MS2-tagged mRNAs will contain dozens of nuclear localization sequences due to the recruited fluorescent proteins (Tyagi, S., “Imaging Intracellular RNA Distribution and Dynamics in Living Cells,” Nat. Methods 6:331-338 (2009), which is hereby incorporated by reference in its entirety).

The RNA aptamers described herein do not introduce a cellular trafficking element and may therefore bypass this concern.

[0213] To investigate the use of RNA aptamers in intracellular imaging, a tag for mRNA imaging consisting of consecutive Pepper aptamers was next generated. In optimization experiments, an mCherry mRNA reporter containing different 3’UTR tags comprising 10 or 20 concatenated Pepper aptamers and Pepper aptamers that were inserted into an RNA three-way junction sequence termed F30 were imaged. Aptamers inserted within the F30 show improved folding (Filonov et al., “In-Gel Imaging of RNA Processing Using Broccoli Reveals Optimal Aptamer Expression Strategies,” Chem. Biol. 22:649-60 (2015), which is hereby incorporated by reference in its entirety). mCherry mRNA was readily detectable as mobile fluorescent puncta in the cytoplasm when the tag contained 20 Pepper aptamers. The brightest puncta were seen when using the (F30- 2xPepper)io tag, which comprises 10 consecutive F30 sequences, with each of the two arms of F30 containing one Pepper aptamer (FIGS. 8A-B; FIGS. 9A-9D; and FIGS. 10A-10C).

[0214] mRNA imaging using RNA-regulated fluorescent fusion proteins of different brightness was also investigated. These proteins comprised 2, 3, or 4 tandem mNeonGreen monomers with a C-terminal tDeg. In these experiments, a RNA-reguated fluorescent fusion protein comprising four mNeonGreens provided the highest signal-to- noise ratio for imaging mRNAs (FIGS. 10A-10C). Although most fluorescent puncta were detected in the cytoplasm, occasional puncta were detected in the nucleus, potentially reflecting mRNAs prior to nuclear export (FIGS. 11 A-l 1C).

[0215] Cellular puncta likely reflect single mRNA molecules rather than Pepper- containing mRNA fragments since northern blotting of total cellular RNA derived from cells expressing (F30-2xPepper)i₀-tagged mRNA, either with or without coexpression of the (mNeonGreen)₄-tDeg showed mostly full-length transcripts (FIG. 12A). Furthermore, puncta derived from mRNAs tagged with (F30-2xPepper)i₀ were the same size and intensity as mRNAs tagged using the PP7 fluorescent protein recruitment system, which was previously shown to reflect single mRNA molecules (Yan et al., “Dynamics of Translation of Single mRNA Molecules In Vivo,” Cell 165:976-989 (2016), which is hereby incorporated by reference in its entirety) (FIGS. 12B-12D).

[0216] Adding the Pepper tag to an mRNA could adversely affect mRNA fate.

However, the (F30-2xPepper)i₀ Pepper tag was not found to substantially alter the stability of the mCherry transcript (FIG. 13 A). Similarly, a significant difference in protein translation between the untagged and Pepper-tagged mCherry mRNA transcript was not observed (FIGS. 13B-13D). Lastly, expression of RNA-regulated fluorescent fusion proteins did not significantly affect total cellular proteasome activity (FIG. 13E). [0217] mRNAs that exhibit specific subcellular localizations were next imaged. mRNA localization to the endoplasmic reticulum (ER) was imaged using an ER-targeted reporter mRNA that encodes the first 29 amino acids of cytochrome P450, CytERM (cytoplasmic end of an endoplasmic reticulum signal-anchor membrane protein) (Costantini et al., “Assessing the Tendency of Fluorescent Proteins to Oligomerize Under Physiologic Conditions,” Traffic 13:643-649 (2012), which is hereby incorporated by reference in its entirety). This sequence tethers the mRNA to the outer ER membrane during protein translation, and restricts the mRNA’s mobility. Indeed, fluorescent puncta with low mobility were observed when this mRNA was expressed with a 3’UTR (F30- 2xPepper)io Pepper tag (FIGS. 14A-14D). Treatment with puromycin, which disrupts the ribosome and dissociates the mRNA from the nascent peptide, significantly increased puncta mobility, consistent with dissociation of the reporter mRNA from the ER (FIGS. 14A-14D).

[0218] Next, b-actin mRNA containing a 3 ’UTR (F30-2xPepper)i₀ tag was expressed and its localization was imaged in response to arsenite treatment, which induces stress granule formation (Tourriere et al., “The RasGAP-Associated Endoribonuclease G3BP Assembles Stress Granules,” J Cell Biol. 160:823-831 (2003), which is hereby incorporated by reference in its entirety). Upon application of 500 mM arsenite, the individual fluorescent puncta rapidly accumulated to form stress granules as evidenced by coexpression of Halo-tagged G3BP1 to label stress granules (FIGS. 15A-C and FIGS. 16A-B).

Example 5 - Imaging of Pepper-Regulated mVenus and Pepper-Regulated mCherry

[0219] To expand the color palette of RNA-regulated fluorescent fusion proteins, two tandem copies of mVenus and two tandem copies of mCherry were fused with a C- terminal tDeg tag to convert them into RNA-regulated fluorescent fusion proteins, respectively, for imaging mRNAs. In both cases, fluorescent puncta were detected in the yellow and red fluorescence channels, respectively (FIGS. 17A-17B). Together, these data show that Pepper-tagged mRNAs can be imaged in different colors using different fluorogenic proteins.

Discussion of Examples 1-5

[0220] The studies described infra demonstrate how constitutively fluorescent proteins can be converted to fluorescent proteins that are regulated by RNA aptamers. RNA-regulation was conferred to a protein by making its proteomic stability controlled by an RNA aptamer, Pepper. In this way, unbound RNA-regulated fluorescent fusion protein is rapidly degraded, but the RNA-regulated fluorescent fusionprotein bound to an specific RNA aptamer ( e.g ., Pepper) remains stable. Thus, these Pepper-regulated fluorescent fusion proteins are functionally analogous to RNA-regulated fluorogenic dyes. This system has the advantage of being able to use diverse fluorescent proteins with diverse spectral properties. Additionally, unlike the Spinach system (Paige et al., RNA Mimics of Green Fluorescent Protein,” Science 333:642-646 (2011), which is hereby incorporated by reference in its entirety), the fluorescent system described herein is fully genetically encoded.

[0221] Fluorophore maturation kinetics may also contribute to the low fluorescence of the Pepper system. Since the tDeg tag is highly efficient, it is possible that newly synthesized mNeonGreen is degraded prior to chromophore maturation. mNeonGreen that is bound to the RNA may persist for a sufficiently long time to mature to a fluorescent form while bound to RNA. This may further contribute to the low background fluorescence in cells.

[0222] Unlike previous mRNA imaging systems, no nuclear localization elements are added to fluorescent proteins to lower cytosolic background fluorescence. Instead, low background fluorescence is achieved by the highly efficient degradation of the unbound RNA-regulated fluorescent fusion protein. The simplicity of this system should simplify mRNA imaging.

[0223] An important question is whether the tagged mRNA faithfully recapitulates behavior of the endogenous mRNA. The Pepper tag did not substantially affect the stability, translation, and localization of the specific mRNAs described herein. Nevertheless, imaging tags are best used when comparing two mRNAs that differ by a single sequence alteration, or the same mRNA compared in two different conditions. In this way the role of a putative functional RNA element or RNA-regulatory pathway can be inferred and then validated with the endogenous mRNA.

[0224] Although the RNA-regulated destabilization domains were used to create fluorescent fusion proteins for RNA imaging, the ability to control protein expression levels through the Pepper aptamer can potentially enable novel synthetic biology applications. For these applications, Pepper can be expressed on its own, rather than part of an mRNA. By expressing tDeg-tagged proteins, diverse types of protein functions can be regulated by RNA aptamer expression levels.

Example 6 - The tDeg-Pepper System can be used to Selectively Modify RNA- Binding Proteins.

[0225] RNA-binding proteins (RBPs) bind to RNA molecules to orchestrate most biological functions in the cell. A major way to uncover previously unknown biological functions is to discover the RBPs involved in these processes. Current methods for discovering RBPs have low sensitivity. This is because current methods rely on recruiting a biotin ligase or a peroxidase to an RNA of interest to biotinylate any RBPs that are bound to this RNA. The major problem of these methods is the promiscuous activity of the biotin ligase or peroxidase would also nonspecifically biotinylate irrelevant proteins in the cytosol. [0226] To address this problem, new method for identifying RBPs with high sensitivity was developed. In this method, a biotin ligase and a peroxidase, whose activity is only turned on when it binds to the RNA target, was engineered. To achieve this, tDeg was fused to a biotin ligase, called TurboID, and an engineered peroxidase, called APEX2, respectively. The stability of these two proteins can be regulated by the Pepper RNA. This method drastically decreases the nonspecific biotinylation due to the promiscuous activity of this biotin ligase and peroxidase, thereby enabling the discovery of RBPs in living cells with high sensitivity.

[0227] tDeg confers Pepper RNA-dependent regulation of a biotin ligase,

TurboID, and a peroxidase, APEX2. FIG. 18A-18B show that HEK293T cells transiently express EGFP-TurboID-tDeg (FIG. 18 A), and EGFP-APEX2-tDeg (FIG. 18B), with and without the Pepper RNA aptamer, respectively. In each case, proteins were nearly undetectable unless coexpressed with the Pepper RNA. FIG. 18C provides a schematic showing that a selectively activated biotin ligase (TurboID-tDeg) specifically biotinylates an RNA-binding protein (CELF1) that bind to the RNA sequence of interest (EDEN15). FIG. 18 D shows that TurboID-tDeg enables selective biotinylation of CELF1, while minimizing nonspecific biotinylation of proteins that do not bind to the RNA of interest (EDEN15). These results demonstrate that the tDeg-Pepper system can be used to selectively modify RNA-binding proteins.

Example 7 - Tat-GG Confers Pepper RNA-Dependent Regulation

[0228] Next, whether a variant of tDeg, Tat-GG, can be regulated by the Pepper

RNA aptamer was examined. In these experiments, U20S cells transiently expressed mNeonGreen-Tat-GG fusion protein with and without the circular Pepper RNA aptamer, respectively. Cells showed undetectable levels of green fluorescence without the circular Pepper RNA aptamer (FIG. 19). The green fluorescence of mNeonGreen-Tat-GG was only restored when the circular Pepper RNA aptamer was coexpressed (FIG. 19). Thus, these results confirm that the tDeg variant Tat-GG can be regulated by the Pepper RNA aptamer.

Example 8 - HIV Tat-RRRG Confers HIV TAR-Dependent Regulation

[0229] Next, whether HIV Tat-RRRG (RKKRRQRRRG; SEQ ID NO: 127) can be regulated by the HIV TAR sequence

ACGAAGCUUGAUCCCGUUUGCCGGUCGAU CGCUUCGA (SEQ ID NO: 128) was examined. In these experiments, cells transiently expressed YFP-HIV Tat-RRRG fusion protein with and without the circular HIV TAR RNA aptamer, respectively. Cells showed undetectable levels of yellow fluorescence without the circular HIV TAR RNA aptamer (FIG. 20). The yellow fluorescence of YFP-HIV Tat-RRRG was restored when the circular HIV TAR RNA aptamer was coexpressed (FIG. 20). Thus, these results confirm that HIV Tat-RRRG can be regulated by the HIV TAR RNA aptamer.

Claims

WHAT IS CLAIMED

1. A nucleic acid molecule encoding an RNA-regulated fusion protein, said nucleic acid molecule comprising: a first nucleic acid sequence encoding a protein of interest and a second nucleic acid sequence encoding an RNA-regulated destabilization domain, wherein the second nucleic acid sequence is operably coupled to the first nucleic acid sequence.

2. The nucleic acid molecule according to claim 1, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

3. The nucleic acid molecule according to claim 2, wherein the protein of interest is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

4. The nucleic acid molecule according to claim 2, wherein the protein of interest is a bioluminescent protein.

5. The nucleic acid molecule according to claim 4, wherein the bioluminescent protein is selected from the group consisting of luciferase, b- galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b-glucuronidase, and b- glucosidase.

6. The nucleic acid molecule according to claim 5, wherein the bioluminescent protein is a luciferase selected from the group consisting of Nanoluc luciferase (Nluc), Firefly luciferase, and Renilla luciferase (Rluc).

7. The nucleic acid molecule according to claim 2, wherein the protein of interest is an enzyme.

8. The nucleic acid molecule according to claim 7, wherein the enzyme is a biotin ligase.

9. The nucleic acid molecule according to claim 8, wherein the biotin ligase is selected from the group consisting of TurboID, miniTurbo, and . coli BirA.

10. The nucleic acid molecule according to claim 7, wherein the enzyme is a methyltransferase selected from the group consisting of a histone methyltransferase, an N-terminal methyltransferase, a DNA/RNA methyltransferase, a natural product methyltransferase, a non-SAM dependent methyltransferase, or a radical SAM methyltransferase.

11. The nucleic acid molecule according to claim 10, wherein the histone methyltransferase is a histone-lysine N-methyltransferase selected from the group consisting of enhancer of zeste homolog 1 (EZH1), enhancer of zeste homolog 2 (EZH2), disruptor of telomeric silencing 1-like (DOTl-like), ASH1L, euchromatic histone-lysine N-methyltransferase 1 (EHMT1), euchromatic histone-lysine N-methyltransferase 2 (EHMT2), histone-lysine N-methyltransferase 2A, histone-lysine N-methyltransferase 2D (KMT2D), lysine N-methyltransferase 2C (KMT2C), myeloid/lymphoid or mixed-lineage leukemia 4 (MLL4), lysine methyltransferase 2E, and nuclear receptor binding SET domain protein 1 (NSD1). In other embodiments, the histone methyltransferase is a histone-arginine N-methyltransferases selected from the group consisting of protein arginine N-methyltransferase 1, protein arginine N-methyltransferase 3, protein arginine N-methyltransferase 4, protein arginine N-methyltransferase 5, and protein arginine N- m ethyl transferase 7.

12. The nucleic acid molecule according to claim 2, wherein the protein of interest is a transcription factor.

13. The nucleic acid molecule according to claim 12, wherein the transcription factor is selected from the group consisting of c-Myc, c-Fos, c-Jun, CREB, GATA-2, GAL4, GAL4Npl6, c-Myb, MyoD, and NFKB, and TetR.

14. The nucleic acid molecule according to any one of claims 1-13, wherein the RNA-regulated destabilization domain is a bifunctional peptide comprising: a lentiviral transactivator of transcription (Tat) peptide and a degron peptide.

15. The nucleic acid molecule according to claim 14, wherein the lentiviral transactivator of transcription (Tat) peptide has the amino acid sequence of SEQ ID NO: 54.

16. The nucleic acid molecule according to claim 15, wherein the lentiviral transactivator of transcription (Tat) peptide has the amino acid sequence of SEQ ID NO: 55.

17. The nucleic acid molecule according to claim 14, wherein the lentiviral transactivator of transcription (Tat) peptide comprises an RNA binding site corresponding to amino acid residues 4-17 of SEQ ID NO: 54 or amino acid residues 4- 17 of SEQ ID NO: 55.

18. The nucleic acid molecule according to claim 17, wherein the RNA binding site is specific for an RNA aptamer having the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

19. The nucleic acid molecule according to claim 18, wherein the RNA binding site is specific for an RNA aptamer having the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

20. The nucleic acid molecule according to claim 14, wherein the degron peptide is selected from the group consisting of a monopeptide, a dipeptide, a tripeptide, a tetrapeptide, a pentapeptide, a hexapeptide, a heptapeptide, and an octapeptide.

21. The nucleic acid molecule according to claim 20, wherein the degron peptide is selected from the group consisting of P, E, RG, GG, EE, AP, RP, NP,

DP, CP, EP, QP, GP, HP, IP, LP, KP, MP, FP, PP, SP, TP, WP, YP, VP, SA, SR, SN, SD, SC, SE, SQ, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, AN, RN, NN, DN, CN, EN, QN, GN, HN, IN, LN, KN, MN, FN, PN, SN, TN, WN, YN, VN, AD, RD, ND, DD, CD, ED, QD, GD, HD, ID, LD, KD, MD, FD, PD, SD, TD, WD, YD, VD, CA, CR, CN, CD, CC, CE, CQ, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, AE, RE, NE, DE, CE, EE, QE, GE, HE, IE, LE, KE, ME, FE, PE, SE, TE, WE, YE, and VE.

22. The nucleic acid molecule according to claim 14, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

23. The nucleic acid molecule according to any one of claims 1-22 further comprising: a third nucleic acid sequence encoding a second protein of interest, wherein the third nucleic acid sequence is located between the first nucleic acid sequence and second nucleic acid sequence.

24. The nucleic acid molecule according to claim 17, wherein the second protein of interest is selected from the group consisting of a fluorescent protein, a bioluminescent protein, an enzyme, or a transcriptional regulator.

25. A nucleic acid molecule encoding a lentiviral transactivator of transcription (Tar) RNA aptamer sequence.

26. The nucleic acid molecule according to claim 25, wherein the nucleic acid molecule has the sequence of SEQ ID NO: 64, SEQ ID NO: 66, or SEQ ID NO: 68, wherein N can be A, C, G, or T; S can be C or G; H can be A, C, or T; Y can be C or T; W can be A or T; B can be C, G, or T; M can be A or C; and D can be A, G, or T.

27. The nucleic acid molecule according to claim 25, wherein the nucleic acid molecule has the sequence of SEQ ID NO: 65, SEQ ID NO: 67, or SEQ ID NO: 69.

28. The nucleic acid molecule according to claim 25, wherein the Tar RNA sequence is selected from the group consisting of (Pepper)iotag (SEQ ID NO: 60), (F30-lxPepper)i₀tag (SEQ ID NO: 61), (Pepper)₂₀tag (SEQ ID NO: 62), or (F30- 2xPepper)i₀tag (SEQ ID NO: 63).

29. A vector comprising the nucleic acid molecule according to any one of claims 1-28.

30. The vector according to claim 29, wherein the vector is selected from the group consisting of a plasmid, a phage, a transposon, a cosmid, a chromosome, and a virus.

31. The vector according to claim 29, wherein the vector comprises the nucleic acid sequence of SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or SEQ ID NO: 79.

32. An expression system comprising an expression vector into which is inserted a nucleic acid molecule according to any one of claims claim 1-28.

33. A host cell comprising the nucleic acid molecule of any one of claims 1-28 or the vector of any one of claims 29-32.

34. The host cell of claim 33, wherein the host cell is a mammalian cell.

35. An RNA-regulated fusion protein comprising a protein of interest and an RNA-regulated destabilization domain.

36. The RNA-regulated fusion protein according to claim 35, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

37. The RNA-regulated fusion protein according to claim 35, wherein the RNA-regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

38. The RNA-regulated fusion protein according to claim 37, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

39. A molecular complex comprising: an RNA-regulated fusion protein comprising

(i) a protein of interest and

(ii) an RNA-regulated destabilization domain; and an RNA aptamer bound specifically to the RNA-regulated destabilization domain.

40. The molecular complex according to claim 39, wherein the protein of interest is a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

41. The molecular complex according to claim 39, wherein the RNA- regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

42. The molecular complex according to claim 39, wherein the RNA- regulated destabilization domain is tDeg (SEQ ID NO: 63).

43. The molecular complex according to claim 39, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

44. The molecular complex according to claim 43, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant- 1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

45. The molecular complex according to claim 43, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

46. A host cell containing the molecular complex according to any one of claims 38-45.

47. The host cell according to claim 46, wherein the host cell is a mammalian cell.

48. A method of imaging RNA in a cell, said method comprising: providing a first vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or enzyme fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; transfecting the host cell with the first vector and the second vector; and imaging said transfected cells.

49. The method according to claim 48, wherein the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

50. The method according to claim 48, wherein the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, b-galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b -glucuronidase, and b- glucosidase.

51. The method according to claim 48, wherein the RNA-regulated fusion protein is an enzyme and wherein the enzyme is a biotin ligase.

52. The method according to claim 48, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

53. The method according to claim 52, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

54. The method according to claim 48, wherein the RNA of interest is a messenger RNA.

55. The method according to claim 54, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

56. The method according to claim 54, wherein the RNA aptamer sequence is located upstream of the 5' UTR, within the 5' UTR, within the 3' UTR, or downstream of the 3 ' UTR.

57. The method according to claim 48, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

58. The method according to claim 48, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

59. The method according to claim 48, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

60. The method according to claim 48, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

61. A method of imaging RNA in a cell, said method comprising: providing a vector encoding an RNA-regulated fusion protein, wherein the

RNA-regulated fusion protein comprises a fluorescent protein, a bioluminescent protein, or enzyme fused to an RNA-regulated destabilization domain; transfecting the host cell with the first vector; contacting said transfected cell with an RNA molecule comprising (i) an RNA sequence of interest and (ii) an RNA aptamer sequence, where the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; and imaging said contacted cells.

62. The method according to claim 61, wherein the RNA-regulated fusion protein is a fluorescent protein selected from the group consisting of Green Fluorescent Protein, Enhanced Green Fluorescent Protein (EGFP), Enhanced Yellow Fluorescent Protein (EYFP), Venus, mVenus, Citrine, mCitrine, Cerulean, mCerulean, Orange Fluorescent Protein (OFP), mNeonGreen, moxNeonGreen, mCherry, mTagBFP, Venus, mVenus, mTurquoise, mScarlet, mWasabi, mOrange, and dTomato.

63. The method according to claim 61, wherein the RNA-regulated fusion protein is a bioluminescent protein selected from the group consisting of luciferase, b-galactosidase, b-lactamase, peroxidase, alkaline phosphatase, b -glucuronidase, and b- glucosidase.

64. The method according to claim 61, wherein the RNA-regulated fusion protein is an enzyme and wherein the enzyme is a biotin ligase.

65. The method according to claim 61, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

66. The method according to claim 65, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

67. The method according to claim 61, wherein the RNA of interest is a messenger RNA.

68. The method according to claim 67, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

69. The method according to claim 67, wherein the RNA aptamer sequence is located upstream of the 5' UTR, within the 5' UTR, within the 3' UTR, or downstream of the 3 ' UTR.

70. The method according to claim 61, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

71. The method according to claim 61, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

72. The method according to claim 61, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

73. The method according to claim 61, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

74. A method of selectively modifying an RNA-binding protein, said method comprising: providing a first expression vector encoding a RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises an enzyme fused to a RNA- regulated destabilization domain; providing a second expression vector encoding (i) a RNA sequence of interest and (ii) an RNA aptamer sequence, wherein the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; transfecting a host cell with the first and second expression vectors; allowing the enzyme to be expressed, wherein the expressed enzyme selectively modifies a protein that binds to the RNA sequence of interest.

75. The method according to claim 37, wherein the enzyme is selected from the group consisting of a ligase and a peroxidase.

76. The method according to claim 74, wherein the enzyme is a biotin ligase selected from the group consisting of TurboID, miniTurbo, and E. coli BirA.

77. The method according to claim 74, wherein the enzyme is a peroxidase selected from the group consisting of an ascorbate peroxidase and a horseradish peroxidase.

78. The method according to claim 77, wherein the ascorbate peroxidase is APEX2.

79. The method according to claim 74, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

80. The method according to claim 79, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

81. The method according to claim 74, wherein the RNA of interest is a messenger RNA.

82. The method according to claim 81, wherein the RNA aptamer sequence is located within a coding region of the mRNA.

83. The method according to claim 82, wherein the RNA aptamer sequence is located upstream of the 5' UTR, within the 5' UTR, within the 3' UTR, or downstream of the 3 ' UTR.

84. The method according to claim 74, wherein the RNA of interest is a noncoding RNA (ncRNA) selected from the group consisting of ribosomal RNA (rRNA), transfer RNA (tRNA), heterogeneous nuclear RNA (hnRNA), small cytoplasmic RNA (scRNA), small nuclear (snRNA), small nucleolar (snoRNA), ribozymes, and regulatory RNA.

85. The method according to claim 74, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

86. The method according to claim 85, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

87. The method according to claim 74, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

88. The method according to any one of claims 74-87, further comprising: identifying a protein that is selectively modified by the enzyme within the transfected cells.

89. A method of regulating expression of an RNA-stabilized protein of interest, said method comprising: providing a first vector encoding an RNA-regulated fusion protein, wherein the RNA-regulated fusion protein comprises a protein of interest fused to an RNA-regulated destabilization domain; providing a second vector encoding an RNA aptamer sequence, wherein the RNA-regulated destabilization domain specifically binds to the RNA aptamer sequence; providing a host cell comprising a functional ubiquitination system; transfecting the host cell with the first and second expression vectors; and

Ill expressing the first and second expression vectors within the host cell, wherein said expressing the first and second expression vectors regulates proteomic stability of the RNA-regulated fusion protein; wherein, in the absence of any expressed RNA aptamer sequence in the host cell, the RNA-regulated destabilization domain promotes degradation of the RNA-regulated fusion protein by the ubiquitination system; and wherein the RNA-regulated fusion protein is stabilized by the expressed RNA aptamer sequence.

90. The method according to claim 89, wherein the protein of interest is selected from the group consisting of a fluorescent protein, a bioluminescent protein, an enzyme, or a transcription factor.

91. The method according to claim 89, wherein the protein of interest is selected from the group consisting of a G-protein coupled receptor (GPCR), a nuclear receptor, a voltage gated ion channel, a ligand gated channel, a receptor tyrosine kinase, a growth factor, a phosphatase, a protein kinase, a viral regulator, a bacterial cell division protein, a scaffold protein, a DNA repair protein, a cytoskeletal protein, a ribosome, a histone deacetylase, an apoptosis regulator, a chaperone protein, a kinase, a phosphorylase, a phosphatase, deacetylase, a cytoskeletal protein (e.g, myosin, actin, dynein, kinesin, and tubulin).

92. The method according to claim 89, wherein the RNA-regulated destabilization domain comprises the consensus sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

93. The method according to claim 92, wherein the RNA-regulated destabilization domain is tDeg (SEQ ID NO: 63).

94. The method according to claim 89, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

95. The method according to claim 94, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant-1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

96. The method according to claim 89, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

97. The method according to claim 89, wherein the host cells is a mammalian cell.

98. A treatment method comprising: contacting a cell with an RNA aptamer, wherein upon said contacting, the aptamer interacts with an RNA-regulated destabilization domain fused to a protein of interest in the cell to stabilize the protein of interest in the cell.

99. The treatment method according to claim 98, wherein the RNA aptamer comprises the consensus sequence of SEQ ID NO: 56, SEQ ID NO: 58, or SEQ ID NO: 60, wherein N can be A, C, G, or U; S can be C or G; H can be A, C, or U; Y can be C or U; W can be A or U; B can be C, G, or U; M can be A or C; and D can be A, G, or U.

100. The treatment method according to claim 98, wherein the RNA aptamer comprises the sequence of wild-type TAR RNA (SEQ ID NO: 57), TAR Variant- 1 (SEQ ID NO: 59), or TAR Variant-2 (Pepper; SEQ ID NO: 61).

101. The treatment method according to claim 98, wherein the RNA aptamer comprises the sequence of SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, or SEQ ID NO: 73.

102. The treatment method according to claim 98, wherein the RNA- regulated destabilization domain has the sequence of SEQ ID NO: 62, wherein X at position 1 is S or A; X at position 2 is G or A; X at position 3 is P or A; X at position 4 is R or K; X at position 5 is P, A, I, Y, K, or R; X at position 6 is R, K, V, or Y; X at position 7 is G, A, or R; X at position 8 is T or A; X at position 9 is R or K; X at position 10 is G or A; X at position 11 is K or A; X at position 12 is G or A; X at position 13 is R or K; X at position 14 is I or A; X at position 15 is R, K, Y, or G; X at position 16 is R, K, V, T, or Y; X at position 17 is any amino acid; and x at position 18 is optional and can be any amino acid.

103. The treatment method according to claim 98 further comprising: introducing the protein of interest into the cell prior to said contacting.

104. The treatment method according to claim 103, wherein the cell is in a patient.

105. The treatment method according to claim 104, wherein said introducing is carried out by any one or more of injecting mRNA encoding for the protein of interest into the patient, injecting a plasmid encoding for the protein of interest into the patient, injecting the protein of interest into the patient, or systemically delivering the protein of interest into the patient.

106. The treatment method according to claim 104, wherein the patient is a human.